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I.   ZUSAMMENFASSUNG 
 
Die embryonale Herzentwicklung ist ein sehr präzise regulierter Vorgang, der 
hauptsächlich mittels Zellproliferation und Differenzierung der Herzmuskelzellen 
(Kardiomyozyten) stattfindet. Nach der Geburt verlieren Kardiomyozyten 
sukzessive ihre Proliferationsfähigkeit, so dass das Herzwachstum überwiegend 
durch die physiologische Größenzunahme sowie eine Reifung der 
Kardiomyozyten erfolgt. Diese Prozesse werden durch eine große Zahl an 
Transkriptionsfaktoren gesteuert, deren Störung zu Defekten und einem 
Versagen des Herzens führen kann. TEAD1 ist ein Transkriptionsfaktor, der die 
Expression von vielen muskelspezifischen Genen reguliert und dennoch bleibt 
vieles über seine Rolle in Kardiomyozyten unbekannt. Um die biologische 
Funktion von TEAD1 im Herzen zu untersuchen, wurde die vorliegende Studie 
an die Analyse unterschiedlicher Kardiomyozyten-spezifischer konditioneller 
Tead1 Knockout- und Überexpression-Mauslinien sowie an die Identifizierung 
von Kardiomyozyten-spezifischen TEAD1-regulierten Genen gerichtet. Die 
Ergebnisse der Studie zeigen, dass TEAD1 für die Proliferation, Differenzierung 
und Reifung der embryonalen sowie postnatalen Kardiomyozyten erforderlich ist. 
Der spezifische Verlust von Tead1 in embryonalen Kardiomyozyten führt zu einer 
frühen embryonalen Sterblichkeit, die durch eine erniedrigte Kardiomyozyten-
Proliferation sowie eine erhöhte Apoptose gekennzeichnet ist. Außerdem weisen 
Kardiomyozyten eine Verzögerung in der Entwicklung von Myofibrillen- sowie 
Glanzstreifen auf. Die spezifische Inaktivierung von Tead1 in postnatalen Stadien 
führt zu einer frühen Sterblichkeit, die durch die Entwicklung einer 
Herzinsuffizienz sowie darauffolgendem Herzversagen gekennzeichnet ist und 
bis spätestens 30 Tage nach der Geburt eintritt. Darüber hinaus geht der Verlust 
von Tead1 in postnatalen Kardiomyozyten mit einer verminderten 
Kardiomyozyten-Plastizität einher, die zu einer frühzeitigen Reifung führt. Die 
Untersuchung des Transkriptions-Profils von isolierten Tead1 Knockout-
Kardiomyozyten kombiniert mit einem genomweiten TEAD1-Bindungsmuster in 
isolierten Wildtyp-Kardiomyozyten zeigt, dass TEAD1 für die Regulation der 
Gene verantwortlich ist, die in Wachstum, Differenzierung, Reifung, Kontraktion, 
Organisation des Zytoskellets, Umbau von Sarkomeren, sowie 
Energiehomöostase der Kardiomyozyten involviert sind. Alle diese 
Untersuchungsergebnisse deuten auf eine wichtige biologische Funktion von 
TEAD1 in Entwicklung und Reifung, sogenannte Plastizität, von embryonalen 
sowie postnatalen Kardiomyozyten hin, die einen regelrechten, physiologischen 
Herzumbau erlauben. 
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II.   ABSTRACT  
 
Heart development is a tightly regulated process directed to control 
cardiomyocyte proliferation and differentiation. After birth, cardiomyocytes 
steadily lose the ability to proliferate and the heart growth is maintained by 
physiological hypertrophy and differentiation of the cardiomyocytes. Numerous 
transcription factors are involved in these processes and deregulation of them 
can lead to heart defects, heart failure and death. TEAD1 is a transcription factor 
that governs the expression of numerous muscle specific genes, however, little 
is known about the role of TEAD1 in cardiomyocytes. In order to study the role of 
TEAD1 in the heart, the present study aimed at analyzing TEAD1 function in 
cardiomyocytes based on loss- and gain-of-function studies to decipher postnatal 
TEAD1 regulated transcriptional networks. Our data indicate an essential role of 
TEAD1 for the cardiomyocyte differentiation and maturation in both, embryonic 
and postnatal hearts. Specifically, early deletion of Tead1 in cardiomyocytes is 
embryonically lethal and characterized by decreased cardiomyocyte proliferation 
and increased apoptosis. In addition, cardiomyocytes displayed delay in the 
development of myofibrils and intercalated discs. In contrast, mice harboring 
cardiomyocyte-specific Tead1 inactivation in postnatal stage die within 4 weeks 
after birth due to impaired cardiac function and heart dilatation. Moreover, 
postnatal Tead1-deficient cardiomyocytes showed decreased proliferation and 
increased apoptosis rate. In addition, in postnatal cardiomyocytes, Tead1 
inactivation leads to diminished cardiomyocyte plasticity characterized by 
premature differentiation of cardiomyocytes. Importantly, the lethal heart 
phenotype of our conditional Tead1-deficient mice was rescued by 
cardiomyocyte-specific Tead1 overexpression. Transcriptome profiling of Tead1-
deficient cardiomyocytes combined with genome-wide TEAD1 binding studies in 
wild-type cardiomyocytes revealed that TEAD1 regulates genes responsible for 
cardiomyocyte growth, differentiation, maturation, contraction, energy 
homeostasis, sarcomere and cytoskeleton organization. Taken together, these 
data indicate an important role of TEAD1 in embryonic and postnatal 
cardiomyocyte plasticity thus enabling proper physiological heart remodeling. 
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1   INTRODUCTION 
 
The cellular and molecular processes of myocardial remodeling leading to heart 
diseases have been studied intensively both, in vivo and in vitro. However, the 
underlying mechanisms are largely unknown and more studies are certainly 
needed to understand whether the regulation of cardiomyocyte-specific gene 
expression in the pathological heart differs from that in normal, physiological 
hearts. Therefore, identification of signaling pathways and transcription factors 
regulating the expression of these genes in normal and pathological hearts may 
give important mechanistical insights into the pathogenesis of cardiac diseases 
and new therapeutic strategies. 
Cardiomyocytes are the major cell type in the heart and any changes of their 
structural and functional characteristics can potentially lead to heart dysfunction 
[1-4]. It has been shown that activation of cardiomyocyte-specific genes is 
regulated by multiple transcription factors (TFs), including GATA4, MEF2, NKX2-
5 and HAND [5-9]. Recently, transcription enhancer factor 1 (TEAD1) has been 
identified as an important regulator of muscle specific genes. In cardiomyocytes, 
however, only a few genes, which are directly regulated by TEAD1 have been 
documented so far [10-19]. 
 
1.1 Heart development and myocardial remodeling 
During mammalian embryogenesis, the heart grows primarily via cardiomyocyte 
proliferation referred to as hyperplasia [20-23]. After birth, cardiomyocytes 
undergo a switch from cell division to incomplete cell cycle, resulting in 
approximately 80–90% binucleated cardiomyocytes in adult mice and rats (Figure 
1) [24-27]. In contrast, the non-cardiomyocyte cell fraction of the heart (e.g. 
fibroblasts, smooth muscle cells, endothelial cells, etc.) retain their proliferation 
capacity.  
The adult mammalian heart is able to functionally and structurally adapt to 
alternations of the workload settings [28] via cardiomyocyte cell enlargement 
referred to as hypertrophy [29, 30]. The major features of physiological and 
pathological hypertrophy are schematically presented in Figure 2. 
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Figure 1. Cell cycle activities in fetal, postnatal and adult mammalian 
cardiomyocytes. During embryogenesis, the ballooning of the chamber and further 
growth of the heart are sustained by cardiomyocyte proliferation. After birth, 
cardiomyocytes gradually stop proliferation and exit the cell cycle (G0/G1 phase). Initially 
this arrest is reversible so that newborn cardiomyocytes can re-enter the cell cycle and 
proliferate upon injury. During postnatal development, cardiomyocytes undergo 
additional incomplete cycles lacking cytokinesis, which finally results in binucleated or 
polyploid postnatal cardiomyocytes. In pathological hypertrophy, adult cardiomyocyte re-
enter cell cycle and undergo polyploidization, endomitosis and polynucleation. This is a 
common feature of heart failure (adapted from [31]). 
 
 
 
Figure 2. Types of cardiac hypertrophy. Physiological hypertrophy is characterized 
by a uniform ventricular wall and septum growth leading to proportional increase in 
chamber dimension. This phenotype is associated with cardiomyocyte hypertrophy in 
which sarcomeres are added both, in series to lengthen the cell (longitudinal area) or at 
the periphery to increase the cell width (cross-sectional area). Pathological cardiac 
hypertrophy can produce concentric hypertrophy in which the ventricular wall and 
septum thicken with a net decrease in ventricular chamber dimensions. This remodeling 
is associated with a greater and disproportional increase in cardiac myocyte width than 
length. Cardiac dilation can result from a growth response in which sarcomeres are 
predominantly added in series to individual myocytes. DCM - dilated cardiomyopathy; 
LV - left ventricle; RV - right ventricle (adapted from [30]). 
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During acute myocardial infarction (MI), cardiomyocytes die due to necrosis, 
apoptosis and autophagy. Cardiomyocyte loss in the infarct area is partially 
compensated by proliferating fibroblasts and extracellular matrix deposition [32-
34]. This process, which is also referred to as replacement fibrosis, finally results 
in loss of contractility and in increased heart stiffness, whereby the remaining 
cardiomyocytes compensate the increased workload via hypertrophic growth 
referred to as hypertrophic remodeling processes (Figure 3). During this process 
cardiomyocytes undergo an extensive remodeling, which includes re-expression 
of fetal genes, like Myh7 (Myosin Heavy Chain 7, cardiac muscle b Isoform) and 
Acta2 (Smooth Muscle a-Actin 2), as well as reorganization of the cytoskeletal 
and contractile apparatus (Figure 4) [35-37]. However, under certain conditions 
cardiomyocyte remodeling can also lead to heart failure, which is defined as 
inability of the heart to adequately pump blood in response to systemic demands 
[38]. 
 
 
Figure 3. Regeneration of mammalian postnatal and adult hearts after myocardial 
infarction. The postnatal mouse heart possesses regenerative capacity, which is 
characterized by an early response to cardiac injury-induced cardiomyocyte loss, 
accompanied by an inflammatory infiltration, activation of epicardial-specific genes and 
angiogenesis. Global proliferation of cardiomyocytes in the injured heart replaces the 
scar tissue with cardiomyocytes and restores cardiac function within 3 weeks after injury. 
The regenerative capacity of the mammalian postnatal heart declines with age, whereas 
cardiac fibrosis increases with age in response to injury. The regenerative potential of 
the murine heart upon injury is lost from the postnatal day 7, when fibrotic scar tissue 
replaces dead cardiomyocytes culminating in reduced cardiac function and heart failure 
(adapted from [39]). 
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Figure 4. Acta2 and Myh7 expression in embryonic and adult cardiomyocytes 
under physiological and pathological conditions. Embryonic cardiomyocytes 
express Acta2 and Myh7. During differentiation and maturation processes, postnatal 
cardiomyocytes successively loose Acta2 and Myh7 expression. Under pathological 
conditions adult cardiomyocytes dedifferentiate and re-express Acta2 and Myh7. 
 
1.2 TEAD transcription factors  
The TEAD transcription factor family comprises four members, TEAD1 (TEF1, 
NTEF-1), TEAD2 (TEF4, ETEF), TEAD3 (TEF5, DTEF-1, ETFR-1) and TEAD4 
(TEF3, RTEF-1, ETFR-2, FR-19). All four family members share a highly 
conserved N-terminal 68 amino acid TEA/ATTS DNA binding motif, which binds 
to muscle specific MCAT (5´- CATTCCT-3´) as well as to SV40 GT-IIC, SphI and 
SphII enhancer-motives [10, 40]. The TEA/ATTS DNA binding motif is 
evolutionary conserved from fungi (AbaA), yeast (Tec1), fly (Scalloped) to 
vertebrates. In Aspergillus nidulans AbaA regulates terminal development of 
specialized hyphal brunches, which produce spore in asexual way [41]. The yeast 
orthologue Tec1 (Transposon Enhancement Control 1) has been identified to 
control Ty1-mediated gene activation, regulating independently transcription or 
acting in combination with additional transcription factors, like Ste12, which 
enables promoter-specific transcriptional activation and controls development, 
cell adhesion and filament formation [42, 43]. The Drosophila melanogaster 
TEAD ortholog Scalloped forms with the cofactor Vestigial a protein complex and 
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regulates wing morphogenesis via binding to essential sites in wing-specific 
enhancers [44]. Transcriptional activation of target genes can also be controlled 
under certain physiological conditions by interaction with additional transcription 
factors as well as cofactors to provide tissue-specific control of gene expression 
during cell fate decisions and organogenesis [45]. 
Several studies have shown that Tead1, Tead3 and Tead4 are widely expressed 
in the mammalian organism including heart, skeletal muscles, vessels, lung, 
pancreas, placenta and digestive system from early embryonic to adult stages. 
On the contrary, Tead2 expression is restricted to a subset of embryonic tissue 
including fore- and hindlimb, tail bud, testis and cerebellum during murine 
embryonic development [46]. 
TEAD1 was initially identified in HeLa cells as a 53 kDa protein, which binds to a 
specific sequence of the SV40 enhancer motif [40]. In 1994 Chen et al. showed 
that gene-trap based constitutive Tead1 inactivation resulted in early embryonic 
lethality at embryonic day (E)11.5 [12]. Mutant embryonic hearts displayed an 
enlarged pericardial cavity with abnormal thin and hypotrabeculated ventricular 
walls (Table 1). It is worth noting that transmission electron microscopy analysis 
of homozygous mutant hearts showed no obvious alterations in mitochondria, 
fascia adherens and sarcomeric structures of the cardiomyocytes. Interestingly, 
expression levels of potential TEAD1 downstream target genes including Tnnt2 
(Troponin T2, cardiac type), Tnni3 (Troponin I3, cardiac type) and Myosins were 
not altered.  
Striated muscle specific overexpression of Tead1 under control of the muscle 
creatine kinase (MCK) promoter displayed age-dependent heart dysfunction 
characterized by decreased cardiac output, stroke volume, ejection fraction and 
fractional shortening as well as an increased MYH7 protein level [17]. At the 
transcriptional level, TEAD1 gain-of-function (GOF) mutants displayed an 
elevated expression of fetal genes including Nppa (Natriuretic Peptide A), Nppb 
(Natriuretic Peptide B), Myh7 and Acta1 (Skeletal Muscle a-Actin), which 
remained constantly high from fetal stages until adulthood. Moreover, histological 
analysis revealed altered alignment of cardiomyocytes, septal wall thickening and 
myocardial fibrosis. Importantly, these mice were unable to tolerate pressure-
induced overload leading to heart failure and death (Table 1). 
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In skeletal muscle Tead1 overexpression shifted the expression of contractile 
proteins towards slow muscle phenotype resulting in reduction of shortening 
velocity as well as longer contraction and relaxation times [47].  
 
Table 1. Overview of relevant mouse models for TEAD TFs gain- and loss of 
function mutants. DCM – dilated cardiomyopathy, E – embryonic day 
 
 
TEAD2 is exclusively expressed in embryonic tissues and constitutive Tead2 
knockout mutants displayed an incomplete penetrance of neural tube closure 
defects [49, 54]. Moreover, Tead1 and Tead2 double-knockout (dKO) led to 
embryonic lethality at embryonic stage E9.5 accompanied by severe growth 
defects, morphological abnormalities, reduced proliferation and increased 
Genetic 
modification Method Effects Ref. 
Tead1 
knockout 
constitutive, 
retroviral gene trap in 
embryonic stem cells  
• Embryonic lethal at E11.5  
Heart: 
• Enlarged pericardial cavity and thin 
hypotrabeculated ventricular walls 
[48] 
Tead1 
overexpression 
conditional, 
under control of  
striated muscle-specific 
MCK-Cre   
 
Heart: 
• Decreased cardiac output, stroke 
volume, ejection fraction and 
fractional shortening  
• Altered alignment of cardiomyocytes, 
septal wall thickening and fibrosis, no 
cardiac hypertrophy. 
Skeletal muscle: 
• Transition toward a slow muscle 
contractile protein phenotype 
[17, 
47] 
Tead1 
knockout 
conditional, inducible 
deletion under control of 
cardiomyocyte- specific 
Myh6-Cre   
Deletion in adult cardiomyocytes: 
• Severe, lethal DCM 
• Impaired excitation-contraction 
coupling 
• Decreased SERCA2a activity 
[18] 
Tead2 
knockout 
Conditional, 
under control of the 
ubiquitous Ella-Cre  
• Elevated risk for neural tube closer 
defects during embryonic 
development.  
[49] 
Tead1/Tead2 
double 
knockout 
constitutive  • Growth retardation and severe 
morphological abnormalities at E8.5,  
• Defects in mesoderm development, 
especially in the notochord. 
[50] 
Tead4 
knockout 
conditional,   
under control of the 
ubiquitous EIIa-Cre 
• Defects in preimplantation stages of 
specification and development of the 
trophectoderm lineage 
[51, 
52] 
Tead4 
overexpression 
conditional, 
under control of 
cardiomyocyte-specific 
Myh6-Cre  
 
• Impaired cardiac conduction and 
arrhythmias.  
• Increased dephosphorylation of 
cardiac connexin40 and 43. Impaired 
gap-junctional conductance. 
[53] 
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apoptosis rate [50]. This aggravated phenotype of Tead1/Tead2 dKOs is 
indicative for redundant function of both genes. 
TEAD3 is highly expressed in cardiac muscle and to a lesser degree in skeletal 
muscle [55]. Adrenergic stimulation of postnatal rat cardiomyocytes enhances 
TEAD3 binding to MCAT-elements and activation of corresponding target genes 
including Acta1. This finding indicates that in addition to TEAD1, also TEAD3 is 
able to regulate expression of Acta1 in response to the a1-adrenergic signaling 
pathway in postnatal rat cardiomyocytes, although, a Tead3 KO mutant has not 
been described so far [56]. 
TEAD4 was initially described in 1996 by Hsu et al. as a TEF-1- (TEAD1)-related 
gene, which is activated by FGF-1 (Fibroblast Growth Factor 1) mediated 
mitogenic stimulation of quiescent fibroblasts as well as during differentiation of 
C2C12 myoblasts [57]. Tead4 is highly expressed in skeletal muscles and lung, 
whereas the heart and placenta display lower expression levels [58]. TEAD4 as 
well as TEAD1 can activate Myh7 and Acta1 promoters in response to a-
adrenergic signal indicating that TEAD4 can mediate a1-adrenergic response in 
hypertrophic myocytes [59]. Cardiac specific Tead4 GOF mice displayed chronic 
elevation of protein phosphatase 1b, which resulted in an enhanced 
dephosphorylation of the gap junctional connexin-40 and -43, decreased impulse 
velocity and thus cardiac conduction defects [53].  
Notably, TEAD4 in myofibroblasts regulates Acta2 transcription, whereas, 
TEAD1 in differentiated smooth muscle cells (SMCs) controls Acta2 expression 
[60]. Tead4 overexpression in endothelial cells upregulates vascular endothelial 
growth factor B, which in turn is able to stimulate hypertrophic gene expression 
in cardiomyocytes [61]. Constitutive inactivation of Tead4 in mouse resulted in a 
lethal preimplantation phenotype, caused by absence of trophoblast stem cells 
due to failed expression of the trophectoderm-specific genes, such as Cdx2, 
whereas deletion of Tead4 after implantation state did not influence embryonic 
development [51].  
Chromatin immunoprecipitation sequencing (ChIP-seq) of mature mouse muscle 
fibers identified a number of TEAD4-occupied sites, which are highly enriched for 
promoters of muscle-specific actins and cytoskeletal binding proteins. 
Inactivation of Tead4 in mature muscle fibers caused no obvious phenotype 
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under physiological conditions, however, under pathological condition in the 
settings of myotoxic injury, Tead4 inactivation delayed muscle regeneration 
indicating an important role of TEAD4 during myogenic differentiation. It is worth 
to note that the concomitant inactivation of Tead4 and Tead1 in differentiating 
C2C12 cells resulted in impaired differentiation, whereas the inactivation in 
primary myoblasts revealed a relatively mild phenotype [48]. 
Taken together, it is becoming increasingly evident that each member of the 
TEAD TF family regulates specific and unique downstream-target genes. On the 
other hand, several TEAD TFs can regulate expression of a single gene by 
providing a back-up network. 
 
1.3 Regulation of TEAD TFs target genes via MCAT-elements 
TEAD TFs bind predominantly to conserved DNA sequences, so called MCAT 
elements (Muscle Specific Cytidine-Adenosine-Thymidine-Sequence (5´-
CATTCCT-3`). Initially MCAT elements have been discovered in promoter 
regions of numerous skeletal-, heart- and smooth muscle gene promoters e.g. 
cardiac Tnnt2, Myh7, Acta2 as well as Acta1 (Table 2), where they play a crucial 
role in transcriptional regulation of these genes [10, 62-64]. However, MCAT-
elements are not restricted exclusively to the muscle-specific genes but are also 
located in promoter regions of non-muscle genes, like simian virus 40 enhancer, 
human papilloma virus type 16, E6 and E7 oncogenes, chorionic 
somatomammotropin as well as Foxo2 (Forkhead Box A2) genes [40, 65-67]. 
MCAT-elements can occur as a single regulatory element (Acta1 promoter), as 
well as in clusters (Tnnt2 or Myh7 promoters) [10, 62, 64]. 
Tnnt2 promoter studies have shown that the maximal transcriptional activation 
requires activation of both MCAT-elements [10]. In addition, it has been shown 
that the distance between two MCAT-elements play an important role in the 
transcription activation efficiency [68]. These findings indicate that not only one 
MCAT-element, but also combinations of several MCAT-elements as well as their 
interplay with additional regulatory elements are important for a specific 
transcriptional activation of target genes.  
Myh7 promoter studies revealed, that two MCAT-elements regulate 
transcriptional activation in cardiomyocytes under normal as well as under 
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hypertrophic conditions and mutations within these MCAT-elements diminish the 
basal promotor activity. In addition, the binding rate of MCAT-elements in 
cardiomyocytes were increased upon stimulation with a1-adrenergic agonists, 
e.g. phenylephrine, and during chronic pressure overload of the heart [69].  
 
Table 2. MCAT-elements in muscle-specific genes. Myh6 - Myosin Heavy Chain 6, 
cardiac muscle a Isoform; Chrnb1- β-Acetylcholine Receptor; Myocd -Myocardin; Adra1c 
- α1c-Adrenergic Receptor; Tpm1 - α-Tropomyosin (adapted and modified from [70]). 
Genes Species Sequence and Position References 
Tnnt2 chicken 
MCAT1: CATTCCT (−95/−89 bp) 
MCAT2: CATTCCT (−72/−66 bp) 
[10] 
Myh7 mouse 
distal: CATTCCA (−275/−281 bp) 
proximal: CATGCCA (−205/−211 bp) 
[62] 
Acta2 Rat 
MCAT1: CATTCCT (−178/−184 bp) 
MCAT2: CATTCCT (−314/−320 bp) 
[63] 
Acta1 mouse CATTCCT (−69/−63 bp) [64] 
Myh6 Rat CATTCCA (−42/−48 bp) [13] 
Chrnb1 Rat CATTCCT (−49/−43 bp) [71] 
Myocd mouse CATTCCA (∼−30 kb) [16] 
Adra1c mouse CATGCCA (−916/−910 bp) [72] 
Tpm1 frog CATTCCT (−59/−65 bp) [73] 
 
1.4 TEAD TFs are involved in Hippo-pathway mediated cellular 
processes 
The Hippo-pathway is a crucial signal transduction pathway, which partially 
signals via TEAD TFs to activate the expression of downstream target genes. 
This pathway is involved in multiple processes including regeneration, 
proliferation, stem cell function as well as controlling organ size and development 
(reviewed in [74]).  
Initially, the Hippo-pathway was discovered in a tumor suppressor screen in 
Drosophila melanogaster and comprises the kinases Hippo and Warts as well as 
the kinase-binding proteins Salvador and Mats1. Loss-of-function (LOF) 
mutations of these proteins led to increased cell proliferation and decreased cell 
apoptosis [75, 76].  
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In recent years, a number of Hippo-pathway components have been identified 
and characterized in mammals. The key components of the mammalian Hippo-
pathway are the protein kinases MST1 and MST2 (STE20-like Protein Kinase 1 
and 2) as well as LATS1 and LATS2 (Large Tumor Suppressor Kinases 1 and 2), 
which phosphorylate and thereby trap transcriptional coactivators YAP1 (Yes-
Associated Protein 1) and WWTR1 (WW Domain Containing Transcription 
Regulator 1, TAZ) in cytoplasm (Figure 5). However, in the case of inactive Hippo-
pathway, unphosphorylated YAP1 and WWTR1, enter the nucleus, where they 
interact with transcription factors, e.g. TEAD TFs, to drive the expression of target 
genes. In addition, there is increasing evidence suggesting that additional 
signaling cascades, such as WNT or GPCR, can also interfere with the Hippo-
pathway [77].  
 
 
Figure 5. Schematic view of key players of the Hippo signal transduction network 
and its interaction with other signaling pathways. P - phosphorylation; M - 
methylation; LPA - lysophosphatidic acid; S1P - sphingosine 1-phosphate (adapted from 
[78]). 
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Cardiac-specific Mst1 overexpression in mice activates caspases resulting in 
increased apoptosis and dilated cardiomyopathy (DCM). In contrast, suppression 
of Mst1 by a dominant-negative approach in mice prevents cardiomyocyte 
apoptosis as well as myocardial fibrosis and hence abolishes cardiac 
dysfunctions [79, 80]. MST1 in turn activates LATS 1 or 2 via phosphorylation. 
Moreover, it has been shown that LATS2 limits cardiomyocyte hypertrophy 
without affecting cardiomyocyte apoptosis in the heart. Inactivation of Hippo-
pathway by a dominant negative Lats2 approach resulted in hypertrophied 
cardiomyocytes accompanied by inhibited apoptosis, whereas activation of Lats2 
caused heart atrophy with unchanged cardiomyocyte apoptosis rate [81]. These 
results underline a role of LATS2 in cardiomyocyte hypertrophy, which are 
supported by the observation of increased endogenous Lats2 expression in 
chronic pressure overloaded hearts [81]. 
 
1.5 Crosstalk between TEAD TFs and Hippo-pathway via 
cofactors   
A typical feature of TEAD TFs is the lack of a transactivation domain, which 
implicates TEAD interaction with specific cofactors to activate transcription of 
target genes. So far, several TEAD TFs cofactors have been reported including 
paralogs YAP1 and WWTR1, VGLL-1 (Vestigial Like Family Member 1), VGLL-2 
(Vestigial Like Family Member 2, VITO-1) as well as VGLL-4 (Vestigial Like 
Family Member 4) (Figure 6) [82-86]. A characteristic feature of these cofactors 
is the lack of a DNA binding domain and therefore the transactivation of 
downstream transcriptional networks relies on a physical interaction of TEAD TFs 
and cofactors. This in turn implicate a tightly regulated activation, based on 
differential TEAD-cofactor interaction. In particular YAP1 and WWTR1 are 
broadly expressed and play an important role in Hippo-pathway mediated control 
of organ size via cell proliferation, cell differentiation as well as stemness. During 
Hippo-pathway activation, both cofactors, YAP1 and WWTR1 are 
phosphorylated and excluded from the nucleus, whereas Hippo-pathway 
inactivation results in nuclear translocation of YAP1 and WWTR1 and 
subsequent transcriptional activation of target genes via complex formation with 
transcription factors, e.g. TEAD TFs [87].  
Introduction 
 
 12 
 
Figure 6. Domain architecture of TEAD1 and corresponding coactivators. TEADs 
contain a N-terminal TEA domain that binds DNA and a C-terminal transactivation 
domain, which interacts with corresponding coactivators. YAP1 and TAZ (WWTR1) 
encode a N-terminal TEAD-binding motif, one or two WW domains and an activation 
domain. VGLL-1,-2,-3 cofactors contain one conserved Vg-motif (TDU-domain), which 
facilitates interaction with TEAD TFs, whereas VGLL-4 encodes two Vg motifs (adapted 
from [88]). 
 
In the myocardium, TEAD TFs and YAP1 regulate cardiomyocyte proliferation, 
cardiac morphogenesis and myocardial trabeculation [89-91]. Lin at al. showed 
that a-catenin modulates subcellular localization as well as transcriptional activity 
of YAP1, triggered by extracellular signals, which facilitated the release of YAP1 
from the a-, b- and g-catenin complex located in intercalated disks of 
cardiomyocytes, which in turn caused YAP1 translocation to the nucleus and 
subsequent activation of mitogenic gene expression [91]. Early cardiac specific 
inactivation of Yap1 resulted in hypoplasia of the myocardium as well as in 
reduction of proliferative cardiomyocytes during embryonic development, leading 
to late gestational lethality around E16.5. Specific overexpression of Yap1 in the 
embryonic heart led to hypertrabeculation and increased cardiomyocyte 
proliferation, however, cardiac-specific overexpression of Yap1 in adult mouse 
hearts promoted cardiomyocyte proliferation without affecting heart function. 
Moreover, Yap1 overexpression after myocardial infarction led to improved 
cardiac function indicating positive impact of Yap1 overexpression in terms of 
improving heart regeneration [89, 90].  
WWTR1 is 45% identical to YAP1 and contains 3 conserved domains: WW-
domain, a 14-3-3-binding site and a C-terminal PDZ-binding motif [92, 93]. 
WWTR1 and YAP1 co-regulate distinct cellular processes such as myoblast 
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proliferation, whereas myogenic differentiation is exclusively regulated by 
WWTR1 [94]. 
The Vestigial-like family, deduced from the Drosophila Vestigial gene, represent 
an additional TEAD TFs cofactors and consists of 4 members: VGLL-1, VGLL-2, 
VGLL-3 and VGLL-4. A key motif of the Vestigial family is the tondu (TDU)-
domain which mediates physically and functionally interaction with TEAD TFs 
[85]. VGLL-1 and VGLL-3 expression is mainly restricted to placenta and 
therefore might function in combination with TEAD TFs in proliferative processes 
of placenta cells. VGLL-2, also referred to as VITO-1, is exclusively expressed in 
skeletal muscle tissue starting from E8.5 in somatic myotome of the mouse 
embryo and contributes to a myogenic program [95, 96]. Moreover, Günther et 
al. showed that VGLL-2 interacts with TEAD1 and enhances MYOD-mediated 
myogenic program [84]. In contrast to VGLL-2, VGLL-4 is highly expressed in the 
heart. Cardiac specific VGLL-4 overexpression enhances the TEAD1 mediated 
activation of Acta1 promoter [97]. On the contrary, Lin et al. reported that VGLL-
4 negatively regulates TEAD TFs stability as well as TEAD-YAP1 interaction and 
serves thereby as a repressor of the TEAD1-YAP1 driven cardiac growth [86].  
 
1.6 Orchestrated TEAD TFs mediated gene activation in 
transcriptional networks 
Multiple lines of evidence indicate that a regulatory network of TFs is involved in 
muscle-specific gene activation. Among them, muscle restricted as well as 
broadly expressed TFs regulate cell type specific transcriptional networks. It has 
been previously demonstrated that TEAD TFs have the potential to interact with 
numerous transcription factors including MAX (MYC Associated Factor X), SRF 
(Serum Response Factor), MEF2 (Myocyte Enhancer Factor 2), IRF2BP2 
(Interferon Regulatory Factor 2 Binding Protein 2) and FOXO to specifically 
activate transcription of target genes [14, 16, 98-101]. Gupta et al. showed that 
the basic Helix-Loop-Helix-Leucine zipper protein, MAX, binds in a complex with 
TEAD1 to E-box-M-CAT-hybrid motif, which in turn regulates basal transcription 
of the cardiac Myh6 gene in rat cardiomyocytes, indicating a concomitant 
activation of gene expression [14]. In this study the authors also reported a 
physical interaction of TEAD1 and SRF in vitro as well as in vivo, which in turn 
Introduction 
 
 14 
synergistically induces the promoter activity of the Acta1 gene in cardiomyocytes 
[98]. In contrast, Liu et al. showed that TEAD1 suppresses expression of smooth 
muscle-specific genes including Acta2 in SMCs via competition with Myocardin 
(MYOCD) for SRF binding. This subsequently results in the disruption of 
MYOCD-SRF interaction, which finally lead to a decreased expression of smooth 
muscle-specific genes [102]. Furthermore, two additional studies suggest TEAD 
TFs interactions with MEF2 and FOXO to control muscle specific gene 
expression [16, 99]. In addition, TEAD TFs have been reported to form a complex 
with several transcription factors simultaneously, e.g. downstream of TGFb 
(Transforming Growth Factor b) pathway. In malignant mesothelioma cells, 
TEAD4 forms a complex with YAP1-SMAD2/3-P300 on a specific site of the Ctgf 
(Connective Tissue Growth Factor) promoter indicating a synergistic action of 
TEAD4 and SMAD3 [101].  
 
1.7 Muscle related genes regulated by TEAD TFs   
In recent years, several studies have attempted to identify direct TEAD TFs target 
genes. One of the best characterized TEAD1 target gene in striated muscle cells 
is Myh7, which encodes b heavy chain subunit of cardiac myosin. MYH7 is a 
crucial member of the cardiomyocyte contractile apparatus, which exerts an 
important role in heart maturation as well as in myocardial remodeling. Myh7 is 
predominantly expressed during fetal heart development and replaced after birth 
by Myh6, an additional member of myosin proteins family. In the adult heart, Myh7 
is re-expressed under pathophysiological conditions such as chronic pressure 
overload or DCM [103, 104]. In cultured hypertrophied postnatal cardiomyocytes, 
Myh7 expression is mediated by a1-adrenergic stimulation and b protein kinase 
C, which in turn facilitates binding of TEAD1 to the MCAT-sequence of the Myh7 
promoter, resulting in transcriptional activation [105]. Moreover, the mammalian 
Myh7 promoter contains four MCAT-elements, which are involved in the maximal 
promoter activity. Under basal conditions TEAD1 binding is restricted to one 
MCAT-element, whereas under hypertrophic conditions TEAD1 binds to all 4 
MCAT-sequences to enhance Myh7 expression [15]. In addition, it has been 
shown that TEAD1 is recruited to the promoter region of Acta1, a key component 
of the cardiac muscle cell contractile apparatus [106]. In contrast to the Myh7 
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expression, which is activated by TEAD1 via MCAT-elements, the activation of 
Acta1 is orchestrated by a combinatorial recruitment of several regulatory 
elements including MCAT, CArG as well as Sp1 and therefore simultaneous 
binding of multiple transcription factors including TEAD1 and SRF is required 
[64]. These findings demonstrate the divergence in TEAD1 transcriptional 
regulation of target genes within one cell type.  
Apart from facilitating gene activation, TEAD TFs can function as transcriptional 
repressors under certain conditions, e.g. target genes or cell types. In cultured 
SMCs, binding of TEAD TFs to MCAT-elements repress transcription of Acta2, 
whereas in cultured myoblasts, fibroblasts and endothelial cells TEAD binding 
activates transcription [63]. TEAD4 knockdown experiments showed that TEAD4 
regulates Acta2 expression in cultured myofibroblasts, but not in differentiated 
SMCs. Furthermore, quantitative ChIP assays in myofibroblasts revealed that 
TEAD4 binds preferentially to the MCAT-containing regions within the Acta2 
promoter, whereas in undifferentiated SMCs TEAD1 binds to the same region of 
Acta2 promoter [60]. In addition, analyses of transgenic mice harboring mutations 
within MCAT-elements of Acta2 promoter showed delayed as well as reduced 
Acta2 activation in SMCs, cardiac and skeletal muscle cells during early 
embryogenesis, whereas expression in adult SMCs remained unaltered [60]. A 
possible explanation for delayed Acta2 expression in MCAT mutants might be 
compensatory effects of Myocardin (MYOCD), which is one of the key regulators 
of smooth as well as cardiac muscle gene expression [107]. In this regard, it has 
been shown that TEAD TFs act also upstream of MYOCD, thereby regulating 
smooth muscle development during embryogenesis [16]. Strikingly, in 
proliferating SMCs TEAD1 represses the expression of the smooth muscle-
specific genes including Acta2 by abolishing the MYOCD function via competition 
with MYOCD for the direct binding to SRF, indicating opposing transcriptional 
mechanisms mediated by TEAD TFs [102]. This competitive binding is of 
biological importance in healing processes after arteria injury, where TEAD1 
induction and binding to SRF enables SMCs to proliferate. These findings 
suggest multiple functions of TEAD TFs in cell-type specific regulation of Acta2 
gene.  
In summary, the published data suggest that TEAD TFs are involved in 
transcriptional regulation of muscle specific gene program. In cardiomyocytes, 
Introduction 
 
 16 
however, only a few direct TEAD1 cardiomyocyte-specific target genes have 
been investigated so far [10, 14-18, 64, 73, 108]. Importantly, genome-wide 
TEAD1 binding studies, especially in cardiomyocytes, are still pending.  
 
1.8 Aim of the present study  
The present study aimed at investigating the biological function of TEAD1 
transcription factor in murine embryonic and postnatal cardiomyocytes by 
analyzing cardiomyocyte-specific conditional Tead1 knockout and Tead1-
overexpressing mice. In addition, this study set out to identify target genes that 
are regulated by TEAD1 in cardiomyocytes by using global transcriptome 
analysis combined with genome-wide TEAD1 binding studies. Finally, it was 
intended to investigate the effects of the FGF2-FGFR1 pathway on TEAD1 in 
cardiomyocytes. 
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2   MATERIAL AND METHODS 
 
2.1 Transgenic mice 
The animal experiments in this study were performed in full agreement with 
institutional guidelines and with approval of the Committee for Animal Rights 
Protection of the State of Hessen (Regierungspräsidium Darmstadt; B2/1125, 
B2/K5312). The animals were kept in individual ventilated cages accompanied 
with environmental enrichment under sterile approved conditions with an 
appropriate day and night cycle in the Animal House Facility of Max Planck 
Institute for Heart and Lung Research, Bad Nauheim, Germany. For separate 
experiments were used age-matched littermates. The number of animals used in 
each experiment is listed in the figure legends. 
 
2.1.1 Generation of mice with cardiomyocyte-specific Tead1 deletion  
Conditional Tead1 mutant mice (Tead1fl/fl) carrying exon 3 to 5 flanked by loxP 
sites, encoding for DNA-binding TEA-domain of TEAD1 were generated by 
Nadine Kirchner in domo. The crossing of conditional Tead1 mutant mice with 
deleter mouse strain carrying cell-type specific Cre-recombinase resulted in non-
functional TEAD1 protein in a cell-type specific manner.  
Conditional, Cre-recombinase mediated Tead1 deletion in cardiomyocytes was 
achieved by crossbreeding of Tead1fl/fl with either XMLC2-Cre [109] or MCK-Cre 
[110] deleter mouse strains to facilitate deletion in embryonic (genotype: 
XMLC2::Tead1fl/fl) or postnatal (genotype: MCK-Cre::Tead1fl/fl) mice, accordingly. 
Inducible Cre-mediated deletion of Tead1 in isolated P3 cardiomyocytes was 
performed by crossbreeding of Tead1fl/fl mice with tamoxifen-inducible Rosa26-
CreERT2 transgenic mice [111] and subsequent administration of 2 µmol/L 4-
Hydroxytamoxifen (4-HT) (Sigma, H7904-5MG) for 8 days in culture.  
 
2.1.2 Conditional overexpression of Tead1 tagged by Flag-HA 
Conditional transgenic overexpressing Tead1-Flag-HA mice were generated in 
domo utilizing a modified ROSA26 targeting locus carrying a synthetic CAG 
promoter [112]. The Flag-HA tagged plasmid of mouse Tead1 was PCR-amplified 
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(primers used: FlagHA-BigT-forward and FlagHA-BigT-revers) to introduce NheI 
and NotI sites, and cloned into the pBigT-CAG vector. The generated pBigT-
CAG-Tead1-Flag-HA cassette was subcloned in PacI and AscI site of the 
pRosa26-PA construct. The final construct was electroporated into V6.5 F1 
hybrid embryonic stem cells and targeted stem cell clones were selected by G418 
treatment and screened by Southern blotting with 5’ genotyping by EcoRV. 
Positive embryonic stem cell clones were injected into C57BL/6 (B6) blastocysts. 
The resulted chimeric mice were backcrossed to C57BL/6 mice to generate 
transgenic mice harboring a single mutant allel (genotype: Tead1-Flag-HATg/+). 
Conditional Cre-mediated overexpression of Tead1-Flag-HA in embryonic 
cardiomyocytes was achieved by crossbreeding of Tead1-Flag-HATg/+ transgenic 
mice with XMLC2-Cre mice (genotype: XMLC2-Cre::Tead1-Flag-HATg/+). The 
XMLC2-Cre::Tead1-Flag-HATg/+ allele were used as heterozygous in all 
experimental studies.  
 
Table 3. List of primers used for mouse cloning experiments 
Name Sequence 
pBigT-
rev1 
5’-AGTTTGTCCTCAACCGCGAG-3’ 
pBigT-
for1 
5’-TGGGAAGACAATAGCAGGCA-3’ 
Flag-HA-
for 5’-CTCTTAATTAAGGATCCAATATACTCGAGGACTACAAGGACGACGATGA-3’ 
Flag-HA-
rev 5’-GAGGGCGCGCCCTAGGCGTAGTCGGGCACGT-3’ 
 
2.2 Genotyping of mice 
2.2.1 Extraction of genomic DNA from mouse tail biopsies 
The mouse-tail biopsies were digested in 500 µL TENS-buffer (Table 17) with 5 
µL Proteinase K (10 mg/mL Proteinase K; Roth) overnight at 56°C. After complete 
digestion, the samples were centrifuged (Centrifuge 5417R, Centrifuge 5430 - 
Eppendorf) at 14000 rpm for 5 minutes. Thereafter, each supernatant was 
transferred to a new 1.5 mL tube containing 500 μL 100 % Isopropanol and 
vortexed. After another 10 minutes centrifugation step (14000 rpm), the pellets 
containing genomic DNA were washed with 70 % Ethanol (EtOH) for 5 minutes 
at 14000 rpm. Finally, the dried DNA pellets were dissolved in 300 μL sterile TE-
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Buffer (Table 17) for 3h at 56 °C. The tail DNA was then ready to use for 
genotyping PCRs with self-designed primers (listed in Table 4) using appropriate 
cycling conditions (2.2.2).  
 
2.2.2 Genotyping Polymerase Chain Reaction (PCR)   
The genotyping of distinct mouse strains was performed on extracted genomic 
tail DNA (2.2.1) using corresponding primer combinations (Table 4) either with a 
homemade Taq-mix or with the REDTaq® ReadyMix™ PCR Reaction Mix 
(Sigma-Aldrich, R2523).  
The master mix using a homemade Taq-Polymerase for one PCR reaction was 
prepared as followed: 
Components Concentration 
10 x PCR buffer 1 x 
MgCl2 1.5 mmol/L 
Primer-for 0.2 µmol/L 
Primer-rev 0.2 µmol/L 
dNTP 0.2 mmol/L  
Taq-Polymerase 1.25 U 
dd. H2O up to 25 µL 
 
Table 4. List of primers used for genotyping-PCR and corresponding PCR-product 
sizes. WT -wild-type allel, TG – transgenic allel, bp – base pair 
Gene 
name Name Sequence 
Product 
size (bp) 
Tead1 Tead1-LoxP-for 
Tead1-LoxP-rev 
5’-GCAGTGGTCACTGGCTCACT-3’ 
5’-GCTCTTATGTCTGAACACAGGT-3’ 
WT - 340 
TG – 370 
Cre Cre61-for 
Cre63-rev 
5’-GACCAGGTTCGTTCACTCATGG-3’ 
5’-AGGCTAAGTGCCTTCTCTACAC-3’ TG – 250 
SRY  
SRY-for 
SR Y-rev 
5’-TTGTCTAGAGAGCATGGAGGGCCATGTCAA-3’ 
5’-CCACTCCTCTGTGACACTTTAGCCCTCCGA-3’ 273 
RosaCAGG 
AS2645-for 
AS2648-rev1 
AS2427-rev2 
5’-CTTGCTCTCCCAAAGTCGCTCTGAG-3’ 
5’-CTTTAAGCCTGCCCAGAAGACTCCC-3’ 
5’-ACCGTAAGTTATGTAACGCGGAACTCC-3’ 
WT - 249 
TG – 325 
MCM-Cre MCM-for 
MCM-rev 
5’-CAA CAT GAA ATG CAA GAA CG-3’  
5’-GGA AAC CAT TTC CGG TTA TTC-3’ TG - 400  
 
Material and methods 
 20 
PCRs were performed in a Thermocycler (Mastercycler Nexus – Eppendorf, 
Labcycler – Sensoquest) at a cycle program corresponding to the PCR 
conditions. The PCR products were loaded on a 1 – 2% agarose gel (LE Agarose, 
Biozym, 840004) and separated in TAE (Tris-acetate- EDTA) buffer (Table 17) at 
100 – 180 mV (Power Supply: E455 – Consort, Power Pack P25 T – Biometra, 
T100 Thermal Cycler – Biorad). Gel documentation was performed with a UV 
light and gel documentation device (BioDocAnalyze - Biometra).  
 
The following Thermocycler conditions were used for the genotyping of:  
 
Tead1: 
Steps Temperature (°C) time Repeat 
1. Initialization  94 3 min  
2. Denaturation 94 30 sec Step 2 to 4 
35 times 3. Annealing  60 30 sec 
4. Elongation 72 30 sec 
5. Final elongation 72 5 min  
6. Final hold 12 ∞  
 
MCK-Cre, XMLC2-Cre, MCM-Cre: 
Steps Temperature (°C) time repeat 
1. Initialization  94 3 min  
2. Denaturation 94 30 sec Step 2 to 4 
36 times 3. Annealing  55 30 sec 
4. Elongation 72 30 sec 
5. Final elongation 72 5 min  
6. Final hold 12 ∞  
 
RosaCAGG: 
Steps Temperature (°C) time repeat 
1. Initialization  94 3 min  
2. Denaturation 94 30 sec Step 2 to 4 
36 times 3. Annealing  57 30 sec 
4. Elongation 72 30 sec 
5. Final elongation 72 5 min  
6. Final hold 12 ∞  
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SRY: 
Steps Temperature (°C) time repeat 
1. Initialization  94 3 min  
2. Denaturation 94 30 sec Step 2 to 4 
34 times 3. Annealing  58 30 sec 
4. Elongation 72 40 sec 
5. Final elongation 72 5 min  
6. Final hold 12 ∞  
 
2.3 Cloning and preparation of plasmid DNA 
2.3.1 Generation of Tead1-GFP and Tead1-Flag-HA expression constructs 
Expression constructs containing TEAD1 tagged either by GFP or Flag-HA were 
obtained by using a pCAGIPuroxPA-vector containing ampicillin and puromycin 
resistance cassettes (Figure 7).  
 
 
Figure 7. Scheme of the pCAGIPuroxPA-vector containing ampicillin and 
puromycin resistance cassettes. Left panel: Puromycin resistance cassette is located 
on 3´-end of IRES element (pink). Gene of interest (Tead1-X in green) is subcloned into 
pCAGIPuroxPA-vector via AscI and Pac1 restriction sites. Right panel: Schematic 
drawing of the insert encoding Tead1 tagged either with GFP (X) or Flag-HA (X) 
containing Pac1, Sla1 and AscI restriction sites. X = GFP or Flag-HA 
 
The sequence of murine Tead1 was amplified using specific primers containing 
on the 5’-end the Pac1 and on the 3’-end the Sla1 restrictions sides. The Tead1 
amplicon was than ligated by using T4-DNA-Ligase (Promega, M1801) with 
amplified either FGP- or Flag-HA-tag containing on the 5’-end the Sla1 and on 
the 3’-end the AscI restrictions sides at 16°C overnight. Thereafter, the inserts 
containing Tead1 tagged either by GFP or Flag-HA were subcloned in PacI and 
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AscI sites of the pCAGIPuroxPA vector by using T4-DNA-Ligase (Promega, 
M1801) overnight by 16 °C in molar ration vector-to-insert as followed: 
 𝑉𝑒𝑐𝑡𝑜𝑟	(𝑛𝑔) ∙ 𝐼𝑛𝑠𝑒𝑟𝑡	𝑠𝑖𝑧𝑒(𝑘𝑏)𝑉𝑒𝑐𝑡𝑜𝑟𝑠𝑖𝑧𝑒	(𝑘𝑏) 	 ∙ 𝑀𝑜𝑙𝑎𝑟	𝑟𝑎𝑡𝑖𝑜 𝐼𝑛𝑠𝑒𝑟𝑡	(3)𝑉𝑒𝑐𝑡𝑜𝑟	(1) = 𝑛𝑔	𝐼𝑛𝑠𝑒𝑟𝑡 
 
The ligation reaction was prepared as followed: 
Components Volume 
DNA (Insert) x µL 
2 x Ligation-Puffer 5 µL 
pCAGIPuroxPA (Vector) 1 µL 
T4 DNA-Ligase 1 µL 
Total 10 µL  
 
Table 5. List of primers used for cloning 
Name Sequence 
TEAD1-GFP-
for 
5’-CTCTTAATTAACGTCCACCATGGAAAGGATGAGCGACTC-3’ 
TEAD1-GFP-
rev 
5’-GAGGGCGCGCCTTACTTGTACAGCTCGTCCATG-3’ 
Flag-HA-for 5’-CTCTTAATTAAGGATCCAATATACTCGAGGACTACAAGGACGACGATGA-3’ 
Flag-HA-rev 5’-GAGGGCGCGCCCTAGGCGTAGTCGGGCACGT-3’ 
 
2.3.2 Preparation of electrocompetent bacteria 
One XL1 blue E. coli colony was placed in Erlenmeyer flask containing 50 mL 
lysogeny broth medium (LB-Medium (Lennox) - Roth, X964.2) without antibiotics 
and incubated for 16-18 hours (h) at 37°C and 220 rpm, overnight. Next, 3-4 mL 
of this culture were transferred to 200 mL LB-medium in a new Erlenmeyer flask 
and incubated by 37°C at 220 rpm. During incubation the optical density (OD) of 
culture was constantly measured in order to reach the value of 0.5 - 0.6 indicating 
the exponential growth phase of bacteria. Bacterial cultures with optimal OD were 
transferred to 200 mL centrifuge tubes and cooled down on ice for 30 min. 
Thereafter, the precooled cultures were centrifuged (Sorvall Evolution RC) for 15 
min, at 0°C and 3500 rpm. After centrifugation the supernatants were discarded, 
pellets were gently resuspended in 200 mL of ice-cold sterile water each on ice 
and centrifuged again. The wash step in 200 mL of ice-cold sterile water was 
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repeated two times more. After the third wash step, pellets were gently 
resuspended in 40 mL of ice-cold sterile 10 % glycerol (10 % glycerol / 90 % 
sterile water), transferred in a precooled 50 mL centrifuge tube and centrifuged 
at 0°C, 6000 rpm for 20 min. After centrifugation the supernatant was discarded, 
pellets were gently resuspended in 2 mL ice-cold 10 % glycerol and aliquoted á 
50 µL in precooled 1.5 mL centrifuge tubes. The aliquots were snap frozen in 
liquid nitrogen and stored at -80°C. 
 
2.3.3 Transformation of electrocompetent bacteria with plasmid DNA  
The amplification of plasmids was performed by means of bringing a foreign DNA 
into bacterial microorganisms. For this purpose, electrocompetent XL1 blue E. 
coli bacteria (see: 2.3.2), were transformed by electroporation with an 
electroporator (Gene PulserTM– Bio-Rad). At first, a 50 μL of XL1blue bacteria 
stock was diluted with an appropriate amount of pre-cooled sterile H2O (maximum 
500 μL) and 100 μL of this bacterial dilution was transferred into a pre-cooled 
electroporation cuvette (Electroporation Cuvettes, blue cap – Peqlab, 71-2020). 
Thereafter, 250 ng – 1 μg of plasmid DNA was added and the cuvettes were 
subjected to electroporation. Sterile H2O instead of plasmid DNA served as the 
transformation control. The electroporation was performed at 2.5 kV for 4.6 to 4.7 
ms. The electroporated bacteria were resuspended in 400 μL cold LB-medium 
(LB-Medium (Lennox) - Roth, X964.2) without antibiotics and incubated at 37°C 
on a heating block (Thermo Mixer F 1.5 - Eppendorf) for 30 min. Thereafter the 
bacteria suspension was transferred and uniformly distributed to antibiotic 
containing (50-100 μg e.g. Ampicillin, Amp) agar dishes (LB-Agar (Lennox) – 
Roth, X965.2). Finally, the agar dishes were dried and placed in a bacteria 
incubator (Heraeus, 26126010) at 37°C overnight. 
 
2.3.4 Preparation of plasmid DNA  
Successfully transformed bacteria with the plasmid DNA of interest (see: 2.3.3), 
formed colonies on the Amp-agar dish. Thereafter, the colonies were picked with 
a sterile pipet tip, placed in a glass tube containing 2 mL LB-Amp and then 
incubated at 37°C in a bacteria shaker (Innova® 44 Incubator Shaker Series – 
New Brunswick Scientific) overnight. For mini-DNA preparation, the bacteria 
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suspension was transferred in a 1.5 mL tube and centrifuged at 14000 rpm for 3 
minutes. After removing the supernatant, the pelleted bacteria were resuspended 
in 150 µL ice-cold Buffer I. Then, 200 µL Buffer II was added and the samples 
were inverted several times to mix both buffers and incubated at room 
temperature (RT) for 5 minutes. After incubation, 200 µL Buffer III was added and 
samples were centrifuged for 20 minutes at 14000 rpm. Following centrifugation, 
for DNA precipitation the supernatant was transferred to a new 1.5 mL tube 
containing 400 µL Isopropanol (Roth; 6752.4) and well shacked. The mixed 
samples were centrifuged for 10 minutes at 14000 rpm. Following supernatant 
removal, the pellets were washed with 500 µL 70 % EtOH (Roth; 9065.4) at 14000 
rpm for 5 minutes. Afterwards the DNA-palettes were air-dried and resuspended 
in 100 µL TE-buffer (Table 17) supplemented with 10 μg RNaseA. Finally, the 
isolated DNA was validated by restriction enzyme digest, which was controlled 
on a 1% agarose gel and sequenced with corresponding primers. 
High amounts of Plasmid-DNA were obtained using a commercially obtained 
NucleoBond® Xtra Maxi-kit (Macherey-Nagel; 740414) in accordance to the 
manufacturer’s instructions. The DNA purity and concentration were measured 
in a spectrophotometer (NanoDrop® ND-2000c - Peqlab)  
 
2.4 Cell culture  
2.4.1 Human Embryonic Kidney Cells (HEK 293T) 
Human Embryonic Kidney Cells (HEK 293T) were cultured in medium (Table 8) 
containing DMEM/10%FCS/1% PSG (1 x Dulbecco’s Modified Eagle Medium 
(DMEM 4.5 g/L D-Glucose – Gibco, 42430-025). The cells were passaged every 
2nd day, followed by washing the cells and incubating them for 2 min with 1 x 
Trypsin-EDTA (Sigma; T4174) in PBS. After complete cell detachment, trypsin 
activity was stopped with a cell medium containing FCS. Cell suspension was 
transferred into a 15 mL centrifugation tube and pelleted at 1000 rpm, RT in the 
centrifuge (Universal 320R; Hettich Zentrifugen). After centrifugation, the 
supernatant was discarded and the pellet was resuspended in an appropriate 
amount of medium and seeded to a culture dish at a density of 2 x 105 cells/100 
mm.  
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2.4.2 Transfection of HEK 293T  
For the transfection of HEK293T cells with expression constructs, a TurboFectTM 
Transfection Reagent (ThermoFisher Scientific, R053) was used according to the 
supplier’s protocol. 
 
2.4.3 Luciferase Reporter Assay 
HEK 293T cells were plated on a 48 well plate and next day were transfected 
with 4 x MCAT-Luc, VGLL-2 (kindly provided by Dr. Stefan Günther [84]) and 
TEAD1, TEAD1-GFP, TEAD1-Flag-HA constructs (Table 6) using TurboFect 
(ThermoFisher scientific; R0531) according to the manufacturer’s protocol. Two 
days after transfection, HEK 293T cells were prepared for Luciferase Reporter 
Assay processed with Dual-LuciferaseÒ Reporter 1000 Assay Systems 
(Promega; E1980) according to the supplier’s protocol. The bioluminescence was 
measured in Multimode Microplate Reader (Mithras LB 940 - Berthold 
Technologies). Untransfected HEK 293T cells were used as a control.  
 
Table 6. List of constructs used in Luciferase Reporter Assay 
Plasmid name Insert Cloning vector 
4 x MCAT-Luc [84] 4 MCAT repeats (CATTCCA) pTa-Luc 
VGLL-2 (VITO1) [84] Complete Vito-1 orf pCS2 MT 
TEAD1 Complete Tead1 orf pCAGIPuroxPA 
TEAD1-GFP Complete Tead1 with N-terminal GFP tag pCAGIPuroxPA 
TEAD1-Flag-HA Complete Tead1 with N-terminal Flag-HA tag pCAGIPuroxPA 
 
2.4.4 Isolation of early postnatal mouse cardiomyocytes  
In order to isolate early postnatal mouse cardiomyocytes (PCMs), 2-3 days old 
postnatal mice (P2-P3) were rinsed quickly with 70% EtOH to sterilize the skin. 
Pups were quickly sacrificed using sterile scissors and the chest was opened 
along the sternum to allow the access to the heart. The hearts were prepared 
with Dumont forceps (#7 curved tip, F.S.T., 11272-30) and directly transferred to 
a new bacterial dish containing PBS on ice. The surrounded heart tissues (lung, 
big vessels) were removed with Vannas Spring Scissors (straight, sharp tip, 
F.S.T., 15018-10) and transferred to a 2 mL tube containing ice-cold PBS. 
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Cardiac cell dissociation was performed using the Neonatal Heart Dissociations 
Kit (Miltenyi Biotec; 130-098-373) and gentleMACS Octo Dissociator with 
Heaters (Miltenyi Biotec; 130-096-427) according to the manufacture’s protocol. 
After dissociation, the cardiomyocyte cell fraction was isolated using a mouse 
Neonatal Cardiomyocyte Isolation Kit (Miltenyi Biotec; 130-100-825) according to 
the manufacture’s protocol. Both protocols are available at 
www.miltenyibiotec.com. 
Freshly isolated cardiomyocytes were used either directly for RNA and protein 
extraction or cultured for further experiments. Another set of freshly isolated 
cardiomyocytes was gently resuspended in DMEM, supplemented with 5 % FCS 
and 1 % L-glutamine-penicillin-streptomycin (P/S/G) (Table 8), and seeded on a 
precoated with 10 % fibronectin (PromoCell; C-43050) cell culture dish at the 
density of 1.5 x 105 cells per cm2. Cardiomyocytes were maintained at 37°C and 
5 % CO2. 
 
2.4.5 Adenoviral transduction of cultured early postnatal mouse 
cardiomyocytes (P2-P3) 
The required multiplicity of infection (MOI) was calculated using the titer of 
adenoviral solution (Cre Recombinase Adenovirus (Ad-CMV-iCre), titer 1x10^10 
PFU/mL - VECTOR BIOLABS, 1045N) and formula: 
 𝑃𝑙𝑎𝑞𝑢𝑒	𝑓𝑜𝑟𝑚𝑖𝑛𝑔	𝑢𝑛𝑖𝑡𝑠	(𝑃𝐹𝑈)𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐𝑒𝑙𝑙𝑠 	= 𝑀𝑂𝐼 
 
The calculated amount of virus solution was added to culture dishes with 
cardiomyocytes and kept for 6 h in a 5 % CO2 incubator at 37 °C. After incubation, 
the medium containing virus was removed, cardiomyocytes were washed with 
PBS to completely remove virus particles and further maintained in culture in 
fresh medium (Table 8). Cultured cells were monitored with Live-Cell Analysis 
System (IncuCyte®, Essenbioscience). Extraction of RNA and proteins was 
performed 4 days after viral transduction.   
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2.4.6 Isolation of adult mouse cardiomyocytes  
Adult cardiomyocytes were isolated from 8 weeks old male mice. The animals 
were anesthetized by intraperitoneal (i.p.) injection of Buprenorphine/Ketamine 
in 0.9 % NaCl with 0.2 mL heparin (Braun, 1708.00.00) to prevent blood clotting. 
The chest was rinsed with 70 % EtOH and opened along the sternum to allow 
access to the heart. The heart with parts of the lungs was prepared and 
transferred into Petri dish filled with PBS. The lung tissue was removed and the 
aorta was cut below the aortic arch. Thereafter, the heart was connected to a 
Langendorff perfusion system and perfused with 15 mL of Ca2+-free buffer (Table 
17) as previously described [113, 114]. Then the heart was perfused with an 
Enzyme-Buffer containing Liberase und Trypsin (Table 17) for 30 min. After 
perfusion the heart was removed from the cannula, the ventricles were dissected 
from the atria and transferred to a new Petri dish containing 5 mL Stop-Buffer 1 
(Table 17). The ventricles were carefully cut into small pieces using forceps and 
transferred to a 50 mL tube for centrifugation at 300 rpm for 3 minutes. The 
supernatant was transferred to a 15 mL tube and centrifuged at 300 rpm for 1 
minute. The pellets from both, 50 mL and 15 mL centrifugation tubes were 
combined and resuspended in 10 mL Stop-Buffer 2 (Table 17). Cell suspensions 
were passed through a 100 µm cell strainer to a new 50 mL centrifugation tube. 
Thereafter Ca2+ concentration was adjusted up to 1 mmol/L in 5 steps every 4 
min. After adjustment of Ca2+ concentration, the cell suspension was centrifuged 
at 300 rpm for 1 min and the supernatant was discarded. Freshly isolated 
cardiomyocytes were used either directly for RNA and protein extraction or for 
cell culture. For the latter experiments, freshly isolated cardiomyocytes were 
seeded on pre-coated with laminin (10 µg/µL laminin in MEM media) cell culture 
dishes and cultured in 5 % CO2 in incubator at 37°C. After firm cardiomyocyte 
attachment to the culture substrate (2-3 h), the medium was replaced by freshly 
prepared medium (Table 8) to remove cell debris and non-cardiomyocytes.   
 
2.4.7 Isolation of adult rat cardiomyocytes  
The chest of anesthetized (Buprenorphine/Ketamine in 0.9 % NaCl, i.p.) 10 
weeks old adult male rat (Sprague–Dawley rat) was rinsed with 70 % EtOH and 
opened along the sternum to allow the access to the heart. The heart with parts 
of lung tissue was prepared and transferred into a Petri dish filled with PBS (Table 
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17). The lung tissue was removed and the aorta was resected below the aortic 
arch. Adult rat cardiomyocytes were isolated as described by Lorchner et al. 
[115]. Briefly, the aorta was connected to a Langendorff perfusion system and 
the heart was perfused with Krebs-Henseleit bicarbonate buffer (Table 17) 
constantly mixed with 95 % O2 and 5 % CO2 at 37°C for 8 min. Thereafter, 0.04 
% collagenase II (Worthington; LS004176) and 40 µmol/L Ca2+ (Roth; 5239.2) 
were added to the Perfusion Buffer and further perfused of 30 min. After perfusion 
the ventricles were carefully cut into small pieces using forceps in the same 
collagenase solution containing 1.25 % fatty acid-free albumin (BSA - Sigma; 
A8806). Dissociated heart cells were washed with increasing calcium 
concentration of 0.2 and 0.5 mmol/L at 200 rpm for 3 min. Next, cardiomyocytes 
were sedimented using MEM media with 4 % BSA and 1 mmol/L Ca2+ followed 
by centrifugation at 200 rpm for 1 min. The cell pellet consisting mostly of 
cardiomyocytes was resuspended in the Cell Medium (Table 8). The 
cardiomyocytes were seeded on precoated with laminin (10 µg/mL, Sigma; # 
L2020) 24 well cell culture plates at the density of 1.5 x 104 cells/cm2. Two hours 
later, the medium was replaced by 2 % fetal bovine serum (FBS - Sigma, F6178) 
containing medium and cultured for two days. The medium was changed every 
second day.  
 
2.4.8 FGF2 stimulation of cultured adult rat cardiomyocytes 
To study the effects of FGF2 stimulation on TEAD1 in cultured adult rat 
cardiomyocytes, freshly isolated adult rat cardiomyocytes were cultured for two 
days in medium (Table 8) containing 2 % FBS (Sigma; F6178). On the 3rd day, 
either FGF2 (Recombinant Human FGF-basic - ReproTech; 100-1813) at 
concentration of 50 ng/mL for stimulation, or BSA (Sigma, A8806), as a control, 
were added to the culture medium and were replaced every second day. 
 
2.4.9 SiRNA knockdown in cultured adult rat cardiomyocytes 
To study the effects of the impairment in FGF2-FGFR1 pathway and of TEAD 
TFs deficiency in cultured adult rat cardiomyocytes, siRNA mediated knockdown 
(KD) experiments were performed. For this purpose, cultured adult rat 
cardiomyocytes were transfected with 0.5 µmol/L of appropriate siRNA (Table 7) 
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per well using DharmaFECT 2 transfection reagent (Dharmacon; T-2002-01) 
according to the manufacturer’s instruction. FGF2-stimulation (2.4.8) was started 
2 days after siRNA-mediated KD.  
 
Table 7. List of siRNAs used in this study 
siRNA Company Catalog No. 
ON-TARGETplus Rat Tead1 
siRNA- SMARTpool Dharmacon (GE Healthcare) L-083793-00-0005 
ON-TARGETplus Rat Tead2 
siRNA-SMARTpool Dharmacon (GE Healthcare) L-082568-02-0005 
ON-TARGETplus Rat Tead3 
siRNA-SMARTpool Dharmacon (GE Healthcare) L-094426-02-0005 
ON-TARGETplus Rat Tead4 
siRNA-SMARTpool Dharmacon (GE Healthcare) L-107973-01-0005 
ON-TARGETplus Rat Fgfr1 
siRNA- SMARTpool Dharmacon (GE Healthcare) L-095313-02-0005 
ON-TARGETplus Non-
targeting Control Pool  Dharmacon (GE Healthcare) D-001810-10-20  
 
 
Table 8. Components of cell culture media 
Medium Composition 
HEK 293T cell culture medium 
DMEM with 4.5 g glucose supplemented with 10 % 
FBS; 100 u/mL Penicillin; 0.1 mg/mL Streptomycin; 
2 mmol/L Glutamine 
Early postnatal cardiomyocyte 
culture medium (P2-P3) 
DMEM with 4.5 g glucose supplemented with 5 % 
FBS; 100 u/mL Penicillin; 0.1 mg/mL Streptomycin; 
2 mmol/L Glutamine 
Adult mouse cardiomyocyte 
culture medium (pH 7.4) 
M 199 (Earle’s salt) supplemented with 5 mmol/L 
creatinine x H2O; 2 mmol/L L-carnitine x HCl; 5 
mmol/L taurine; 25 mmol/L HEPES; 100 U/mL 
penicillin; 100 µg streptomycin; 10 % FCS (Insulin, 
Transferrin, Selenium supplements) 
Adult rat cardiomyocyte culture 
medium 
M 199 medium supplemented with 25 mmol/L 
HEPES; 25 mmol/L NaHCO3; 100 U/mL penicillin; 
100 µg streptomycin; 2 mmol/L L-carnitine; 5 
mmol/L creatine; 5 mmol/L taurine 
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2.5 RNA preparation and cDNA synthesis 
2.5.1 RNA preparation with peqGold® TriFast™ reagent         
In order to isolate RNA of mouse heart tissue, the isolated hearts were perfused 
with PBS and then snap frozen in liquid nitrogen. The frozen hearts were either 
stored at -80°C until use or directly placed in 2 mL tubes, resuspended in 1 mL 
of peqGold® TriFast™ reagent (VWR Peqlab; 30-2010) with a help of 1 sterile 
grinding ball (grinding balls ss 5 mm – Retsch, 22.455.0003) in a tissue 
homogenizer (Retsch, MM301) for 5 min with frequency of 30/s. After 
homogenization, cell debris were removed via centrifugation at 14 000 rpm for 5 
min and the supernatant was transferred to a new 1.5 mL tube. Further RNA 
isolation was proceeded following the manufacturer’s instruction. The final RNA 
pellets were fully dissolved in in 20-40 µL of RNase free water or TE Buffer (TE 
buffer pH 7.0 - Ambion; AM9860) and stored at –80°C until further use. The RNA 
concentration of the purified RNA samples was measured with a 
spectrophotometer (NanoDrop ND-2000c Spectrophotometer - Peqlab). and 0.5 
– 2 μg of RNA were used for the synthesis (2.5.2). 
To isolate RNA from cells, the cultures were first washed with PBS (Table 17) 
and then 1mL peqGold® TriFast™ reagent per 5-10 x 106 cells was directly added 
to the dish and incubated for 1 min at RT. Thereafter cells were harvested using 
cell scraper (Sarstedt, 83.1830), transferred to a fresh 1.5 mL tube and 
resuspended by gentle pipetting. Samples obtained from cultured cells were 
further processed for RNA isolation using a protocol identical to that of heart 
tissue. 
 
2.5.2 Complimentary DNA (cDNA) synthesis 
In order to perform relative quantitation of RNA expression levels (qRT-PCR, 
2.6), cDNA was synthesized. Therefore, 1 μg RNA was reverse transcribed to 
cDNA using the SuperScriptTM II Reverse Transcriptase (Table 19) according to 
the manufacture protocol as followed:  
Volume  Components 
X µL (1 µg) RNA 
1 µL Oligo(dT)15 Primer (Promega; C110A) 
1 µL dNTP (Fermentas; R0186) 
10 – x µL MilliQ H2O 
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Reactions were adjusted to 65°C for 5 min and after cooling down, 8 µL of 
synthesis mixture were added. 
 
Synthesis mixture setup: 
Volume  Components 
4 µL 5 X first strand buffer (Invitrogen; P/N y02321) 
2 µL 0,1 M DTT (Invitrogen; P/N y00147) 
1 µL RNasin RNase Inhibitor (Promega; N261B) 
1 µL SuperScript®II reverse transcriptase (Invitrogen; P/N 100004925) 
 
Reactions were adjusted to 42°C for 50 min and further to 70°C for 15 min. After 
cooling down, 1 µL of RNaseH (Promega; M428C) per reaction was added and 
kept at 37°C for 20 min. After synthesis, cDNA was stored at -80°C until further 
use. 
 
2.6 Quantitative real-time polymerase chain reaction using 
TaqMan® Gene Expression Assays  
In order to perform quantitative real-time polymerase chain reaction (qRT-PCR), 
the synthesized cDNA (2.5.2) was diluted 1:100 with MilliQ H2O for use in 
TaqMan® Gene Expression Assays (Applied Biosystems) using specific TaqMan 
probes (Table 9) on a StepOnePlus Real-Time PCR System. 
 
The master mix for one qRT-PCR reaction was prepared as followed: 
Volume  Components 
0.5 µL Specific TaqMan Gene Expression Assay (20x) 
0.5 µL GAPDH TaqMan Gene Expression Assay (20x) 
5 µL TaqMan Gene Expression Master Mix (2x) 
4 µL cDNA Template (1-100 ng) 
 
Thermocycler condition were used as followed: 
Steps Temperature (°C) Time  Number of cycles 
1 50 2 min  
2 95 10 min  
1 95 15 sec 40x 
2 60 1 min 
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Each sample was examined in triplicates. The quantitation was performed using 
a qPCR thermocycler (Step OnePlus Real-Time PCR Cycler – Applied 
Biosystems). The calculated fold changes (RQ-values) of the examined samples 
were based on their ∆∆Ct values normalized to Gapdh, as an internal 
housekeeping control, using a Step One Software (StepOneTM Software v2.3). 
 
Table 9. List of specific TaqMan Gene Expression Assay (20x) 
Gene Assay Dye Species 
Tead1 Mm01271498_m1 FAM mouse 
Crhr2 Mm00438303_m1 FAM mouse 
Acta2 Mm00725412_s1 FAM mouse 
Myocd Mm01325105_m1 FAM mouse 
Myh7 Mm00600555_m1 FAM mouse 
Mylk4 Mm01161239_m1 FAM mouse 
Coro6 Mm01241331_m1 FAM mouse 
GAPDH mm999999915_g1 VIC mouse 
 
2.7 Microarray analysis and Gene Set Enrichment Analysis 
(GSEA)  
For microarray analysis, the total RNA was extracted from isolated 
cardiomyocytes using RNA isolation kit (Direct-zol™ RNA MiniPrep - Zumo 
research, R2050). For this purpose, the cardiomyocytes were lysed in 600 µL (for 
up to 5 x 106 cells) TRI Reagent (Zumo research, R2050-1-50) and the extraction 
was processed following the manufacturer’s instructions. The quality of extracted 
RNA was verified with RNA 6000 Nano Kit on an Agilent 2100 Bioanalyzer. RNA 
was labeled accordingly to the Affymetrix Whole Transcript Sense Target 
Labeling protocol and hybridized to Affymetrix ClariomTM D assays. The data 
were processed and analyzed by RMA algorithm using the Affymetrix Expression 
Console. The statistical analysis was performed using DNAStar Arraystar 11 to 
calculate FC values in combination with students t- test of log2-transformed data 
to identify significantly differentially expressed transcripts [116].  
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The functional gene set enrichment analysis of microarray data in this study was 
performed and visualized using GSEA software (available on 
http://software.broadinstitute.org/gsea/index.jsp [117]). GraphPad Prism 6 was 
used to generate the heat maps and graph bars. 
 
2.8 Protein extraction and immunoblot analysis 
2.8.1 Protein extraction from cultured cells and tissue samples  
Protein extraction from cultured cells was performed using EB/LB-Buffer (Table 
17) supplemented with protease inhibitors (Table 21) to homogenize the 
samples. For this purpose, the cultured cells were washed with PBS (Table 17) 
and harvested with a cell scraper (Sarstedt, 83.1830) after adding EB/LB-Buffer 
(1 mL per one confluent 10 cm dish) directly to the dish. After transfer to a fresh 
1.5 mL tube, the samples were resuspended by gentle pipetting and 
homogenized with a sonicator (Sonicator - Bandelin Sonopuls, HD2070). After 
sonication, the protein homogenates were centrifuged at 14000 rpm for 5 min at 
RT to remove debris. The supernatant containing pure protein lysate was then 
transferred to a fresh 1.5 mL tube and the protein concentration was measured 
using Bradford Method (2.8.2). Protein lysates were diluted to a concentration of 
1-2 µg/µL with a corresponding lysis buffer, denatured by supplementation of 1 
mol/L DTT (4 μL per 100 μL sample) and subsequent heating up to 99°C for 2 
min and stored at –20°C until further use.  
Protein extraction from isolated mouse hearts was performed using Extraction 
Buffer (EB Buffer; Table 17) supplemented with protease inhibitors (Table 21) to 
homogenize the samples. For this purpose, the frozen mouse heart tissues were 
sonified and centrifuged at 14000 rpm for 5 min to remove debris. The 
supernatant containing pure protein lysate was then transferred to a fresh 1.5 mL 
tube and protein concentration was measured using Bradford Method (2.8.2). 
Samples obtained from heart tissue were further processed identical to those of 
cells.   
 
2.8.2 Determination of protein concentration with Bradford Method 
The determination of protein concentration was performed using DC™ 
ProteinAssay (BioRad; Reagent A - 500-0113; Reagent B - 500-0114) in 96 well 
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plate (Microplate - Greiner-Bio-One, 655101) according to the manufacturer’s 
instruction and measured on Microplate reader (FLUOstar Galaxy - BMG). A 
blank (only lysis buffer) and a BSA protein standard row (BSA dilution series: 1, 
5, 10, 20, 30 μg; 100x BSA – NEB, B9001S) was used for calibration. All samples 
were prepared in duplicates. The protein concentrations were calculated based 
on the standard regression curve in an Excel sheet. 
 
2.8.3 Polyacrylamide gel electrophoresis (PAGE) 
Western Blot technique was employed to analyze proteins, which were loaded in 
equal amounts (10 – 15 μg per well) on a self-made polyacrylamide gel (Table 
10). The gels were filled in a purchased NOVEX® Cassettes (1 mm – Invitrogen, 
NC2010) to perform a separation of the proteins by their mass via 
electrophoresis. The electrophoresis was performed in a gel running chamber 
(NOVEX® Electrophoresis Mini-Cell - Invitrogen, EI001) at separation time of 1.5 
– 2 h using MES running buffer (Table 17). For a better separation, the running 
buffer was supplemented with 5 mmol/L sodium bisulfite (1 mol/L sodium 
bisulfite). The protein mass was detected by using the Protein-Marker VI (Peqlab, 
27-2311). After electrophoresis, the immunoblotting was processed (2.8.4). 
 
Table 10. Composition of gel electrophoresis 9 % Bis-Tris Polyacrylamid gel (PAA) 
Separation gel:  9% 
 Rotiphorese® Gel 30 (37.5:1) (Roth, 3029.1) 2.1 mL  
3.5 x bis-Tris pH 6.5 – 6.8  2 mL  
Milli-Q H2O  2.9 mL  
10 % Ammoniumperoxodisulfat (APS – Merck, 1.01201)  25 μL 
TEMED (Roth, 2367.1)  7 μL 
Stacking gel:  5% 
Rotiphorese® Gel 30 (37.5:1) (Roth, 3029.1)  0.29 mL  
3.5 x bis-Tris pH 6.5 – 6.8  0.5 mL  
Milli-Q H2O  0.96 mL  
10 % Ammoniumperoxodisulfat (APS – Merck, 1.01201) 8 μL 
TEMED  3 μL 
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2.8.4 Western Blot Analysis (protein immunoblotting) 
For Western Blot analysis, the proteins were transferred from a polyacrylamide 
gel to a nitrocellulose membrane (AmershamTM ProtranTM 0.45 μm NC - GE 
Healthcare, 10600002). The protein transfer was performed using Transfer Buffer 
(Table 17) and blotting time of 2 h at 30 mV (Power Pac 200 – Bio-Rad) in a 
blotting chamber (NOVEX® X Cell IIä Blot Module - Invitrogen; EI9051). To 
visualize transferred proteins, the membrane was stained with 1x Red Alert 
(dilution of 10 x RedAlert™ Western Blot Stain – Millipore, 71078-50ML) for 10 
min on a shaker (Rotamax120 – Heidolph). After documentation, the staining was 
removed by washing with TBST (Table 17) and the unstained membrane was 
blocked in 5 % skimmed milk powder solution (Fluka®, 70166-500G) in TBST 
(Table 17) for 1h at RT. After blocking, the membrane was incubated with primary 
antibodies (Table 11) diluted in 3 % skimmed milk (Table 21) in TBST overnight 
at 4°C. After incubation with a primary antibody, the membrane was washed with 
TBST for 5 min and then incubated with a corresponding secondary antibody 
(Table 12) diluted in 3 % skimmed milk in TBST for 1h at RT. After this step, the 
membrane was washed again with TBST and then treated with Super Signal® 
West Femto Maximum Sensitivity Substrate (Thermo Scientific; 34096), 
according to the manufacturer’s instructions. Then, the membrane was exposed 
to the Chemiluminescence Analyzer (ChemiDoc™ MP Imaging System – 
BioRad, 731BR01764) to detect the protein bands. Densitometry and data 
analysis were performed using Image Lab 5.1 software (Bio-Rad).  
 
Table 11. List of primary antibodies for immunoblotting 
Antibody Source Company Catalog No. Dilution 
Tead1 (D9X2L) rabbit Cell Signaling 12292 1:1000 
antiTEF-1 mouse BD Biosciences 610923 1:1000 
anti HA rat Roche 11867423001 1:1000 
GFP rabbit Abcam ab6556 1:1000 
GAPDH rabbit Cell Signaling 2118 1:1000 
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Table 12. List of secondary antibodies for immunoblotting 
Antibody Source Company Catalog No. Dilution 
anti-Rabbit IgG 
HRP-conjugated goat 
ThermoFisher 
SCIENTIFIC  31460  1:1000 
anti-Rat IgG HRP-
conjugated goat R&D Systems HAF005 1:1000 
anti-Mouse IgG 
HRP-conjugated goat 
ThermoFisher 
SCIENTIFIC  G-21040 1:1000 
 
2.9 Chromatin immunoprecipitation (ChIP) 
In order to analyze the direct binding of TEAD1 in promoter regions of protentional 
target genes, TEAD1 Chromatin Immunoprecipitation (ChIP) experiments were 
performed in early postnatal cardiomyocytes isolated (P2-P3) from wild-type 
mice.  
 
2.9.1 Chromatin shearing using Covaris Focused-Ultrasonicator 
Freshly isolated early postnatal mouse cardiomyocytes (P2-P3) were prepared 
for ChIP using truChIPä Chromatin Shearing Reagent Kit (Covaris, 520154) 
according to the manufacturer’s instructions. In brief, approximately 2 x 107 of 
freshly isolated cardiomyocytes (2.4.4) were washed with PBS, transferred to 1.5 
mL Protein LoBind tubes (Eppendorf, 0030108.116) and fixed in 1 mL Fixing 
Buffer containing 11.1 % formaldehyde (16% Formaldehyde Solution, Methanol 
free - Thermo scientific, 28906) for 5 minutes. The fixation was stopped with 48 
µL Quenching Buffer and washed twice with 1 mL ice-cold DPBS (Gibco, 
14190144). To shear chromatin, the DNA pellets were lysed with 1 mL Lysis 
Buffer for 10 min on a rocker at 4°C. The lysed samples were centrifuged at 1700 
rpm for 5 min and pellets containing nuclei were washed with 1 mL Washing 
Buffer. Thereafter, the samples were shortly centrifuged and equilibrated with 
Shearing Buffer. After equilibration, pellets containing nuclei were resuspended 
in 130 µl Shearing Buffer per 3 x 106 cells and suspensions were transferred to 
microTUBEs (microTUBE AFA Fiber Pre-Slit Snap, Cap 6x16mm (25) – Covaris, 
520045) for shearing by Adaptive Focused AcousticsTM (AFA) in Covaris 
Focused-Ultrasonicator (S220, Covaris) for 10 min using conditions described in 
Covaris protocol. Sheared samples were transferred to 0.5 mL DNA LoBind tubes 
(Eppendorf, 0030108.035) and centrifuged at 4500 rpm for 5 min. Afterwards, 
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supernatants were transferred to new 0.5 mL DNA LoBind tubes and stored at -
80°C for further immunoprecipitation experiments (2.9.3).  
 
2.9.2 Analysis of chromatin shearing efficiency  
For analysis of chromatin shearing efficiency, 25 µL of sheared chromatin was 
treated with 1 µL RNase A (10 mg/mL) at 37°C for 30 min to remove RNA. For 
reverse cross-linking, 1 µL Proteinase K (10 mg/mL) was added and samples 
were incubated overnight at 65°C. After incubation, the probes were purified with 
NucleoSpin Gel and PCR Clean-up kit for SDS containing samples (Macherey-
Nagel, 740609.250) according to the manufacturer’s instructions. The 
concentration of purified DNA was measured with spectrophotometer (NanoDrop 
2000c) and the quality of shearing was analyzed on 2 % agarose gel.  
 
2.9.3 Chromatin Immunoprecipitation (ChIP) 
For ChIP experiments, 20 µL protein A/G magnetic beads (Magna ChIP™ Protein 
A+G Magnetic Beads – Millipore, 16-663) per each immunoprecipitation (IP) 
reaction were used. For this purpose, protein A/G magnetic beads were 
transferred to 0.5 mL DNA LoBind tubes and placed on a magnetic separator 
(MagneSphere® Technology Magnetic Separation Stand (twelve-position) – 
Promega, Z5341) for 30 sec. After separation, the supernatant was discarded 
and the beads were washed with 300 µL Binding/Blocking Buffer (Table 17) and 
placed on magnetic separator again. For coupling magnetic beads to antibodies, 
a solution containing magnetic beads and desired antibodies (Table 13) in 
appropriate amounts in 300 µL Binding/Blocking Buffer (Table 17) was mixed for 
1 h on a rotating wheal at RT. Afterwards, antibody-coupled beads were washed 
in 300 µL Binding/Blocking Buffer (Table 17) and added to 200 µL of sheared 
chromatin (concentration: 50 ng/µL) and incubated at 4°C on a rotating wheal 
overnight. After incubation, IP reactions were placed on a magnetic separator for 
30 sec and supernatant was discarded. The probes were then washed with 400 
µL Low Salt Buffer, 400 µL High Salt Buffer, 400 µL LiCl-Buffer and 400 µL TE 
(Table 17) for 10 min at 4°C each. After the washing steps, beads were dried at 
RT. Then to dried beads was added 50 µL Direct Elution Buffer (Table 17) 
supplemented with 5 µL mixture containing 3 µL Direct Elution Buffer and 2 µL 
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RNase (RNase, DNase free – Roche, 11119915001) per reaction and incubated 
at 37°C for 30 min. In parallel, 20 µL of input sample was adjusted to a total 
volume of 50 µL with Direct Elution Buffer (Table 17) supplemented with 5 µL 
mixture containing 3 µL Direct Elution Buffer and 2 µL RNase and incubated with 
all samples at 37°C for 30 min. For reverse cross-linking, each sample was 
supplemented with 5 µL mixture containing 2.5 µL Proteinase K (Proteinase K 
Solution, RNA Grade – Invitrogen, 25530-049), 1 µL Glycogen (Glycogen for mol. 
biol. – Roche, 10901393001) and 1,5 µL Direct Elution Buffer (Table 17) and 
incubated at 65°C overnight. After incubation, the probes were purified with 
NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel, 740609.250) using NTB 
buffer (Macherey-Nagel, 740595.150) for SDS containing samples according to 
the manufacturer’s instruction. The concentration of purified DNA samples was 
measured on Fluorometer (Qubit® 2.0, Q32866) using a Qubit dsDNA HS Assay 
Kit (ThermoFisher scientific, Q32854) in 0.5 mL Qubit® Assay tubes (Invitrogen, 
Q32856) according to the manufacturer’s instructions. 
 
Table 13. List of antibodies used for chromatin immunoprecipitation 
Antibody Source Company Catalog No. Amount 
Tead1 (D9X2L) rabbit Cell Signaling  12292 5 µg 
H3K9Ac rabbit Abcam Ab10812 5 µg 
ChIPAb+ RNA Pol II - ChIP  mouse MILLIPORE 17-620 5 µg 
Rabbit IgG 
Isotype control rabbit Cell Signaling 2729S 5 µg 
Mouse (G3A1) mAb IgG1 
Isotype control mouse Cell Signaling 5415S 5 µg 
 
2.9.4 ChIP sequencing and analysis  
For ChIP sequencing (seq), 0.5-10ng of DNA was used as input for TruSeq ChIP 
Library Preparation Kit (Illumina) with following modifications. Instead of gel-
based size selection before final PCR step, libraries were size selected by SPRI-
bead based approach after 18 cycles of PCR. For this purpose, the samples were 
purified using 1x bead/1xDNA ratio to eliminate residuals from the PCR reaction, 
followed by 2-sided-bead cleanup step with a 0.6x bead/1xDNA solution to 
exclude larger fragments. The supernatant was transferred to a new tube and 
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incubated with additional beads in a 0.2x bead/1xDNA solution for eliminating 
smaller fragments, such as adapter and primer dimers. Bound DNA samples 
were washed with 80% EtOH, dried and resuspended in TE buffer. Library 
integrity was verified with a BioAnalyzer 2100 (Agilent) or LabChip Gx Touch 24 
(Perkin Elmer). Sequencing was performed on the NextSeq500 instrument 
(Illumina) using v2 chemistry with 1x75bp single end setup.  
The resulting raw reads were assessed for quality, adapter content and 
duplication rates with FastQC (Andrews S. 2010, FastQC: a quality control tool 
for high throughput sequence data. Available online at: 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Reaper version 13-
100 was employed to trim reads after a quality drop below a mean of Q20 in a 
window of 10 nucleotides [118]. Only reads between 30 and 150 nucleotides were 
cleared for further analyses.  
Trimmed and filtered reads were aligned versus the mm10 (GRCm38) version of 
the mouse genome using STAR 2.5.2b with the parameter “--
outFilterMismatchNoverLmax 0.1” to increase the maximum ratio of mismatches 
to mapped length to 10% [119] and retaining only unique alignments to exclude 
reads with uncertain arrangement. Reads were further deduplicated using Picard 
2.9.0 (Picard: A set of tools (in Java) for working with next generation sequencing 
data in the BAM format) to mitigate PCR artefacts leading to multiple copies of 
the same original fragment. 
The MUSIC peakcaller (version from Dec. 2015) [120] was employed to detect 
enriched regions. In order to determine thresholds for significant peaks per IP, 
the data were manually inspected in Integrative Genomics Viewer (IGV 2.3.52) 
[121]. Thresholds ranged from 1000-5000 for the p-value normalization window 
length (l_p), with a minimum enrichment of treatment versus input reads of 2 – 4-
fold, and a maximum FDR of 0.05 to 1. Peaks overlapping ENCODE blacklisted 
regions (known misassemblies, satellite repeats) were excluded. 
For assessment of the peak’s reproducibility, the resulting lists of significant 
peaks were overlapped and unified to represent identical regions. A background-
correction was performed to correct read counts on various regions (unified 
peaks, promoters, genes). Treatment and Input samples were normalized for 
sequencing depth, before subtracting reads of the Input sample from reads of the 
respective Treatment sample in windows of 50nt length [122]. All windows with 
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negative values (Input > Treatment) were set to zero [123]. Background-
corrected counts for regions were calculated using bigWigAverageOverBed 
(UCSC Tools) and normalized with DESeq2 [124]. For Peaks were annotated 
with the promoter (TSS ± 5000 nt) of the gene most closely located to the center 
of the peak based on reference data from GENCODE v25. Spearman 
correlations were produced to assess the degree of reproducibility between 
samples. To permit comparative display of samples in Integrative Genomics 
Viewer (IGV), raw BAM files were scaled with DESeq2 size factors based on all 
unified peaks using bedtools genomecov resulting in normalized BigWig files 
[125]. 
For analysis of MCAT motifs in TEAD1-occupied sites, Tead1 ChIP seq data were 
screened for the enrichment of the following nucleotide sequences: CATTC, 
CATTCC(TA) and their combination. In brief, a region of 100 nucleotides was 
centered on summit of identified in ChIP seq peaks, background regions of 
promoters were set to 100 < TSS > 0 and background repetitions number to 100. 
Summit of peaks was found and extracted ± 50 bp using Fuzznuc 
(http://www.bioinformatics.nl/cgi-bin/emboss/fuzznuc). Background distribution 
was calculated by random promoter sequence of same number (same as input 
peaks) and size (100 < TSS > 0) and repeated 100-times. List of hits was ranked 
and, for significant enrichment, P-values were calculated. 
  
2.9.5 Verification of TEAD1 ChIP by qRT-PCR using SYBR® Green 
In order to verify selected binding peaks identified in ChIP-seq (2.9.3), the qRT-
PCR method was performed using specific self-designed primers showed in 
Table 14. The purified DNA was diluted 1:100 with MilliQ H2O for use in KAPA 
SYBR® FAST qPCR Master Mix (Kapa Biosystems, KM4104) on a StepOnePlus 
Real-Time PCR System. 
The master mix for one qRT-PCR reaction was prepared as followed: 
Volume  Components 
7.5 µL KAPA SYBR® FAST qPCR Master Mix (2x) (Kapa Biosystems) 
4 µL Purified DNA (1-100 ng) 
2.7 µL MilliQ H2O  
0.4 µL Primer forward 
0.4 µL Primer reverse 
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Each sample was performed in triplicates. The quantitation was performed by a 
qPCR thermocycler (Step OnePlus Real-Time PCR Cycler – Applied Biosystems) 
that identified Ct values, which were further log2-transformed and normalized to 
10% Input using Microsoft Excel. GraphPad Prism 6 was used to generate graph 
bars. 
 
Table 14. List of primers used for verification of ChIP-seq results 
Name Sequence 
PZ84-Myh7-ChIP-for 
PZ85-Myh7-ChIP-rev 
5’-TGGTCGTGGTCAGCTTACTCT-3’ 
5’-CCTTCCCTTGTCCAAACAGT-3’ 
PZ96-Acta2-ChIP-for 
PZ97-Acta2-ChIP-rev 
5’-CCTTCCTTATCCAAGTCCTCAGCT-3’ 
5’-GCTCAGCTGCTTATGGGGATAAAC-3’ 
 
2.10 Histology 
2.10.1 Preparation of paraffin embedded hearts  
The mice were narcotized (Buprenorphine/Ketamine in 0.9 % NaCl, i.p.) and 
perfused first with PBS (Table 17) and then with freshly prepared 4% 
paraformaldehyde (PFA - Roth, 0335.4) (Table 17) via the left heart ventricle. 
Hearts were then isolated and fixed with 4 % PFA overnight at 4°C. After fixation 
the hearts were rinsed with PBS for 10 min at RT and further processed in a 
dehydration series of 70 %-, 80 %-, 90 %- and 100 %- EtOH (Rothipuran® Ethanol 
> 99.8 % (EtOH) – Roth, 9065.4) for 2 h on a shaker at RT each step. Heart 
samples were than incubated with 100 % isopropanol for maximum 2h at RT on 
a shaker and then transferred to 50 % isopropanol/ 50 % paraffin mixture at 56°C 
overnight. For a better paraffin penetration, the samples were transferred to 100 
% liquid paraffin and immersed for 3 h in a vacuum chamber at -3 bar and 56°C. 
Finally, the hearts were embedded in paraffin using a tissue embedding center 
(Leica EG1150C). Thick sections (10 µm) were obtained using a microtome 
(Leica RM2125RT) and collected on a glass slide (Superfrost Ultra Plus® - 
Thermo Scientific, J3800AMNZ). Sections were dried on a heating plate (42°C; 
HI1220 – Leica) and stored in a box at RT. 
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2.10.2 Hematoxylin and eosin staining 
Paraffin sections (2.10.1) were first deparaffinized by dipping two times in 100 % 
xylene (Roth, 9713.3) for 2 min and rehydrated in decreasing EtOH concentration 
series (100 %-, 90 %-, 80 %- and 70 %- EtOH) (Table 17) and thoroughly rinsed 
with dd.H2O. Afterwards, sections were exposed to Mayer’s Hematoxylin 
(Haemalaum, acidic Mayer – WALDECK, 2E-038) (Table 17) for 10 minutes at 
RT and then dipped 2-times in dd.H2O. Thereafter, the sections were dipped 10 
times in 70% RtOH/ 1% hydrochloric acid solution (Table 17) and then 5-times in 
tap water followed by a 5 min staining with eosin (Eosine Solution – WALDECK, 
2C-140) (Table 17) at RT. Afterwards, the tissue slides were dehydrated again in 
increasing EtOH concentration series (70 %-, 80 %-, 90 %-EtOH – 2 dips each 
and 100 % EtOH 10 min) and 100 % xylene (Roth, 9713.3) for 5 min. Finally, the 
sections were mounted in Entellan (Merck-Millipore, 1.07961.0100) and 
photographed with a Keyence (Keyence BZ-9000) or Zeiss Axioplan 2 
microscopes. 
 
2.10.3 Preparation of mouse hearts or mouse embryos for cryosections 
The mice were narcotized (Buprenorphine/Ketamine in 0.9 % NaCl, i.p.) and 
perfused with PBS (Table 17) via the left heart ventricle. For this purpose, the 
chest was opened and the perfusion system was connected to the left heart 
ventricle. After perfusion with PBS, the hearts were dissected and directly frozen 
in liquid nitrogen and stored at –80 °C until further use. The embryos were 
isolated from pregnant mice and immersed in FSC 22® clear (Leica, 3801480) for 
12 h at 4°C followed by embedding in FSC 22® clear at 20°C and stored at –80 
°C until further use.  
The embedded hearts and embryonic tissue were fixed on a special metal holder 
followed by cryosectioning using a Leica cryotome (Leica CM1950). Cryosections 
(6 µm thick) were mounted on a glass slide (Superfrost ultra plus - Thermo 
scientific, J3800AMNZ), shortly dried at RT and fixed in fresh 4% PFA (Table 17) 
for 2 min at RT, washed with PBS (Table 17) and either directly proceeded with 
staining or stored at 4°C.  
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2.10.4 Beta galactosidase (LacZ) staining 
Cryosections were fixed in Fixing Solution (Table 17) for 5 min at RT and rinsed 
with Wash Solution (Table 17) for 10 min at RT. Thereafter, the slides were 
incubated in Staining Solution (Table 17) at 37°C overnight, in the dark. 
Afterwards, the sections were rinsed with Wash Solution (Table 17) for 10 min at 
RT and stained with eosin (2.10.2). After eosin staining, the sections were 
dehydrated in 70 %-, 80 %-, 90 %- and 100 %- EtOH series followed by 10 min 
100% xylene (Roth, 9713.3). Finally, the sections were mounted in Entellan 
(Merck-Millipore, 1.07961.0100). Images were acquired with Keyence 
microscope (Keyence BZ-9000) or Zeiss Axioplan 2 microscope.  
 
2.10.5 Immunofluorescence analysis 
Immunofluorescence labeling of fixed cultured cells and tissue sections was 
performed using standard antibody staining protocols in accordance to the data 
sheet of antibodies (Tables 15 and 16) and adjusted depending on the examined 
cells or tissues. For immunofluorescence analysis, cells were either cultured on 
cover slips (cover slips 13 mm - Hecht-Assistant, 41001113) or chamber slides 
(Lab Tek® Chamber SlideTM system, 4-well Permanox® Slide - Nunc/Sigma-
Aldrich, 177437). Cultured cells were fixed with freshy prepared 4 % PFA (Table 
17) for 2 min at RT, washed 3-times with PBS (Table 17) for 5 min to remove 
fixative solution.  
Prior to immunolabeling, tissue sections (2.10.3) and cultured cells were 
permeabilized with 0.5 % Triton-X1 (Roth, 6683.1) in PBS for 2 min. 
Permeabilized cells and cryosections were incubated with the primary antibodies 
(Table 15) in a humidified chamber over night at 4°C or for 2h at RT. After 
incubation, tissue sections or cells were washed 3-times with PBS for 5 min at 
RT and incubated with the corresponding secondary antibodies (Table 16) for 1h 
at RT in a humidified chamber. Cell nuclei were stained with DAPI (Molecular 
ProbesTM, Thermo Fisher, D1306) for 5 min at RT in a humidified chamber (dark), 
washed 3-times with PBS for 5 min at RT and mounted with Mowiol (Millipore, 
475904-100GM).  
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Table 15. List of primary antibodies for immunofluorescence analysis 
Antibody Source Company Catalog No. Dilution 
ACTN2 Mouse Sigma A 7811 1:200 
Dystrophin Mouse Sigma D 8168 1:200 
Dystrophin (H-300) Rabbit SantaCruz sc-15376 1:200 
Tead1 (D9X2L) Rabbit Cell Signaling 12292 1:200 
antiTEF-1 Mouse BD Biosciences 610923 1:200 
Smooth muscle 
Actin –Cy3 Mouse Sigma C6198 1:200 
Mylk4 Antibody Rabbit Abcam ab107994 1:200 
Collagen1 Rabbit Rockland 600-401-103-0.5 1:200 
anti HA high affinity Rat Roche 11867423001 1:200 
GFP Rabbit Abcam ab6556 1:500 
anti-FLAG Mouse Sigma F1804 1:200 
 
Table 16. List of secondary antibodies and detection systems for 
immunofluorescence analysis 
Antibody Source Company Catalog No. Dilution 
Phalloidin-FITC 
(F-Actin) 
Amanita 
phalloides Sigma P5282 1:200 
Phalloidin-TRITC 
(F-Actin) 
Amanita 
phalloides Sigma P1951 1:200 
Phalloidin-633 
(F-Actin) 
Amanita 
phalloides Invitrogen A22284 1:200 
DAPI  Roche  10236276001 1:1000 
anti-Mouse Alexa 
594 Goat Invitrogen A11005 1:200 
anti-Rabbit Alexa 
594 Goat Invitrogen A11012 1:200 
anti-Mouse Alexa 
488 Goat Invitrogen A11001 1:200 
anti-Rabbit Alexa 
488 Goat Invitrogen A11070 1:200 
anti-Rat Alexa 
Fluor 488 Goat Invitrogen  A-11006 1:200 
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2.10.6 EdU-based assay for DNA synthesis and cell cycle analysis 
EdU assay is based on incorporation of alkyne-containing thymidine analog EdU 
(5-ethynyl-2´-deoxyuridine) into DNA during active synthesis, which then can be 
detected by a click reaction [126]. For EdU incorporation analysis of the 
embryonic hearts (E12.5), pregnant mice were injected i.p.  with 1 mg EdU diluted 
in 0.9 % NaCl. The embryos were isolated 24 h after EdU administration and 
immersed in PBS with 30 % sucrose at 4°C overnight. Next day, the embryos 
were transferred into 1:1 of FSC 22® clear:30% sucrose in PBS solution for 2 h 
at RT, embedded in FSC 22® clear on dry-ice and stored at -80°C for further use 
or directly proceeded for cryosectioning (2.10.3). 6 µm tick cryosections were 
fixed with 4 % PFA for 2 min at RT, permeabilized with 0.5 % Triton X-100 in PBS 
(Table 17) for 2 min at RT and further processed for EdU detection. 
For the assessment of cardiomyocyte proliferation in early postnatal hearts (P3), 
the P2 mice were i.p. injected with EdU diluted in 0.9 % NaCl, (50 µg per 1 g of 
body weight). After 24 h, the mice were sacrificed, the hearts were isolated and 
snap-frozen in liquid nitrogen. 6 µm thick cryosections were fixed with 4 % PFA, 
permeabilized with 0.5 % Triton X-100 in PBS (Table 17) and further processed 
for EdU detection. 
EdU detection was performed using EdU Click-iT Plus Alexa Fluorâ 594 Imaging 
Kit (Invitrogen, C10639) according to the manufacture’s protocol. For 
quantification of EdUpos cardiomyocytes in embryonic and postnatal hearts, tissue 
sections were immunolabeled with antibodies against dystrophin (DMD) and 
counterstained with phalloidin-Alexa633 for F-Actin and DAPI for nuclei. This 
technique allows a clear delineation of the cardiomyocyte cell borders owing to 
the fact that DMD is present only at the lateral sarcolemma. Quantification of 
EdUpos cardiomyocytes was performed per high-power field (hpf) using a 63-
objective lens (x600, image size 250x250 μm). Five (embryonic hearts) to ten hpf 
(postnatal hearts) were investigated per each mouse. Quantification of EdU was 
performed blindly by counting the total number of cardiomyocytes containing 
nuclei followed by the determination of EdUpos cardiomyocytes. The results are 
presented as percent of EdUpos cardiomyocytes from the total cardiomyocyte 
number. 
For quantification of EdUpos cardiomyocytes in cell cultures, the slides were 
stained with either phalloidin-Alexa633 or with antibodies against sarcomeric 
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alpha-actinin (ACTN2) that permits an unequivocal cardiomyocyte detection. Ten 
hpf were investigated per each culture. 
 
2.10.7 In situ Cell Death Detection  
TUNEL labeling of DNA strand breaks using fluorescein-dUTP method enables 
detection and quantification of apoptosis at single-cell level [127]. For detection 
of cell death (apoptosis), 6 µm thick cryosections (2.10.3) were fixed with 4 % 
PFA (Table 17) for 5 min at RT and processed to TUNEL detection using In Situ 
Cell Death Detection Kit, TMR red (Roche, 2156792910) according to the 
manufacture’s protocol. 
Quantification of TUNELpos cardiomyocytes in embryonic and postnatal hearts 
was similar to that of EdUpos cardiomyocytes (2.10.6). The results are presented 
as percent of TUNELpos cardiomyocytes from the total number of cardiomyocytes. 
 
2.10.8 Isolation of late postnatal cardiomyocytes from PFA fixed hearts     
In order to analyze the morphology of late postnatal cardiomyocytes (P16), 
cardiomyocytes were isolated from PFA-fixed hearts as described by Mollova et 
al. [128]. Briefly, mice were sacrificed, perfused with PBS via the left heart 
ventricle. Perfused hearts were cut in small pieces about 1-2 mm2 of size and 
fixed with 4% PFA at 4°C. For cardiomyocyte isolation, small PFA-fixed heart 
pieces were transferred into a 37°C warm collagenase mixture consisting of 1.8 
mg/mL collagenase B (Roche, 11088807001) and 2.4 mg/mL collagenase D 
(Roche, 11088858001) in CaCl2 (20 µL of 10 mmol/L CaCl2 pro 1 mL DPBS) in 
DPBS (GibcoTM, 14190144) and incubated at 37°C overnight shaking at 220 rpm. 
After incubation the supernatant containing separated cardiomyocytes was 
transferred to a 0.5 mL tube, centrifuged at 300 rpm for 5 min, resuspended in 
PBS and stored at 4°C until further use. For immunofluorescence labeling, 
isolated cardiomyocytes were washed with PBS containing 1 % BSA for 5 min at 
RT and shortly centrifuged. The pelleted cardiomyocytes were incubated with an 
appropriate primary antibody (Table 15) diluted in PBS supplemented with 0.1 % 
triton-X 100 in PBS for 2h at 30°C, shaking at 160 rpm. After incubation, the 
cardiomyocytes were shortly centrifugated and the pellet was incubated with 
appropriate secondary antibodies (Table 16) in PBS with 0.1 % triton-X 100 for 1 
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h at 30 °C. Cell nuclei were stained with DAPI (Molecular ProbesTM, Thermo 
Fisher, D1306) for 5 min at 30 °C. For cardiomyocyte transfer to glass slides, the 
suspensions were centrifuged in Cytospinä (ThermoFisher scientific) at 500 rpm 
for 5 min. Glass slides with cardiomyocytes were mounted in Mowiol (Millipore, 
475904-100GM). 
 
2.10.9 Transmission electron microscopy  
For transmission electron microscopy (TEM) the animals were anesthetized 
(Buprenorphine/Ketamine in 0.9 % NaCl, i.p.) and the hearts were perfused with 
PBS and fixed with 4 % PFA. To isolate embryonic hearts, the pregnant mice 
were sacrificed and the embryos were isolated and placed separately into a fresh 
petri dish containing 4 % PFA to carefully isolate the hearts. Both, isolated 
embryonic or 2 mm thick sections of postnatal hearts were immersion fixed in 2.5 
% glutaraldehyde and 2 % PFA in 0.1 M cacodylate buffer (pH 7.2) for 48 h 
followed by en-bloc staining in cold 0.5 % osmium tetroxide for 60 min and 2 % 
uranyl acetate in the dark for 30 min. The tissue samples were then dehydrated 
through a graded ethanol series, embedded in epoxy resin (Epon 812) from which 
70 nm thin sections were cut with a diamond knife. Ultrathin (70 nm) sections 
were mounted on 300 mesh hexagonal grids and stained with 2 % uranyl acetate 
and lead citrate. Images were obtained using a FEI CM10 and a JEOL 1400 
electron microscopes equipped with 2K and 4K digital cameras. Both TEM 
microscopes were operated at 80 kV. 
 
2.11 Magnetic resonance imaging of the mouse hearts 
Magnetic resonance imaging (MRI) was used to analyze the mouse heart 
function in vivo. The MRI was performed on a 7.0 Bruker PharmaScan, equipped 
with a 300 mT m-1 gradient system, using a custom-built circularly polarized 
birdcage resonator and Early Access Package for self-gated cardiac imaging 
(Intragate, Bruker). First, mice were anesthetized with 1.5 % - 2.0 % Isoflurane 
(CP-Pharma, 1214) and then measured. The measurement was based on the 
gradient echo method (repetition time, 6.3 ms; echo time, 1.6 ms; field of view, 
2.20 × 2.20 cm; slice thickness, 1.0 mm; matrix, 128 × 128; repetitions, 100). The 
imaging plane was placed using scout images showing transverse- and four-
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chamber views of the heart and images were then acquired in short-axis view, 
orthogonal to the septum in both scout images. Multiple contiguous short-axis 
slices consisting of six to seven slices were acquired for complete coverage of 
the left ventricle. MRI images were analyzed with MASS 4Mice 7.1 program. Only 
left ventricular data sets in transversal plane were used for data analysis. 
Therefore, the area of heart in end-diastole (the maximum of ventricular volume) 
and end-systole (the minimum of ventricular volume) by highlighting of endo- and 
epicardial borders in all transversal imaged of the heart were defined and 
calculated in the program (MASS 4Mice 7.1).  
 
2.12 Statistical Analysis 
The data reported in this study were analyzed with Microsoft Excel 2016 
(Microsoft) and Prism Software Version 6 (GraphPad Software, San Diego, CA). 
The results are presented as means ±SD. P-values were determined by two-tail 
Student’s t-test (unpaired) for two groups. One-way ANOVA followed by 
Benferroni’s multiple comparison test was used for three or more groups. Survival 
curve analysis was performed using Kaplan-Meier log-rank (Mantel-Cox) test. 
Values of P < 0.05 were considered as statistically significant and n represents 
the number of separate experiments performed. 
 
 
 
2.13 Materials 
 
Table 17. Buffers and solutions 
Buffer Composition 
Common buffers 
TE buffer 10 mmol/Lol/L Tris-HCl (pH 8.0); 1 mmol/L EDTA (pH 8.0) 
PBS (pH 7.4) 137 mmol/L NaCl; 2.7 mmol/L KCl; 10 mmol/L Na2HPO4; 1.8 mmol/L KH2PO4; in MilliQ H2O 
Genomic DNA extraction 
TENS buffer (pH 7.4) 50 mmol/L Tris/HCl (pH 8.0); 40 mmol/L EDTA (pH 8.0); 100 mmol/L NaCl; 1% SDS; in milliQ H2O 
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Plasmid DNA Preparation 
Buffer I 10 mmol/L EDTA; 50 mmol/L Tris/HCl, pH 8,0; 100 µg/mL RNase A 
Buffer II 0,2 M NaOH; 1% (w/v) SDS 
Buffer III (pH 5.5) 3 M Potassium acetate 
50 x TAE 
Dilute 242 g Tris Base; 57.1 mL acetic acid; 100 mL 0.5 mol 
L-1 EDTA, pH 8.0 in 1000 mL Aqua dest. 
Adult mouse cardiomyocytes isolation 
Calcium-free buffer 
113 mmol/L NaCl; 4.7 mmol/L KCl; 0.6 mmol/L KH2PO4; 
0.6 mmol/L Na2HPO4; 1.2 mmol/L MgSO4; 12 mmol/L 
NaHCO3; 10 mmol/L KHCO3; 10 mmol/L Hepes; 30 
mmol/L Taurine; 10 mmol/L 2,3-Butanedionemonoxime; 
5.5 mmol/L Glucose 
Enzyme-buffer 0.25 mg/mL Liberase DH; 0.14 mg/mL Trypsin; 12.5 µmol/L CaCl2 
Stop buffer 1 90% Enzyme-buffer; 10% FCS; 12.5 µmol/L CaCl2 
Stop buffer 2 95% Enzyme-buffer; 5% FCS; 12.5 µmol/L CaCl2 
Adult rat cardiomyocytes isolation 
Perfusion solution 
(Ca2+-free Krebs-
Henseleit bicarbonate 
buffer (KHB, pH 7.4) 
110 mmol/L NaCl; 2.6 mmol/L KCl; 1.2 mmol/L KH2PO4; 
1.2 mmol/L MgSO4; 11 mmol/L glucose; 10 mmol/L 
HEPES 
Western Blot 
LB buffer 67 mmol/L Tris-HCl; 2% SDS;27% Glycerol; in milliQ H2O 
EB buffer 100 mmol/L Tris-HCl; 10 mmol/L EDTA; 10% SDS; in milliQ H2O 
EB/LB buffer 60% EB buffer; 40% LB buffer 
MES buffer 20 x MES buffer 1:20 dilution in milliQ H2O 
Transfer buffer 190 mmol/L Bicine; 25 mmol/L BisTris; EDTA; 20% Methanol; in milliQ H2O 
TBST buffer 150 mmol/L NaCl; 20 mmol/L Tris, pH 7.5; 0,1 Tween 20 
5 % Immunoblot 
blocking solution Dilute 5 g skim milk in 100 mL 1 x TBS-T 
Chromatin Immunoprecipitation 
Binding/blocking buffer 0,5 % BSA; 0,5 %Tween in PBS (without Ca+2,Mg+2) 
Dilutions buffer 
16.7 mmol/Lol/L Tris-HCl (pH 8.0); 1.2 mmol/L EDTA (pH 
8.0); 167 mmol/L NaCl; 1.1 % Triton X-100; 0.01 % SDS; 
in molecular biology-grade water supplemented with 
protease inhibitors (cOmplete ULTRA Tablets) 
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Low salt buffer 
10 mmol/L Tris-HCl (pH 8.0); 1 mmol/L EDTA (pH 8.0); 
140 mmol/L NaCl; 1 % Triton X-100; 0.1 % SDS; 0.1 % 
Na-DOC; in molecular biology-grade water supplemented 
with protease inhibitors (cOmplete ULTRA Tablets) 
High salt buffer 
10 mmol/L Tris-HCl (pH 8.0); 1 mmol/L EDTA (pH 8.0); 
500 mmol/L NaCl; 1 % Triton X-100; 0.1 % SDS; 0.1 % 
Na-DOC; in molecular biology-grade water supplemented 
with protease inhibitors (cOmplete ULTRA Tablets) 
LiCl wash buffer 
10 mmol/L Tris-HCl (pH 8.0); 1 mmol/L EDTA (pH 8.0); 
250 mmol/L LiCl; 0.5 % NP-40; 0.5 % Na-DOC; in 
molecular biology-grade water supplemented with 
protease inhibitors (cOmplete ULTRA Tablets) 
Direct elution buffer 
10 mmol/Lol/L Tris-HCl (pH 8.0); 5 mmol/Lol/L EDTA (pH 
8.0); 300 mmol/L NaCl; 0.5 % SDS; in molecular biology-
grade water 
Common Histology 
4 % PFA (pH 7.4) 4 % PFA in 1 x PBS 
0.5 % Triton-X100 0.5 % Triton-X100; in 1 x PBS 
0.1 % Triton-X100 0.1 % Triton-X100; in 1 x PBS 
Beta galactosidase (LacZ) staining 
SPP buffer 77.4 mmol/L Na2HPO4; 22.6 mmol/L NaH2PO4 
Fixing solution 0.4 % glutaraldehyde, 2 mmol/L MgCl2; 5 mmol/L EGTA (pH 7.5); in SPP buffer 
Wash solution 2 mmol/L MgCl2; 0.01 % Na-desoxycholate; 0.02% NP-40; in SPP buffer 
Stain solution 5 mmol/L K3FeCN6; 5 mmol/L K4FeCN6; 0.1 % X-Gal 
X-β-Gal stock solution 50 mg X-β-Gal in 1 mL dimethylformamide 
HE staining 
90% ethanol 90% ethanol; in dd. H2O 
80% ethanol 80% ethanol; in dd. H2O 
70% ethanol 70% ethanol; in dd. H2O 
Ethanol/HCl 1% HCl (37%); in 70% ethanol 
Eosin stock solution 2% eosin G; in dd. H2O 
Eosin working solution 0.1% eosin G; 0.0005% acetic acid; in dd. H2O 
 
 
Material and methods 
 51 
Table 18. Agents and Viruses 
Agents / Viruses Company Catalog No. 
4-Hydroxytamoxifen SIGMA-ALDRICH H7904-5MG 
EdU (5-ethyl-2´-deoxyuridine) Invitrogen A10044 
FGF2 (Recombinant Human FGF-basic) ReproTech 100-1813 
Ad-CMV-iCre VECTOR BIOLABS 1045N 
 
Table 19. Transfection reagents 
Reagents Company Catalog No. 
TurboFectTM Transfection 
Reagent ThermoFisher Scientific R0531 
DharmaFECT 2 transfection 
reagent Dharmacon T-2002-01 
 
Table 20. List of enzymes and their appropriate reagents* 
Enzyme Company Catalog No. 
Proteinase K  Carl Roth 7528.2 
SuperScript® II Reverse transcriptase  Invitrogen P/N 100004925 
Oligo(dT)15 Primer * Promega C110A 
dNTP * Fermentas R0186 
5 x First strand buffer * Invitrogen P/N y02321 
0.1 M DTT * Invitrogen P/N y00147 
RNasin RNase Inhibitor * Promega N261B 
RNaseH Promega M428C 
T4-DNA-Ligase Promega M1801 
2 xRapid Ligation-Buffer * Promega C6711 
Taq Polymerase Homemade  
REDTaq® ReadyMix™ PCR Reaction Mix Sigma-Aldrich R2523 
collagenase II Worthington LS004176 
PureLink™ RNase A* (20 mg/mL) Invitrogen 12091021 
RNase, DNase free Roche 11119915001 
Proteinase K Solution, RNA Grade Invitrogen 25530-049 
KAPA SYBR® FAST qPCR Master Mix Kapa Biosystems KM4104 
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collagenase B Roche 11088807001 
collagenase D Roche 11088858001 
Trypsin-EDTA Sigma T4174 
Trypsin Sigma T0303 
EcoR I Jena Bioscience EN-113S 
Sla I  Jena Bioscience EN-134S 
Bgl II Jena Bioscience EN-106S 
Sfi I Jena Bioscience EN-132S 
AscI NEB R0558S 
10x universal Buffer * Jena Bioscience EN-300 
10x restriction Buffer 2 * Jena Bioscience EN-302 
10x restriction Buffer 3 * Jena Bioscience EN-303 
10x restriction Buffer 4 * Jena Bioscience EN-304 
NEBuffer 4 * NEB B7204 
 
Table 21. List of protease inhibitors 
Inhibitor Company Catalog No. 
Aprotinin  Sigma 10820  
Leupeptin  Sigma L8511-5MG  
Sodium fluoride (NaF)  Sigma S7920-100G  
Sodium orthovanadate (Na3Vo4)  Sigma 450243  
Phenylmethylsulfonyl fluoride (PMSF)  Sigma P7626  
protease inhibitors (cOmplete ULTRA Tablets, 
Mini, EASYpack) Roche 05892970001 
 
Table 22. Kits and Assays 
Kits Company Catalog No. 
NucleoBond® Xtra Maxi-kit Macherey-Nagel 740414 
Dual-LuciferaseÒ Reporter 1000 Assay 
Systems 
Promega E1980 
Neonatal Heart Dissociations Kit Miltenyi Biotec 130-098-373 
Mouse Neonatal Cardiomyocyte Isolation Kit Miltenyi Biotec 130-100-825 
Direct-zol™ RNA MiniPrep Zumo research R2050 
DC™ ProteinAssay 
Reagent A 
BioRad;  
 
 
500-0113 
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Reagent B 500-0114 
truChIPä Chromatin Shearing Reagent Kit Covaris 520154 
NucleoSpin Gel and PCR Clean-up kit for SDS 
containing samples Macherey-Nagel 740609.250 
NTB buffer Macherey-Nagel 740595.150 
Magna ChIP™ Protein A+G Magnetic Beads Millipore 16-663 
Qubit dsDNA HS Assay Kit ThermoFisher  Q32854 
EdU Click-iT Plus Alexa Fluorâ 594 Imaging Kit Invitrogen C10639 
In Situ Cell Death Detection Kit, TMR red Roche 2156792910 
 
Table 23. List of chemicals  
Chemicals Company Catalog No. 
0.9 % NaCl B. Braun 9511040 
1 x DPBS Gibco 14190144 
1,4-Dithiothreit (DTT) Carl Roth 6908.2 
10 x RedAlert™ Western Blot Stain Millipore 71078-50ML 
100x BSA NEB B9001S 
16 % Formaldyhyde Solution, Methanol free ThermoScientific 28906 
2,3-Butanedionemonoxime Sigma B0753 
20 x MES buffer Invitrogen NP000202 
Acetic acid Roth 3738.5 
Ammoniumperoxodisulfat (APS)  Merck  101.201 
Bicine Sigma B3876-1KG 
BisTris AppliChem A1025,0500 
Bovine Serum Albumin (BSA) solution Sigma A9576 
Calcium (Ca2+) Roth 5239.2 
Creatinine x H2O Sigma C3630 
Dimethyl sulfoxide (DMSO) Sigma D-4540 
Dimethylformamide Sigma 319937-500ml 
Disodium hydrogen phosphate (Na2HPO4) Sigma P030.2 
DPBS, no calcium, no magnesium Gibco™ 14190144 
Dulbecco’s Modified Eagle Medium (DMEM) 
4.5 g/L D-Glucose, Sigma D5796 
EDTA Roth 8040.3 
EGTA Roth 3054.3 
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Entellan Merck-Millipore 1.07961.0100 
Eosine Solution WALDECK 2C-140 
Ethanol Roth 9065.4 
Ethidium bromide solution (1 %)  AppliChem A1152,0100  
Fatty acid-free BSA Sigma A8806 
Fetal bovine serum (FBS) Sigma F7524  
Fetal calf serum (FCS)  Sigma F7524 
Fibronectin PromoCell C-43050 
FSC 22® clear Frozen Section Compound  Leica 3801480 
Glucose Roth X997.2 
Glutaraldehyde  Sigma G5882  
Glycerol Roth 7533.1 
Glycogen for mol. biol. Roche 10901393001 
Haemalaum, acidic Mayer WALDECK 2E-038 
Heparin Braun 1708.00.00 
HEPES Gibco 15630-056 
Hydrochloric acid (HCl (37%)) Roth 4625.1 
Insulin-Transferrin-Sodium-Selenite  Sigma 11074547001  
Isoflurane CP-Pharma 1214 
Isopropanol Roth 6752.4 
K3FeCN6 Merck 1.04973.0250 
K4FeCN6 Merck 1.04984.0500 
L-carnitine x HCl Sigma A6706 
Laminin Sigma L2020 
LB-Agar (Lennox) Roth X965.2 
LB-Medium (Lennox) Roth X964.2 
LE Agarose Biozym 840004 
Lithium chloride (LiCl) Roth P007.1 
M 199  Sigma M4530-500ML 
M 199 (Earle’s salt) Gibco 31153 
Magnesium chloride x 6H2O (MgCl2) Roth 2189.1 
Magnesium sulfate (MgSO4) Merck 1.05886.1000 
Methanol Roth 4627.5 
Molecular biology-grade water Sigma W4502 
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Mowiol Millipore 475904100GM 
Na-desoxycholate (Na-DOC) Sigma 30970-100G 
Nonidet P-40 (NP-40) Fluka 74385 
NuPAGETM MES SDS Running Buffer  ThermoFisher  NP000202  
Paraformaldehyde (PFA) Roth 0335.4 
Penicillin Roth K029.2 
Penicillin/Streptomycin/Glutamine Sigma G6784 
peqGold® TriFast™ reagent VWR Peqlab 30-2010 
Potassium acetate Roth T874.1 
Potassium bicarbonate (KHCO3) Merck 1.04854.0500  
Potassium chloride (KCl) Roth 6781.3 
Potassium dihydrogen phosphate (KH2PO4) Roth P018.1 
Rotiphorese® Gel 30 (37.5:1)  Roth  3029.1  
SDS Roth 2326.3 
Skimmed milk powder Fluka® 70166-500G 
Sodium bicarbonate (NaHCO3) Merck 1.06329.1000 
Sodium bisulfite Sigma 243973 
Sodium chloride (NaCl) Roth 3957.2 
Sodium dihydrogen phosphate (NaH2PO4) Roth 2370.3 
Sodium hydroxide (NaOH) Roth 6771.2 
Streptomycin Roth HP66.1 
Sucrose Carl Roth  9097.1  
Super Signal® West Femto Maximum 
Sensitivity Substrate ThermoScientific 34096 
TaqMan Gene Expression Master Mix (2x) Applied Biosystems 10525395  
Taurine Sigma T8691 
TE buffer pH 7.0 Ambion AM9860 
TEMED  Roth  2367.1  
TRI Reagent Zumo research R2050-1-50 
Tris-HCl Roth 5429.2 
Triton X-100 Roth 6683.1 
Tween 20 Roth 9127.2 
X-β-Gal Roth 2315.4 
Xylene Roth 9713.3 
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Table 24. Protein and DNA-markers 
Marker Company Catalog No. 
Protein-Marker VI Peqlab 27-2311 
PUC Marker (DNA) Homemade  
 
Table 25. List of equipment 
Equipment Company 
0.5 mL DNA LoBind tubes Eppendorf (0030108.035) 
0.5 mL Qubit® Assay tubes Invitrogen (Q32856) 
1.5 mL Protein LoBind tubes Eppendorf (0030108.116) 
10 cm cell culture dishes Greiner 
7.0 Bruker PharmaScan Bruker 
96 well plate Greiner- Bio-One (655101) 
AmershamTM ProtranTM 0.45 μm NC GE Healthcare (10600002) 
Bacteria incubator Heraeus 
BioDocAnalyze Biometra 
cell culture plate (6-, 12-, 24- and 48 well) Greiner 
Cell scraper Sarstedt (83.1830)  
Centrifuge 5417R Eppendorf 
Centrifuge 5430 Eppendorf 
Centrifuge Universal 320R Hettich Zentrifugen 
ChemiDoc™ MP Imaging System BioRad (731BR01764) 
Covaris Focused-Ultrasonicator S220 Covaris 
Cover slips 13 mm Hecht-Assistant (41001113) 
Cryotome Leica CM1950 Leica 
Dumont forceps - #7 curved tip F.S.T. 
E455 – Consort, Power Pack P25 T Biometra 
EG1150C Tissue Embedding Center Leica 
Electron microscope CM10   FEI 
Electron microscope1400 JEOL 
Electroporation Cuvettes (blue cap) Peqlab 
Eppendorftubes, (0.5 mL, 1.0 mL, 2.0 mL) Eppendorf 
Filter tips (10 μl, 20 μl, 100 μl, 1000 μl)  Fisher Scientific 
Fluorometer Qubit® 2.0 Q32866 
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Gene PulserTM Bio-Rad 
gentleMACS Octo Dissociator with Heaters Miltenyi Biotec (130-096-427) 
Glass slides Superfrost Ultra Plus® Thermo Scientific (J3800AMNZ) 
Greiner centrifuge tubes (15 mL, 50 mL) Sigma-Aldrich 
Grinding balls ss 5 mm Retsch (22.455.0003) 
Heating block IKA Labortechnik  
HERA Cells150i, CO2 cell culture incubator Thermo Scientific 
HERAsafe KS laminar flow hood Thermo Scientific 
Incucyte Zoom life cell imager  Essen BioScience 
Innova® 44 Incubator Shaker Series New Brunswick Scientific 
Lab Tek® Chamber SlideTM system, 4-well 
Permanox® Slide Nunc/Sigma-Aldrich (177437) 
Labcycler Sensoquest 
MagneSphere® Technology Magnetic 
Separation Stand (twelve-position) Promega (Z5341) 
Mastercycler Nexus Eppendorf 
Microplate reader FLUOstar Galaxy BMG 
Microscope Biorevo BZ-9000 Keyence 
Microscope Imager Z1 Axio Zeiss 
Microscope M205 FA Leica 
Microscope Zeiss Axioplan 2  Zeiss 
Microtome Leica RM2125RT Leica 
microTUBE AFA Fiber Pre-Slit Snap – Cap 
6x16mm (25) Covaris (520045) 
Multimode Microplate Reader - Mithras LB 940 Berthold Technologies 
NanoDrop ND-2000c Spectralphotometer Peqlab 
Neubauer improved cell counting chamber Marienfeld 
NOVEX® Cassettes 1 mm Invitrogen (NC2010) 
NOVEX® Electrophoresis Mini-Cell Invitrogen (EI001) 
NOVEX® X Cell IIä Blot Module Invitrogen (EI9051) 
pH meter HANNA instruments  
Pipettes Rainin 
Power Pac 200 Bio-Rad 
Shaker Rotamax120 Heidolph 
Sonicator Bandelin Sonopuls Bandelin Sonopuls (HD2070) 
Sorvall Evolution RC Sorvall 
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Step OnePlus Real-Time PCR Cycler Applied Biosystems 
T100 Thermal Cycler Biorad 
Thermo Mixer F 1.5 Eppendorf 
Tissue homogenizer Retsch (MM301) 
UV Transilluminator  INTAS 
Vannas Spring Scissors straight, sharp tip, F.S.T. 
Vortex mixer  Scientific Industries, Inc.  
Waterbath  Leica  
 
Table 26. Analysis software 
Software Company 
MASS 4Mice 7.1 Medis medical imaging systems  
StepOneTM Software v2.3 Applied Biosystems™ 
GSEA GSEA/MSigDB 
GraphPad Prism 6 GraphPad Software 
Image Lab 5.1 software Bio-Rad 
Excel 2016 Microsoft 
Image J / Fiji NIH 
SeqBuilder Pro DNAStar, Inc.  
Integrative Genomic Viewer (IGV)  Broad Institute and the Regents of the University of California 
IncuCyte S3 Software Essen BioScience 
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3   RESULTS 
 
3.1 TEAD1 expression and protein abundance in embryonic end 
postnatal mouse hearts  
In order to analyze TEAD1 mRNA and protein levels during embryogenesis as 
well as postnatal heart growth, qRT-PCR (Quantitative Real-Time Polymerase 
Chain Reaction) and western blot analysis of the wild-type (WT) mouse hearts 
were performed.  
 
 
Figure 8. TEAD1 mRNA expression and protein levels in embryonic and postnatal 
hearts. (A) Tead1 mRNA expression levels in embryonic (E13.5, n=2), postnatal (P3, 
n=3 and P15-P19, n=3) and adult (8 weeks, n=3) WT mouse hearts. Tead1 expression 
level initially increases about 1.5-times from embryonic to early postnatal (P3) stage and 
afterwards gradually decreases in late postnatal (P15-P19) and adult (8 weeks) stages. 
Tead1 expression levels were normalized to Gapdh expression. (B) Representative 
western blots of embryonic (E13.5, n=1), postnatal (P3, n=3) and adult (8 weeks, n=3) 
WT mice hearts show that the protein levels of TEAD1 constantly decrease from 
embryonic to adult stages. Protein levels of TEAD1 were normalized to GAPDH protein 
levels. Data are means ± SD; ns = not significant (P ≧ 0.05); ** = P < 0.005; **** = P < 
0.001. 
 
As shown in figure 8A, Tead1 mRNA expression initially increased form 
embryonic (embryonic day (E)13.5) to early postnatal stage (postnatal day (P)3) 
and afterwards began gradually to decrease until adult stage (8 weeks). At both, 
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late postnatal stage (P15-P19) and 8 weeks adult hearts, Tead1 mRNA levels 
were approximately 2-times lower compared to P3 hearts. There were no 
significant differences between P15-P19 and 8 weeks hearts in the Tead1 mRNA 
expression levels. Concomitant western blot analysis indicated that TEAD1 
protein levels gradually decreased from embryonic (E13.5) to adult (8 weeks) 
stages (Figure 8B). In adult hearts, the TEAD1 protein abundance was 4.5-fold 
lower in comparison to P3 hearts.  
 
3.2 Loss of Tead1 in embryonic mouse cardiomyocytes results 
in embryonic lethality 
In order to investigate the role of TEAD1 in cardiomyocytes in vivo, a conditional 
Tead1 knockout mouse approach (Tead1fl/fl) was used by insertion of loxP sites 
in introns 2 and 5 of Tead1 gene (Figure 9). This conditional inactivation resulted 
in deletion of exon 3 to 5 accompanied by a frameshift and premature 
translational stop. In order to analyze TEAD1 function during early embryonic 
heart development, a XMLC2-Cre::Tead1fl/fl mouse line, which were later referred 
to as e(embryonic)Tead1-cKO, was generated. Cardiomyocyte-specific Tead1-
deletion in this mice is achieved in the early myocardium starting at E7.5 [109].  
 
 
Figure 9. Schematic view of XMLC2-Cre driven recombination in the eTead1-cKO 
mouse line results in a conditional deletion of Tead1 Exon3 to Exon5. 
 
Homozygous eTead1-cKO mice were embryonic lethal at E13.5 and were 
characterized by a smaller body size compared to control littermates. 
Morphological analysis revealed that mutant embryos displayed dilated heart 
ventricles and pericardial cavity, enlarged fourth brain ventricle and cranial 
hemorrhages (Figure 10A). The heart ventricular walls in eTead1-cKO mice were 
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approximately 2-fold thinner compared to control embryos, although no difference 
between Tead1 mutants and controls in the atrial wall thickness was observed 
(Figure 10B). In addition, the heart ventricles of eTead1-cKO embryos 
consistently exhibited thinner trabecular layer (hypotrabeculation) as compared 
to controls (Figure 10C).  
 
 
Figure 10. Embryonic retardation, enlarged cardiac cavity, thin ventricular wall and 
hypotrabeculation in eTead1-cKO (E11.5). (A) Representative example of eTead1-
cKO (right panel, cKO) and control (left panel, Ctrl) embryos. Note that eTead1-cKO 
embryo exhibits enlarged fourth brain ventricles (asterisk), cranial hemorrhages (arrow), 
developmental retardations and dilated heart cavities (outlined with dashed line) in 
comparison to control. (B) Reduced ventricular wall thickness in eTead1-cKOs (mean 
9.4 µm, n=3) compared to controls (mean 22 µm, n=3), however there is no significant 
difference in atrial wall thickness. Data are means ± SD; ns = not significant (P ≧ 0.05); 
**** = P < 0.001. (C) HE-stained paraffin sections of a representative eTead1-cKO (right 
panel) embryo in comparison to control (left panel). eTead1-cKO embryo displays a 
thinner ventricular wall (outlined with dashed black line) and reduced trabeculation (TL) 
in comparison to control. Notice that the atrial wall thickness is not altered. TL – 
trabecular layer, CL – compact layer (outlined with dashed black line), Epi – epicardium.  
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Immunohistochemical analysis of control embryos (E12.5) showed that TEAD1 
localizes in nuclei of the vast majority of cardiac cells, including cardiomyocytes 
as well as non-cardiomyocytes (Figure 11). In contrast, in eTead1-cKO hearts 
(E12.5) residual TEAD1 protein was restricted to non-cardiomyocytes, 
demonstrating cardiomyocyte-specific deletion of TEAD1 (Figure 11).  
 
 
Figure 11. Absence of TEAD1-positive cardiomyocytes in eTead1-cKO embryonic 
hearts (E12.5). Fluorescent images of control (A) and eTead1-cKO (B) embryonic 
hearts. Note that in mutant hearts (B), TEAD1 is present in non-cardiomyocytes 
(asterisk) of the trabecular layer (TL) and in epicardial cells while almost all 
cardiomyocytes of the trabecular layer are TEAD1neg (arrow). In contrast, all 
cardiomyocytes and non-cardiomyocytes of compact and trabecular layer as well as 
epicardial cells in control embryonic heart are TEAD1pos. CL – compact layer (outlined 
with dashed white line); Epi – epicardium; green – TEAD1, red – F-Actin, blue – DAPI. 
Scale bar: 30 µm. 
 
Next, it was reasoned that deficient cardiomyocyte proliferation might be a cause 
for severe heart phenotype in eTead1-cKO mutants. The proliferation assay at 
E12.5 showed that eTead1-cKO hearts exhibited 3.4-times less EdUpos 
cardiomyocytes compared to control heterozygous littermates (Figure 12).  
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Figure 12. Reduced cardiomyocyte proliferation in eTead1-cKO embryonic hearts 
(E12.5). Fluorescent images of EdU labeling in control (A) and eTead1-cKO (B) 
embryonic hearts showing reduced number of EdUpos (red) cardiomyocytes (F-Actin, 
green) in eTead1-cKO hearts (B). Red – EdU, green - F-Actin, blue - DAPI; RV – right 
ventricle, LV – left ventricle, TL – trabecular layer, CL – compact layer (outlined with 
dashed white line), Epi – epicardium. (C) The number of EdUpos cardiomyocytes in 
eTead1-cKO (mean 8%, n=3) is approximately 3-times lower than in control hearts 
(mean 27%, n=3). Data are means ± SD; * = P < 0.05. 
 
Further it was also reasoned that cell death might be involved in the manifestation 
of the severe heart phenotype in eTead1-cKO embryos. The number of TUNELpos 
apoptotic cells in eTead1-cKO embryonic hearts was 5-fold increased compared 
to control hearts (Figure 13).  
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Figure 13. Increased number of apoptotic cells in eTead1-cKO embryonic hearts 
(E12.5). TUNEL staining of control (A) and corresponding eTead1-cKO (B) embryonic 
hearts shows increased number of TUNELpos cells in eTead1-cKO embryonic hearts 
compared to control. RV – right ventricle, LV – left ventricle; red -TUNEL, green - F-Actin, 
blue - DAPI. (C) The percent of TUNELpos cells in eTead1-cKO (n=3) hearts is 
approximately 5% compared to 1% in controls (n=3). Data are means ± SD, **** = P < 
0.001. Scale bar: 100 µm. 
 
Next, transmission electron microscopy (TEM) was performed to analyze the 
ultrastructure of eTead1-cKO and control E12.5 embryonic hearts revealing a 
reduced ventricular wall thickness and a reduced trabeculation in eTead1-cKO 
hearts. The size of individual cardiomyocytes in eTead1-cKO hearts was smaller 
than that in controls. Moreover, the packing density of cardiomyocytes within the 
ventricular wall appeared more dispersed in eTead1-cKO hearts than in control 
hearts. (Figure 14). Despite the more condensed myofibrillar pattern in control 
hearts, there were no differences between control and eTead1-cKO hearts in the 
ultrastructural organization of individual sarcomeres (Figure 15). In both groups, 
sarcomeres had a similar length and exhibited discernible Z-discs in the absence 
of M-bands.  
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Figure 14. Representative TEM images comparing the left ventricular wall in 
control and eTead1-cKO embryonic hearts (E12.5). eTead1-cKO (low panel) heart 
displays a more disperse packing pattern of cardiomyocytes and thinner ventricular wall 
compared to control (upper panel). Note the difference between groups by comparing 
the outlined cardiomyocytes. N - nuclei 
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Figure 15. The ultrastructure of sarcomeres in control and eTead1-cKO 
cardiomyocytes (E12.5). Note that the sarcomeres in both, control (left panel) and 
eTead1-cKO (right panel) display discernible Z-disks (Z). There are no apparent 
differences in the sarcomere length of both groups. Arrows denote fascia adherents, m 
– mitochondria, N – nuclei, Z – Z-disks. 
 
 
Taken together, cardiomyocyte-specific deletion of Tead1 during embryogenesis 
led to severe defects in heart development and embryonic lethality. The most 
obvious feature of eTead1-cKO hearts was a decrease of cell proliferation and 
an increase of apoptotic cardiomyocytes. These latter findings were also 
documented by TEM analysis (Figure 16).  
 
 
 
Figure 16. TEM images show completed cytokinesis (arrows, cardiomyocytes are 
outlined with dashed line) in control hearts (left panel) and apoptotic cells (arrow) in 
eTead1-cKO embryonic hearts (right panel) (E12.5). N – nuclei. 
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3.3 Loss of TEAD1 in postnatal mouse cardiomyocytes leads to 
dilated cardiomyopathy, heart failure and premature death  
In order to analyze TEAD1 function in postnatal cardiomyocytes, a MCK-
Cre::Tead1fl/fl mouse line, which were later referred to as p(postnatal)Tead1-cKO 
was generated. Myocardial specific recombination in these mice starts at late 
fetal stages and reaches its maximum around postnatal day 10 (P10) [110, 129]. 
 
 
Figure 17. Recombination in pTead1-cKO mouse line after crossing to MCK-Cre-
deleter mouse leads to the deletion of Tead1 Exon3 to Exon5. 
 
As shown in Figure 17, deletion of Tead1 exons 3 to 5 results in a frame shift of 
subsequent codons and premature stop. In order to determine the time-point of 
highest MCK-Cre (Muscle Creatine Kinase) recombinase activity in the heart, the 
MCK-Cre mouse line was crossed with ROSA26-LacZ (Reverse Oriented Splice 
Acceptor, Clone 26) Cre-reporter line to monitor Cre-recombinase activity [130]. 
To achieve this aim hearts of P0 to P15 knock-in (MCK-Cre::Rosa26fl/+) and 
control (MCK-Cre::Rosa26+/+) mice were isolated and stained for LacZ. Figure 18 
shows that LacZpos cardiomyocytes were present in knock-in hearts at all stages, 
which are gradually increase from P0 to P15. In contrast, control hearts were 
LacZneg at all stages. It is worth to note that not all cardiomyocytes of knock-in 
mice were LacZpos as indicated by some islands of LacZneg cells. 
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The efficiency of cardiomyocyte-specific inactivation of Tead1 in pTead1-cKO 
mice (MCK-Cre::Tead1fl/fl) was determined by immunohistochemistry, qRT-PCR 
and western blot. Immunohistochemical analysis of P10 and P24 heterozygous 
control animals showed that almost all cardiomyocytes displayed strong TEAD1 
signal confined to nuclei (Figures 19A - 19D). In contrast, pTead1-cKO hearts 
steadily decreased the population of TEAD1pos cardiomyocytes from P10 toward 
P24 (Figures 19E - 19H). Immunohistochemical analysis also revealed that in 
Figure 18. Stepwise increase in Rosa26-
LacZpos cardiomyocytes during postnatal 
heart maturation (P0 to P15) representing 
activation of CRE recombinase driven by 
the MCK promoter. Representative images 
of heart coronal sections at different stages 
(P1, P5, P10 and P15) stained for LacZ. 
Sections on the left side depict control 
(MCK-Cre::Rosa26-lacZ+/+) littermate hearts 
which show no Rosa26-lacZ-reporter 
activation (red). Sections on the right side 
depict knock-in (Cre::Rosa26-lacZ+/-) hearts 
with an active Rosa26-lacZ-reporter, which 
is represented by LacZ-staining (blue). The 
number of Lac-Zpos cardiomyocytes is 
gradually increasing during the observation 
period. RA – right atrium, LA – left atrium, 
RV – right ventricle, LV – left ventricle. 
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both, pTead1-cKO and control hearts, the non-cardiomyocyte cell population was 
positive for nuclear TEAD1 signal irrespective of the postnatal stage, implying 
that TEAD1 was specifically deleted in pTead1-cKO cardiomyocytes.  
 
 
Figure 19. Gradual cardiomyocyte-specific inactivation of Tead1 in pTead1-cKO 
mutants during postnatal period. (A and B) panels show fluorescent images of P10 
control heart sections in which the vast majority of cardiomyocytes is TEAD1pos 
(asterisk), whereas almost all cardiomyocytes in pTead1-cKO mutant hearts are 
TEAD1neg (panels E, F, arrows). Stars denote non-cardiomyocyte population cell. (G and 
H) show that almost all cardiomyocytes are surrounded by Dystrophin (DMD) in P24 
pTead1-cKO mutants and are TEAD1neg (arrows). Cardiomyocytes in control hearts 
(panels C, D) are TEAD1pos (asterisk). V – vessels; green – TEAD1, red –DMD, blue – 
DAPI. Scale bar: 30 µm. 
 
As a next step, isolated cardiomyocytes from different postnatal stages were 
used to determine Tead1 mRNA levels in control and mutant animals. Tead1 
mRNA expression levels in isolated early postnatal (P3) pTead1-cKO 
cardiomyocytes were reduced by approximately 3-times compared to controls 
(Figure 20A) whereas in late postnatal cardiomyocytes (P15-P18), Tead1 mRNA 
transcript levels in pTead1-cKO decreased 12-times in comparison to controls 
(Figure 20A). Western blot analysis of P17 pTead1-cKO mutant hearts revealed 
approximately a 4-fold decrease of TEAD1 protein in comparison to control hearts 
(Figure 20B). Taken together, these data indicate an effective age-dependent 
inactivation of TEAD1 in postnatal cardiomyocytes of pTead1-cKO mutants. 
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Figure 20. Reduced TEAD1 mRNA and protein levels in pTead1-cKO mice. (A) The 
mean Tead1 expression in isolated pTead1-cKO cardiomyocytes) is 2.5-fold reduced in 
P3 mice (n=3) and 12.5-fold reduced in P15-P18 mice (n=3) in comparison to their age-
matched controls (n=3). Tead1 expression levels are normalized to Gapdh expression. 
(B) Western blot and corresponding densitometry measurements of heart protein lysates 
at P17 show reduced TEAD1 levels of approximately 25% in pTead1-cKO hearts (n = 4) 
in comparison to TEAD1 protein content in control hearts (n = 3). Protein levels of TEAD1 
are normalized to GAPDH protein levels. Data are means ± SD, ns = not significant (P ≧ 0.05), * = P < 0.05, ** = P < 0.005. 
 
The present study documented that effective deletion of Tead1 in postnatal 
cardiomyocytes culminated in the lethality of pTead1-cKO mice between P11 – 
P30, while the heterozygous littermates (MCK-Cre::Tead1fl/+, referred to as 
control) had a normal life span (Figure 21A). There were no significant differences 
in body weight and heart weight to tibia length ratio between pTead1-cKO and 
control animals at P12 (Figures 21B and 21C). 
 
 
Figure 21. pTead1-cKO mice die postnatally between P11 and P28. (A) Kaplan-Meier 
curve shows the survival of pTead1-cKO mice (n = 24) in comparison to control 
littermates (n = 9). Note that pTead1-cKO mice die between P11 and P28. (B and C) are 
quantifications of the body weight and heart weight to tibia length demonstrating no 
significant changes in these parameters between pTead1-cKO (n = 3) and control (n = 
6) mice at P12. Data are means ± SD, ns = not significant (P ≧ 0.05). 
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Next, pTead1-cKO hearts were examined macroscopically and microscopically 
at different time points. All pTead1-cKO mice conspicuously displayed dilated 
hearts accompanied by thinner left and right ventricular walls in comparison to 
control littermates (Figures 22A, 22B, 22D and 22E). Morphometric analysis 
showed that the left and right ventricular wall thickness of P16 pTead1-cKO 
animal hearts were 2-fold and 1.5-fold, respectively, decreased compared to 
control hearts (Figures 22G and 22H).   
 
 
Figure 22. Dilated ventricles and thin myocardial walls in P16 pTead1-cKO hearts. 
(A and D) macroscopic views comparing hearts from P16 pTead1-cKO and control 
littermates. pTead1-cKO hearts (D) display dilated left and right ventricles. (B and E) 
Microscopic view of paraffin sections of corresponding hearts. The left-ventricular wall 
and interventricular septum of pTead1-cKO (E) are thinner in comparison to control (B). 
(C and F) are detailed views of the corresponding left ventricular walls. Notice that the 
intercellular space in left ventricular wall of pTead1-cKO (F) is augmented in comparison 
to control (C). RA – right atrium, LA – left atrium, RV – right ventricle, LV – left ventricle, 
V – vessel. (G) The mean value of left ventricular wall thickness in control hearts is 851 
µm (n = 3) and in pTead1-cKO hearts is 456 µm (n = 3). (H) The mean value of right 
ventricular wall thickness of control hearts is 388 µm (n = 3) and of pTead1-cKO hearts 
is 255 µm (n = 3). Data are means ± SD, **** = P < 0.001,  ** = P < 0.005. Scale bar in 
C and F: 50 µm. 
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Moreover, morphometric analysis revealed that pTead1-cKO cardiomyocytes of 
P16 animals were 1.2-times longer and 1.2-times thinner than control 
cardiomyocytes. (Figure 23A). Histogram distribution of the measured 
cardiomyocyte length and width showed that pTead1-cKO cardiomyocytes are 
shifted towards longer and thinner morphology compared to controls (Figure 
23B), which was further confirmed by electron microscopy (Figure 24). 
 
 
 
Figure 23. Shift of pTead1-cKO cardiomyocytes towards longer and thinner 
morphology (P16). (A) Cardiomyocytes show significant length differences between 
control (mean length 87 µm, n=3) and pTead1-cKO mice (mean length 106 µm, n=3). 
Conversely, the cardiomyocytes width of pTead1-cKO mutant is reduced (mean width 
14 µm, n=3) in comparison to controls (mean width 17 µm, n=3). There is no significant 
difference in cardiomyocyte area between control (mean area 1244 µm2, n=3) and 
pTead1-cKO (mean area 1223 µm2, n=3). (B) Length and width distribution of pTead1-
cKO cardiomyocytes is shifted towards longer and thinner cardiomyocyte morphology 
compared to controls. Data are means ± SD, ns = not significant (P ≧ 0.05), **** = P < 
0.001. 
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Figure 24. Representative TEM images of the left ventricle comparing the width 
(black lines) of individual cardiomyocytes at the nuclear level in control and 
pTead1-cKO mice (P16). Note that cardiomyocytes (outlined in red) in pTead1-cKO 
hearts (lower panel) are thinner in comparison to control hearts (upper panel). N – 
nuclei, C – capillary, Z – Z-disks, m – mitochondria. 
 
Magnetic Resonance Imaging (MRI) analysis of left ventricular parameters of 12 
controls and 12 age-matched pTead1-cKO hearts (between P10 and P18) 
revealed contractile dysfunction in pTead1-cKO mice (Figures 25A and 25B). In 
particular, left ventricular ejection fraction (LVEF), which is an important 
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parameter for proper heart function, decreased below 40 % in pTead1-cKO 
mutant and averaged 27 %, in comparison to approximately 60 % in control mice 
(Figure 25C). The severe reduction of LVEF provides a strong evidence for 
contractile heart insufficiency in pTead1-cKO mice.  
 
 
Figure 25. Contractile heart dysfunction in pTead1-cKO animals. (A) MRI images 
show representative four chamber views of control and pTead1-cKO mutant hearts in 
end-systole and end-diastole phases. pTead1-cKO hearts display contractile dysfunction 
in systole phase and are massively dilated in diastole phase compared to control hearts 
(P16). (B) Short axis view visualizes the dilatation of the pTead1-cKO heart in systole 
and diastole compared to control heart (P16). RV – right ventricle, LV – left ventricle. (C) 
Quantitative reduction of LVEF in pTead1-cKO mice (n = 12) with the mean value of 27% 
in comparison to controls (n = 12) with the mean value of 60% (P10-P18). Data are 
means ± SD; **** = P < 0.001. 
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TEM and immunofluorescent techniques were employed to study ultrastructural 
alterations of the myocardium in pTead1-cKO mutants. TEM analysis revealed 
that cardiomyocytes from pTead1-cKO mutant hearts are smaller in size and 
surrounded by numerous fibroblasts accompanied by massive depositions of 
thick collagen fibers (Figure 26). These findings were confirmed by 
immunolabeling for the major fibrillar collagen type I in combination with laser 
confocal microscopy. The images presented in Figure 27 show that collagen 
fibers are more abundant in pTead1-cKO in comparison to controls. Taken 
together, accumulation of fibroblasts and deposition of collagen fibers might 
contribute to contractile heart-dysfunction in pTead1-cKO mutants. 
 
 
 
Figure 26. Representative TEM images comparing the left heart ventricle in control 
and pTead1-cKO mice (P16). Note numerous fibroblasts (arrows) and severe 
deposition of collagen fibers (asterisk) in pTead1-cKO (right panel) hearts compared to 
control counterparts (left panel). Nuc – nuclei, C – capillary, red arrow – lymphocyte. 
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Figure 27. Increased fibrosis in pTead1-cKO mutants (P16). Confocal micrographs 
displaying an increased abundance of collagen I fibers (green) in pTead1-cKO (B) 
compared to control (A) hearts. Nuclei are labeled in blue, F-actin in red. Scale bar: 30 
µm. 
 
Multiple studies have shown that tightly controlled processes of postnatal 
cardiomyocyte proliferation and apoptosis have a fundamental impact on the 
onset of a cardiomyopathic phenotype (reviewed in [131, 132]). In order to 
investigate the proliferation capacity of postnatal control and pTead1-cKO mutant 
cardiomyocytes, 24 hours (h) EdU incorporation in P3 littermates was analyzed. 
The number of EdUpos cardiomyocytes comprised 9 % of the total cardiomyocyte 
number in control hearts, whereas in pTead1-cKO hearts the number of EdUpos 
cardiomyocytes was significantly lower (approximately 3 %). Representative 
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fluorescent images of EdU stained heart sections and quantifications of EdUpos 
cardiomyocytes are depicted in the Figure 28. 
 
 
Figure 28. Reduced cardiomyocyte proliferation in pTead1-cKO (P3). (A - F) 
Representative fluorescent images from sections of EdU-labelled hearts of P3 animals. 
The number of EdUpos cardiomyocytes in pTead1-cKO hearts (D, E) is reduced in 
comparison to controls (A, B). Red – EdU, green – DMD, blue – DAPI. (G) Hearts of 
pTead1-cKO mutants (n = 3) manifest approximately 3-fold reduction of EdUpos 
cardiomyocytes compared to control (n = 3). Data are means ± SD, ** = P < 0.005; hpf 
– high-power field. Scale bar: 30 µm. 
 
 
The number of apoptotic cardiomyocytes, defined here as TUNELpos 
cardiomyocytes, was increased by 3-fold in pTead1-cKO P12 hearts compared 
to control hearts (Figure 29). An increased apoptosis rate was even more 
pronounced at later time points (P24) (Figure 30).  
Results 
 78 
 
Figure 29. Increased cardiomyocyte apoptosis in P12 pTead1-cKO hearts. 
Representative fluorescent images of heart sections of control (A) and pTead1-cKO (B) 
stained using TUNEL assay representing apoptotic cardiomyocytes (arrows, 
TUNELpos/DMDpos/F-Actinpos). Red – TUNEL, green – DMD / F-Actin, blue – DAPI. (C) 
pTead1-cKO hearts exhibit approximately 3-times more TUNELpos cardiomyocytes than 
control hearts. Data are means ± SD, ** = P < 0.005. Scale bar: 30 µm. 
 
 
 
Figure 30. Increased number of apoptotic cardiomyocytes in pTead1-cKO mice 
compared to controls (P24). Representative fluorescent images of heart sections 
stained using TUNEL assay. pTead1-cKO hearts (right panel) show more TUNELpos 
cardiomyocytes (arrows) than control hearts (left panel). Arrowheads denote apoptotic 
interstitial cells. Red – TUNEL, green – F-actin / DMD (boxed region), blue – DAPI. 
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Taken together, these findings indicate that pTead1-cKO hearts are 
characterized by an imbalance between cardiomyocyte proliferation and 
cardiomyocyte cell death. The latter may predispose the pTead1-cKO hearts to 
develop severe myocardial fibrosis and contractile dysfunction. 
 
3.4 Epitope tagged TEAD1 binds to MCAT-elements in vitro 
In order to further study the function of TEAD1 in cardiomyocyte, we generated 
two expression constructs in which TEAD1 was tagged with either Flag-HA or 
GFP and expressed under control of CAGG-promotor. Generation of stable 
Tead1-overexpressing cell lines by random integration of transgenes was 
achieved by an IRES-puromycin-cassette and concomitant puromycin selection. 
For this purpose, HEK 293T cells were transfected with Tead1, Tead1-GFP, 
Tead1-Flag-HA and GFP alone as control vector. Figure 31 shows that 
immunolabeling signal of TEAD1-Flag-HA is confined to nuclei of transfected 
cells. As expected, the GFP signal in GFP control vector transfected cells was 
localized in both, the cytoplasm as well as in the nucleus in contrast to Tead1-
GFP transfected cells where the signal was restricted to nuclei.  
To analyze the abundance of fusion proteins, the lysates of transfected cells were 
validated by western blot with specific antibodies against GFP (GFP and TEAD1-
GFP fusion protein) and HA (TEAD1-Flag-HA fusion protein). According to 
calculation, a 27 kDa band was detected in lysates of transfected cells with GFP 
control, an 80 kDa band in lysates of Tead1-GFP transfected cells and a 60 kDa 
band in lysates of Tead1-Flag-HA transfected cells (Figure 32A).  
In order to test the functionality of the Tead1-overexpression constructs, dual-
luciferase reporter assays (Figure 32B) with a TEAD1-Reporter construct 
containing four copies of TEAD1 consensus binding sites (CATTCCA) combined 
with a minimal promoter were performed as previously described in Günter et al. 
[84]. To monitor the transfection efficiency, Renilla Luciferase containing 
expression vector was co-transfected. Due to the fact that TEAD1 lacks a 
transactivation domain and is not able to activate transcription by itself, VGLL-2 
(VITO-1) [84], a well-known TEAD1-cofactor, was co-transfected. Cells co-
transfected with TEAD1 and VGLL-2 constructs displayed a 4.5-times higher 
reporter activity in comparison to transfection with TEAD1 in the absence of 
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VGLL-2. Co-transfection of TEAD1-GFP and VGLL-2 activated the luciferase 
reporter construct 4-times higher than single TEAD1-GFP transfection. Similarly, 
the luciferase activity in TEAD1-Flag-HA and VGLL-2 co-transfection was roughly 
7-times higher compared to single transfection. 
 
 
 
Figure 31. Nucleus-restricted localization of TEAD1-Flag-HA and TEAD1-GFP in 
transfected HEK 293T cells. (A) In cells transfected with GFP control vector, GFP 
signal (green) localizes to cytoplasm and nuclei. (B) In cells transfected with Tead1, 
TEAD1 signal is detected in cell nuclei. (C) In Tead1-GFP transfected cells the GFP 
signal is restricted to nuclei. (D) In Tead1-Flag-HA transfected cells the HA signal (green) 
is restricted to nuclei. In all images - DAPI signal in blue marks nuclei and F-Actin in red 
marks the cytoplasm. Green – X = GFP / TEAD1 / HA. Scale bar: 20 µm. 
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Figure 32. TEAD1-Flag-HA and TEAD1-GFP fusion proteins activate MCAT-
elements in vitro. (A) Western blot of lysates from HEK 293T cells transfected with 
vectors containing GFP; TEAD1-GFP and TEAD1-Flag-HA. Control GFP protein is 
represented by a 27 kDa band (arrow). TEAD1-GFP fusion protein is represented by a 
calculated 80 kDa band (53 kDa (TEAD1) + 27 kDa (GFP), arrow). TEAD1-Flag-HA 
fusion protein is represented by a calculated 60 kDa band (53 kDa (TEAD1) + 7 kDa 
(Flag-HA, arrow)). The asterisk indicates an unspecific band. (B) Dual-Luciferase 
reporter assay of transfected HEK 293T cells. Transfected cells with TEAD1 and VGLL-
2, as a cofactor, activate the luciferase reporter 4.5-fold higher compared to TEAD1 
single transfection. In cells transfected with TEAD1-GFP and VGLL-2, activation of 
luciferase is 4-fold higher than in cells transfected with TEAD1-GFP alone. TEAD1-Flag-
HA transfected with VGLL-2 activate luciferase-reporter about 7-fold higher compared to 
TEAD1 single transfection. There is almost no activation of luciferase-reporter in 
untransfected control and single transfected cells. Data are means ± SD, * = P < 0.05, 
** = P < 0.005, **** = P < 0.001, n = 3.  
 
3.5 Cardiomyocyte-specific overexpression of Tead1-Flag-HA 
rescues the loss of endogenous Tead1 and results in increased 
cardiomyocyte proliferation  
In order to analyze the impact of an elevated Tead1 expression in 
cardiomyocytes a Rosa26-based CRE-inducible Tead1-Flag-HA overexpression 
mouse line (Tead1-Flag-HATg/Tg) was generated. Figure 33 depicts a scheme of 
the overexpression constructs design encoding a Tead1 cDNA tagged with Flag-
HA and PolyA-tail under the transcriptional control of a CAGG promoter, which is 
inserted between 1st and 2nd exons of Rosa26 locus [133]. The conditional 
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activation of Tead1-Flag-HA is achieved by a Cre-mediated removal of floxed 
PGK-neo cassette in the early myocardium E7.5 mediated by the XMLC2-Cre 
deleter allele [109].   
 
 
Figure 33. Schematic view of Tead1-Flag-HA recombination in Rosa26 locus. The 
upper part resembles the WT Rosa26 locus. The middle part displays the modified 
Rosa26 locus containing a CAGG promoter followed by a transcriptional stop cassette 
(PGK Neo), which is flanked by two loxP sites and a Tead1 cDNA fused to a Flag-HA 
double-tag. The lower part resembles the mutant allel after Cre-mediated deletion of 
transcriptional stop cassette. 
 
Heterozygous (XMLC2-Cre::Tead1-Flag-HATg/+) as well as homozygous 
(XMLC2-Cre::Tead1-Flag-HATg/Tg) gain-of-function (GOF) mice (later referred to 
as e(embryonic)Tead1-cOE) have a normal life span similar to control (Creneg) 
mice (data not shown). Macroscopic examination of homozygous overexpression 
hearts revealed no obvious alterations in comparison to hearts from control 
littermates (Creneg Tead1Tg/Tg littermates) (Figure 34A). At P16, eTead1-cOE 
mice displayed a slightly increased weight in comparison to their control 
littermates, however, there were no significant differences in the heart weight to 
tibia length ratio in control and eTead1-cOE mice (Figures 34B and 34C). Isolated 
cardiomyocytes of P16 eTead1-cOE hearts were 6 % increased in length by an 
unaltered width, which resulted in an 8.5% increased cross-sectional area 
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compared to controls (Figure 34D). TEM analysis revealed no ultrastructural 
alterations of eTead1-cOE cardiomyocytes (Figure 35). 
 
 
Figure 34. No major macroscopic differences between eTead1-cOE and control 
hearts (P16). (A) Macroscopic view of P16 hearts shows no obvious morphological 
differences between eTead1-cOE and controls. RA – right atrium, LA – left atrium, RV – 
right ventricle, LV – left ventricle. (B) Slight increase in the body weight of eTead1-cOE 
mice (mean 8.2 g, n=5) compared to controls (mean 7.5 g, n=6) at P16. (C) eTead1-cOE 
mice display no significant differences in the heart weight to tibia length ratio compared 
to controls at P16. (D) Isolated cardiomyocytes from P16 eTead1-cOE hearts (n=3) show 
a slight increase in cell length (mean 96 µm) compared to control (mean 90 µm, n=3). 
The width of cardiomyocytes in eTead1-cOE mice (mean 15.9 µm, n = 3) is not 
significantly different from controls (mean 15.4 µm, n = 3). The cardiomyocyte area in 
eTead1-cOE (mean area 1261 µm2, n = 3) is slightly bigger compared to controls (mean 
area 1153 µm2, n = 3). Data are means ± SD, ns = not significant (P ≧ 0.05), * = P < 
0.05, ** = P < 0.005, **** = P < 0.001. 
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Figure 35. TEM images of control (upper panel) and eTead1-cOE (lower panel) 
cardiomyocytes demonstrate no ultrastructural differences between groups (P16). 
NUC – nucleus, ID – intercalated disk, C – capillary, Z – Z-disks, m – mitochondria. 
 
Immunohistochemical analysis of P16 eTead1-cOE mice hearts showed 
enhanced TEAD1 signal in cardiomyocytes compared to control hearts. As 
expected, HA as well as FLAG epitope tagged TEAD1 localized exclusively to 
cardiomyocyte nuclei detected in eTead1-cOE cardiomyocytes as shown in 
Figures 36A - 36F. These observations were in line with qRT-PCR results, which 
displayed a 2.5-fold (P2-P3) or a 13-fold (P16-17) increased Tead1 level in 
isolated cardiomyocytes from Tead1 GOF mice (Figure 36G). 
Western blot analysis (anti-HA antibody) of heart protein lysates detected 
TEAD1-Flag-HA fusion protein exclusively in eTead1-cOE hearts (Figure 36H). 
Results 
 85 
 
 
Figure 36. Cardiomyocyte restricted Tead1-Flag-HA overexpression in eTead1-cOE 
mice (P16). (A – F) Representative fluorescent images of P16 eTead1-cOE and P16 
control heart sections. HA and FLAG signals are absent in controls (panels B, C) and 
detectable in cardiomyocyte nuclei of eTead1-cOE hearts (panels E, F; labeled with 
arrows in boxed regions at higher magnification). Note that endogenous TEAD1 protein 
is detected in eTead1-cOE as well as in control (panels A, D; labeled with arrows in 
boxed regions at higher magnification). Red – TEAD1 / FLAG / HA; green – F-actin; blue 
– DAPI. (G) The mean expression of Tead1 in isolated P2-P3 cardiomyocytes is 2.5-
times increased in eTead1-cOE mice (n=3) compared to control (n=3). Isolated 
cardiomyocytes from P16-P17 eTead1-cOE mice (n=3) express 13-times more Tead1 
than their control counterparts (n=3). Tead1 expression levels were normalized to Gapdh 
expression. Data are means ± SD, ns = not significant (P ≧ 0.05), * = P < 0.05, ** = P < 
0.005, *** = P < 0.002, n = 3. (H) Western bolt analysis shows detection of the TEAD1-
Flag-HA fusion protein at the calculated size of 55 kDa by the use of a HA antibody 
exclusively in heart lysates of P16 eTead1-FlagHA overexpressing mice (n=3). Scale 
bar: 30 µm. 
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The functionality of the Tead1 GOF allele was validated on conditional Tead1-
deficient genetic background. For this purpose, conditional MCK-Cre::Tead1fl/fl 
mice were crossed to Tead1-Flag-HATg/Tg mice to create MCK-Cre::Tead1fl/fl 
Tead1-Flag-HATg/Tg mice, referred to as p(postnatal)Tead1-Rescue mice (Figure 
37A). These mice have a normal life span comparable to controls, whereas 
pTead-cKO mice died within 4 weeks after birth (Figure 37B) demonstrating the 
functionality of the exogenous Tead1-Flag-HA construct. Importantly, these data 
demonstrate that overexpression of Tead1-Flag-HA rescues the lethal heart 
phenotype of pTead1-cKO mice. 
 
 
Figure 37. Survival of mice with cardiomyocytes specific Tead1 deletion is rescued 
by cardiomyocytes specific overexpression of Tead1-Flag-HA (pTead1-Rescue 
mice). (A) Schematic illustration of MCK-Cre driven recombination in pTead1-Rescue 
mice. (B) Kaplan-Meier curve of the survival rate shows no differences in the life span of 
control (n = 5) and rescued mice (n = 5). All pTead1-cKO mutants (n = 24) died within 
first 4 weeks after birth. Blue – control; green – pTead1-Rescue; red – pTead1-cKO. 
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As a next step, the proliferation capacity of embryonic and postnatal Tead1-Flag-
HA overexpressing cardiomyocytes was analyzed based on EdU incorporation. 
The results presented in Figure 38 and 39 show that the number of proliferative 
(EdUpos) cardiomyocytes was increased by approximately 1.5-fold in both, E12.5 
and P3 Tead1-Flag-HA overexpressing mice in comparison to control littermates. 
Interestingly, Tead1 GOF hearts displayed a higher number of EdUpos 
proliferating cardiomyocytes in the trabecular layer in comparison to the compact 
layer (Figures 38H and 38I). 
 
 
Figure 38. Increased proliferation of embryonic eTead1-cOE cardiomyocytes 
(E12.5). (A - C) Representative fluorescent images of EdU-labelled E12.5 control hearts. 
(D - F) EdU-labeling in E12.5 eTead1-cOE heart sections displays increased number of 
EdUpos (red) cardiomyocytes, especially in the trabecular layer of eTead1-cOE hearts. 
Of note, eTead1-cOE hearts are hypertrabeculated in comparison to control hearts. Red 
– EdU, green – ACTN2, blue – DAPI; TL – trabecular layer, CL – compact layer (outlined 
with dashed white line), Epi – epicardium. (G) eTead1-cOE hearts (n=3) comprise 32% 
and control hearts (n=3) approximately 21.5% of EdUpos cardiomyocytes. (H) No 
difference in the number of EdUpos cardiomyocytes are detected between compact layers 
of control (n=3) and eTead1-cOE hearts (n=3). (I) The number of EdUpos cardiomyocytes 
in the trabecular layer of eTead1-cOE hearts (n=3) is 2.5-fold increased in comparison 
to control (n=3). Data are means ± SD, ns = not significant (P ≧ 0.05), ** = P < 0.005; 
hpf – high-power field. Scale bar: 30 µm. 
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Figure 39. Increased cardiomyocyte proliferation in eTead1-cOE mutants at P3. (A 
- F) Representative fluorescent images show increase in number of EdUpos 
cardiomyocytes in eTead1-cOE hearts (D-F) compared to control (A-C). Red – EdU, 
green – DMD (dystrophin), blue – DAPI. (G) eTead1-cOE hearts (n=3) display about 
17% and control hearts (n=3) approximately 11.5% of EdUpos cardiomyocytes. Data are 
means ± SD, * = P < 0.05; hpf – high-power field. Scale bar: 30 µm. 
 
 
In contrast, apoptosis rates at P12 displayed no significant differences in the 
number of TUNELpos cardiomyocytes in eTead1-cOE and control mice. Figure 40 
depicts representative images resulting from TUNEL staining reactions and 
corresponding quantifications, which indicate comparable rates of TUNELpos 
cardiomyocytes (around 2%) in both groups. 
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Figure 40. Confocal micrographs showing no differences in the number of 
TUNELpos cardiomyocytes in P12 control and eTead1-cOE hearts. (A and B) 
TUNELpos cardiomyocytes (red) are indicated with arrows. Dystrophin (DMD) is 
immunolabeled in green (left panels), F-Actin is labeled with phalloidin633 in green (right 
panels) and nuclei are blue labeled in all panels. (C) eTead1-cOE (n=3) and control (n=3) 
hearts display comparable number of TUNELpos cardiomyocytes (around 2%). Data are 
means ± SD, ns = not significant (P ≧ 0.05). Scale bar: 30 µm.  
 
Taken together, increased cardiomyocyte proliferation in Tead1 GOF mutants 
indicates a phenotypic shift of the heart towards a transient hyperplasia without 
morphological and functional alterations. 
 
3.6 Altered TEAD1 expression influences proliferation and 
growth of isolated postnatal cardiomyocytes 
For a more comprehensive analysis of postnatal Tead1 knockout as well as 
Tead1-Flag-HA overexpressing cardiomyocytes, P3 cardiomyocytes from 
pTead1-cKO and eTead1-cOE mice were isolated and cultured for 2 days. Figure 
41 compares the overall appearance of cultured control, pTead1-cKO and 
eTead1-cOE cardiomyocytes. By immunofluorescence, cardiomyocytes of 
pTead1-cKO mice were loosely distributed in culture dish and displayed a 
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heterogeneous population of TEAD1pos and TEAD1neg cardiomyocytes due to 
incomplete recombination mediated by MCK-Cre at early postnatal stages as 
previously observed in heart tissue sections of pTead1-cKO hearts (see Figure 
56B). Noticeably, TEAD1neg cardiomyocytes were smaller in size compared to 
TEAD1pos cardiomyocytes (Figure 41B). In marked contrast, Tead1-Flag-HA 
overexpressing cardiomyocytes were apparently larger in size and formed a 
uniform confluent cell layer (Figure 41C). 
 
 
Figure 41. Effects of Tead1 deletion and Tead1 overexpression on isolated P3 
cardiomyocytes. (A) Postnatal cardiomyocytes from control hearts show nuclear 
TEAD1 signal. (B) Cardiomyocyte cultures from pTead1-cKO hearts display 
heterogeneous TEAD1pos and TEAD1neg cardiomyocyte populations. Note that TEAD1neg 
cardiomyocyte (arrow) is much smaller than TEAD1pos cardiomyocyte (asterisk). (C) 
Tead1-Flag-HA overexpressing cardiomyocytes from eTead1-cOE hearts display more 
intense TEAD1 signal and are enlarged in size compared to control cardiomyocytes. Red 
– TEAD1, green – ACTN2, blue – DAPI. Scale bar: 30 µm. 
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In order to validate our in vivo observations of Tead1 loss- and gain-of-function 
hearts we cultured in the next step cardiomyocytes from pTead1-cKO and 
eTead1-cOE P3 hearts and scored for proliferation based on 24 h of EdU 
incorporation. The data presented in Figure 42 show that cultured Tead1-Flag-
HA overexpressing cardiomyocytes display a 4-fold increase of EdUpos cells 
compared to control. In marked contrast, isolated cardiomyocytes from pTead-
cKO mutants showed almost no EdUpos cardiomyocytes (less than 0.5% of cells) 
compared to control (about 9%), which is in line with our in vivo data shown in 
Figures 28 and 39. 
 
 
Figure 42. Tead1 overexpression stimulates proliferation of cultured P3 
cardiomyocytes, whereas Tead1 deficiency reduces proliferation. (A - C) 
Representative fluorescent images of EdU labelled isolated cardiomyocytes show almost 
no EdUpos cardiomyocytes in pTead1-cKO (B, arrow) compared to control (A). Isolated 
and cultured Tead1-Flag-HA overexpressing cardiomyocytes (C) show an increased 
number of EdUpos cardiomyocytes (arrows) as compared to controls (A). (B) Note that 
pTead1-cKO cardiomyocytes are small in size and display only a peripheral rim of 
ACTN2pos contractile filaments (asterisk). Red – EdU, green – ACTN2, blue – DAPI. (D) 
Cultures of eTead1-cOE cardiomyocytes comprise approximately 34%, control about 9% 
and pTead1-cKO less than 0.5% of EdUpos cardiomyocytes. Data are means ± SD, * = 
P < 0.05, n=3; hpf – high-power field. Scale bar: 30 µm. 
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3.7 TEAD1 regulates genes involved in cardiomyocyte 
differentiation, maturation, contraction and energy homeostasis 
in postnatal mouse cardiomyocytes  
An important objective of this study was the identification of TEAD1 target genes 
in the context of myocardial development and maturation. For this purpose, 
microarray-based transcriptome analysis of isolated P2-P3 (later referred to as 
“early”) postnatal cardiomyocytes (PCMs) from conditional loss-of-function 
(pTead1-cKO) as well as gain-of-function (eTead1-cOE) mutants were 
performed. The rationale for using early PCMs resided in the fact that TEAD1 is 
highly abundant on mRNA as well as on protein levels at this stage (Figure 8). 
Expression changes in both, Tead1 loss- and gain-of-function mutants, were 
compared to control (Creneg) littermates and quantified as downregulated by fold 
changes (FC) ≤ 0.75 or as upregulated by FCs ≥ 1.5 with adjusted P-value < 0.05. 
Since multiple studies have shown that TEAD TFs enhance the transcription of 
target genes [67, 134-137], we focused on genes downregulated upon Tead1 
deletion and upregulated upon Tead1 overexpression in PCMs. In total, 
expression of 462 genes was downregulated in Tead1 loss-of-function mutants 
whereas only 12 genes displayed an enhanced expression. In contrast, the 
analysis of Tead1 gain-of-function early PCMs revealed 364 upregulated and 245 
downregulated genes. In total, only 3 genes were identified, which were 
downregulated in Tead1 loss-of-function and upregulated in gain-of-function 
mutants including Olfr1382, Vmn2r86 and Gm15698.  
Due to incomplete MCK-Cre mediated deletion of Tead1 during early postnatal 
stages (Figures 20A, 41B and 56B), a microarray-based transcriptome analysis 
of isolated PCMs at a more advanced stage, P15-P19 (later referred to as “late”) 
was performed. This analysis revealed 742 downregulated and 312 upregulated 
genes upon Tead1 deletion. In contrast, cardiomyocyte-specific Tead1 
overexpression enhanced the expression of 70 genes and repressed the 
expression 725 genes, respectively. 
Gene set enrichment analysis (GSEA) of late PCMs isolated from pTead1-cKO 
mutants showed a negative enrichment score representing downregulation of 
genes involved in cardiac muscle contraction (ES = -0.61), which was inversely 
correlated with upregulation (positive enrichment score, ES = 0.39) in Tead1-
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overexpressing cardiomyocytes (Figure 43A). Similar transcriptional changes 
were detected for genes involved in oxidative phosphorylation, which were 
downregulated (ES = -0.70) upon Tead1 deletion and upregulated (ES = 0.47) 
upon Tead1 overexpression (Figure 43B). 
 
 
Figure 43. GSEA of TEAD1 regulated genes. (A) Genes involved in cardiac muscle 
contraction were downregulated (ES = -0.61, P < 0.001) upon Tead1 deletion and 
upregulated (ES = 0.39, P < 0.001) upon Tead1 overexpression. (B) Expression of genes 
involved in oxidative phosphorylation was decreased (ES = -0.70, P < 0.001) upon Tead1 
deletion and enhanced (ES = 0.47, P < 0.001) upon Tead1 overexpression. ES - 
enrichment score. (pTead1-cKO: n = 3; eTead1-cOE: n = 2; control: n = 4). 
 
In contrast, gene clusters for extracellular matrix (ECM) receptor interaction, focal 
adhesion, cell adhesion molecules (CAMS) as well as gap junction were 
enhanced in Tead1-cKO mutants and vice-versa silenced upon Tead1 
overexpression in late PMCs indicating indirect effects of TEAD1 on these gene 
clusters (Figure 44). 
In addition, GSEA revealed upregulation of the gene clusters encoding the TGF-
b signaling pathway (ES = 0.71) in pTead1-cKO cardiomyocytes (Figure 45A). 
Moreover, gene clusters of adherens junction (ES = 0.64) and VEGF (Vascular 
Endothelial Growth Factor) signaling pathway (ES = 0.56) were also enriched. 
On the contrary, the genes involved in fatty acid metabolism (ES = -0.72), which 
is a common observed phenomenon during heart failure (reviewed in [138]), were 
downregulated (Figure 45A). In Tead1 gain-of-function PCMs genes involved in 
cell proliferation processes including Insulin- (ES = 0.46), mTOR- (ES = 0.45), 
Results 
 94 
ERBB- (ES = 0.37) and WNT-signaling pathways (ES = 0.37) were upregulated 
(Figure 45B).     
 
 
Figure 44. GSEA of TEAD1 regulated genes. (A) Upregulation (ES = 0.79, P < 0.001) 
of genes involved in ECM receptor interaction in pTead1-cKO cardiomyocytes and 
downregulation (ES = -0.54, P < 0.001) upon Tead1 overexpression. (B) Upregulation 
(ES = 0.66, P < 0.001) of genes involved in focal adhesion upon Tead1 deletion and 
downregulation (ES = -0.46, P < 0.001) upon Tead1 overexpression. (C) Upregulation 
(ES = 0.67, P < 0.001) of genes involved in cell adhesion molecules in pTead1-cKO 
cardiomyocytes and downregulation (ES = -0.39, P = 0.007) in eTead1-cOE 
cardiomyocytes. (D) Upregulation (ES = 0.60, P = 0.003) of genes involved in GAP 
junctions upon Tead1 deletion and downregulation (ES = -0.42, P < 0.007) upon Tead1 
overexpression. ES - enrichment score. (pTead1-cKO: n = 3; eTead1-cOE: n = 4; control: 
n = 2). 
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Figure 45. GSEA of TEAD1 regulated genes. (A) Enrichment plots show enhancement 
of TGF-beta signaling pathway (ES = 0.71, P < 0.001), adherens junction (ES = 0.64, P 
< 0.001) and VEGF signaling pathway (ES = 0.56, P = 0.013) as well as downregulation 
of genes involved in fatty acid metabolism (ES = -0.72, P < 0.001) upon Tead1 deletion 
in late PCMs. (B) Enrichment plots show enhancement of Insulin- (ES = 0.46, P < 0.001), 
mTOR- (ES = 0.45, P < 0.001), ERBB- (ES = 0.37, P < 0.001) and WNT-signaling 
pathways (ES = 0.37, P < 0.001) upon Tead1 overexpression in late PCMs. ES - 
enrichment score. (pTead1-cKO: n = 3; eTead1-cOE: n = 2; control: n = 4) 
 
Merging datasets of downregulated genes in early and late pTead1-cKO PCMs 
resulted in total of 8 genes: Mylk4, Lrtm1, Scd4, Abcc8, Crhr2, Emp2, Tns1 and 
nR5s25 (Figure 46A).  
In order to analyze the direct binding of TEAD1 in promoter region of potential 
target genes, TEAD1 chromatin immunoprecipitation combined with sequencing 
analysis (ChIP-seq) in early PCMs isolated from WT mice was performed. This 
analysis revealed that TEAD1-occupied 1675 binding sites in total, 606 of them 
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were located in promoter regions, which were defined as transcription start site 
(TSS) plus 5000 nucleotides up- and down-stream, respectively. In order to 
identify MCAT consensus sequences in TEAD1-occupied sites, the data were 
analyzed for two common consensus MCAT-motives (CATTC and 
CATTCC[TA]). Both consensus sequences were strongly enriched in TEAD1-
occupied sites (CATTC 4-fold and CATTCC[TA] 2-fold).    
In order to identify direct TEAD1 target genes, downregulated genes of pTead1-
cKO late PCMs were merged with TEAD1 promoter occupied sites obtained from 
ChIP-seq analysis, which finally resulted in 63 matched genes, out of them 36 
contained MCAT-elements in the corresponding promoter regions (Figure 46B). 
The histone 3 acetylation on lysine 9 (H3K9Ac) is highly corelated with active 
promoters [139], therefore the ChIP-seq analysis using antibody directed against 
H3K9Ac was performed in murine WT early PCMs and revealed in total 8361 
peaks, among them 7257 were located in promoter regions. In order to identify 
active TEAD1-occupied promoters, the 63 downregulated genes upon Tead1 
deletion were merged with H3K9Ac peaks from our ChIP-seq analysis and 
identified 26 candidates, which displayed TEAD1-occupied sites with active 
H3K9Ac-marked regulatory elements (Figure 46B). 
 
 
Figure 46. Combined transcriptome profiling and genome-wide binding analysis 
identified multiple cardiomyocyte-specific TEAD1 regulated genes. (A) Comparison 
of downregulated genes (FC ≤ 0.75) during early and late stages of pTead1-cKO PCMs 
resulted in 8 genes plus Tead1. (B) Merging of downregulated genes in late Tead1-cKO 
PCMs (FC ≤ 0.75) with TEAD1-occupied promoter sites in WT early PCMs revealed 63 
candidates, 36 of them contained conserved MCAT-motives and 26 contained H3K9Ac 
peaks. 
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In our analysis, we defined direct TEAD1 targets if they fulfill the following 3 
criteria: 1) reduced expression upon Tead1 deletion; 2) direct TEAD1 binding in 
promoter region, and 3) transcriptionally active region. These stringent criteria 
resulted in totally 26 targets, out of them 6 have been previously associated with 
striated muscle dysfunctions including Crhr2, Adprhl1, Nnt, Foxo3, Coro6 and 
Irf2bp2 (Figures 47 and 48). Furthermore, reduced expression of Crhr2 (by 87 %) 
and Coro6 (by 40 %) could be validated by qRT-PCR in late Tead1-deficient 
PCMs (Figure 50A). 
  
 
Figure 47. Examples of candidate genes regulated by TEAD1 in murine 
cardiomyocytes and their Log2 fold changes upon Tead1 deletion (bars: yellow – 
early PCMs and red – late PCMs) and overexpression (bars: green - early PCMs and 
blue - late PCMs) in PCMs. Black T below gene aliases represents TEAD1 peaks, red 
T represents a presence of MCAT sequences as well as TEAD1 peaks, Ac represents 
H3K9Ac peaks, which were detected by our in-house bioinformatics analysis, blue T 
represents peaks identified manually using IGV. Asterisk above the corresponding bars 
resembles transcriptional fold changes with a P-value < 0.05. Early PCMs were isolated 
from control (n = 4), pTead1-cKO (n = 2) and eTead1-cOE (n = 2) hearts. Late PCMs 
were isolated from control (n = 4), pTead1-cKO (n = 3) and eTead1-cOE (n = 2) hearts. 
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Figure 48. TEAD1 binds to the promoter region of transcriptional active Adprhl1 
(A), and Crhr2 (B) in early WT PCMs. Promoter regions of Adprhl1 (A), and Crhr2 (B) 
revealed an intense TEAD1 binding (TEAD1-A and TEAD1-B) visualized by a strong 
peak highlighted by red boxes without comparable peaks in the input (n = 2). H3K9Ac is 
visualized by horizontal blue bars at the bottom, n = 1 (visualized in IGV). 
 
Given that some of strongly dysregulated genes identified in Tead1 loss- or gain-
of-function cardiomyocytes using transcriptome analyses (Figure 47) were not 
detected by our in-house bioinformatics settings for ChIP-seq analysis, the 
TEAD1 ChIP-seq data were manually analyzed with Integrative Genomic Viewer 
(IGV) software (available at: https://software.broadinstitute.org/software/igv/). 
Using this approach, TEAD1 binding sites were identified in promoter regions of 
Acta2, Scd4, Mylk3 and Abcc8 (Figure 47). Although Mylk4 was found to be one 
of the most downregulated genes in Tead1 loss-of-function cardiomyocytes 
(Figure 47), no TEAD1 occupancy of Mylk4 promoter was detected using IGV.  
qRT-PCR validation of Acta2 and Mylk4 expression in Tead1-deficient late PCMs 
confirmed our transcriptome profiling and revealed strongly reduced mRNA levels 
of Mylk4 (by 94%) as well as Acta2 (by 93%) (Figure 50A). Surprisingly, Myocd 
expression was unaltered in Tead1-deficient cardiomyocytes (Figures 50A).  
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Figure 49. Acta2 promoter displays TEAD1 binding, whereas Mylk4 promoter 
shows no TEAD1 binding. (A) In Mylk4 promoter region as well as gene body no 
TEAD1-occupied sites are present. (B) Acta2 display TEAD1 peaks (red boxes) without 
comparable peaks in the input. H3K9Ac is visualized by horizontal blue bars at the 
bottom (visualized in IGV).    
 
Myh7 has been previously reported as a direct TEAD1 target gene in rat and 
mouse cardiomyocytes and is a typical marker for the fetal myocardial gene 
program ([15, 105] and reviewed in [104]). According to our ChIP-Seq analysis 
results, Myh7 showed a strong promoter occupancy by TEAD1 and H3K9Ac, 
respectively, in early PCMs indicating a direct regulation of Myh7 expression by 
TEAD1 (Figures 47 and 51A). Although Myh7 expression was unaltered in 
Tead1-deficient late PCMs (Figures 47 and 50A), elevated Myh7 mRNA levels 
were detected in Tead1-overexpressing cardiomyocytes (Figures 47 and 50B), 
which might be explained by the physiological Myh7 downregulation during 
cardiomyocyte differentiation and maturation shown in Figure 50C.  
Another gene, which partially fulfilled our criteria was Nmrk2, indicated by a 
strong TEAD1 and H3K9Ac promoter occupancy. Early Tead1-deficient PCMs 
displayed a strong downregulation of Nmrk2, whereas in late PCMs Nmrk2 
expression was 2-fold increased (Figure 47). 
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Figure 50. Tead1-deficient late PCMs display reduced Acta2, Mylk4, Crhr2, Coro6 
mRNA levels, whereas Myh7 and Myocd remains unaltered. (A) Tead1 deletion 
results in downregulation of Acta2, Mylk4, Crhr2 and Coro6 mRNAs, whereas, Myh7 and 
Myocd expression levels are unaltered. (B) Tead1 overexpression results in an 
enhanced Myh7 expression. (C) Continuous downregulation of Myh7 expression (by 
98%) during cardiomyocyte differentiation and maturation in WT mice (from E13.5 to 8 
weeks). Values were normalized to Gapdh mRNA levels. X – gene. Data are means ± 
SD, ns = not significant (P ≧ 0.05), * = P < 0.05, ** = P < 0.005, *** = P < 0.002, n = 3. 
 
TEAD1 binding to Myh7 and Acta2 loci was validated by qChIP-PCR using 
specific primers located in the corresponding promoter regions. Our analysis 
revealed an enrichment for TEAD1 as well as RNA-Pol2 and H3K9Ac binding, 
indicating a transcriptionally active promoter for Myh7 and Acta2. No enrichment 
was observed for IgG binding, which served as a background control (Figure 51).  
 
 
Figure 51. qChIP-PCR validation of TEAD1-occupied Myh7 and Acta2 promoters. 
(A) PCR results display an enrichment of RNA-Pol2 (4.5%), H3K9Ac (16.5%) and 
TEAD1 (1.8%) binding in comparison to control IgG (0.02%) in Myh7 promoter, relative 
to 10 % input. (B) PCR results revealed an enrichment of H3K9Ac (13%) and 
TEAD1(1.6%) binding in comparison to control IgG (0.3%) in Acta2 promoter, relative to 
10 % input. Data are means ± SD, ns = not significant (P ≧ 0.05), * = P < 0.05, ** = P < 
0.005, n = 3.  
Results 
 101 
Another group of genes comprising Amotl2 and Ctgf, which have been previously 
reported as TEAD1 target genes [48, 140], displayed strong occupancy by 
TEAD1 and H3K9Ac (Figure 52), however expression levels were nearly 
unaltered in Tead1 loss- and gain-of-function cardiomyocytes (data not shown).  
 
 
Figure 52. TEAD1 occupies promoter regions of transcriptional active Amotl2 and 
Ctgf genes in early PCMs. (A) Amotl2 and (B) Ctgf peaks are highlighted by red boxes. 
H3K9Ac is visualized by horizontal blue bars at the bottom representing transcriptional 
activity of this gene (visualized in IGV). 
 
 
Expression of several known players of the Hippo-pathway downstream targets 
was nearly unaltered in Tead1 loss- and gain-of-function cardiomyocytes with the 
exception of Vgll-2 and Ajuba (Figure 53). Vgll-2 showed a 4-fold enhanced 
expression in pTead1-cKO late PCMs. In contrast, Ajuba revealed a 1.65-fold 
upregulation upon Tead1 deletion and a slight downregulation while Tead1 
overexpression in early PCMs. In addition, TEAD1-occupied also promoter 
regions of Tead4, Vgll-4, Yap1 and Wwtr1, however the expression of the 
corresponding transcripts was unaltered in Tead1 loss- and gain-of-function 
cardiomyocytes (Figure 53).   
Results 
 102 
 
Figure 53. Examples of expressional changes of characterized Hippo-pathway 
players upon Tead1 deletion (yellow and red bars) and overexpression (green and 
blue bars) in early versus late PCMs. Black T above gene aliases represents TEAD1 
peaks, red T represents a presence of MCAT sequences as well as TEAD1 peaks, Ac 
represents an H3K9Ac peaks, which were detected by our in-house bioinformatics 
analysis. Asterisk above the corresponding bars resembles transcriptional fold changes 
with a P-value < 0.05. Early PCMs were isolated from control (n = 4), pTead1-cKO (n = 
2) and eTead1-cOE (n = 2) hearts. Late PCMs were isolated from control (n = 4), 
pTead1-cKO (n = 3) and eTead1-cOE (n = 2) hearts.  
 
Interestingly, TEAD1 binds to its own promoter in H3K9Ac-marked region 
suggesting that TEAD1 positively regulates its own expression (Figure 54).  
 
 
Figure 54. Binding of TEAD1 to its own transcriptional active promoter. TEAD1 
bindings peaks are highlighted by red boxes. H3K9Ac peaks are visualized by horizontal 
blue bars at the bottom representing transcriptional activity of Tead1 gene (visualized in 
IGV). 
 
3.8 TEAD1 activates Acta2 expression in cardiomyocytes  
Smooth muscle actin (ACTA2) has been previously identified as a direct TEAD1 
target in mouse SMCs and myofibroblasts [60, 63]. In the present study, ChIP-
seq analysis of early PCMs showed TEAD1 occupancy in Acta2 promoter region 
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and microarray analysis of pTead1-cKO cardiomyocytes revealed a significant 
Acta2 downregulation indicating a direct transcriptional regulation of Acta2 by 
TEAD1 (Figures 47, 49B, 50A and 51B). To elucidate whether Acta2 expression 
is impaired in embryonic cardiomyocytes of eTead1-cKO mutants, E12.5 
embryonic hearts were co-stained for ACTA2, TEAD1 and F-Actin. Figure 55 
shows that cardiomyocytes in control embryonic hearts were positive for both, 
ACTA2 and TEAD1. In contrast, cardiomyocytes in eTead1-cKO hearts displayed 
reduced ACTA2 signal in TEAD1neg cardiomyocytes. 
 
 
Figure 55. Embryonic cardiomyocytes display decreased ACTA2 in E12.5 eTead1-
cKO hearts. Representative images of E12.5 heart sections co-stained for ACTA2, 
TEAD1, F-Actin and DAPI. (A – C) Embryonic TEAD1pos cardiomyocytes in control hearts 
are ACTA2pos. (D - F) Cardiomyocytes in eTead1-cKO hearts exhibit decreased 
abundance of ACTA2. F-Actin signal intensity is almost unaltered in both, control and 
eTead1-cKO hearts. Note that in eTead1-cKO hearts only epicardial cells are TEAD1pos 
(asterisk in panels D, E, F). Of note, cardiomyocytes in both, control and eTead1-cKO 
hearts display comparable F-Actin staining intensities. Green – TEAD1, red – ACTA2 / 
F-Actin, blue – DAPI, TL – trabecular layer, CL – compact layer (outlined with dashed 
white line), Epi – epicardium. Scale bar: 30 µm. 
 
Numerous studies demonstrated a step-wise decline of Acta2 expression in 
postnatal cardiomyocytes [35, 141, 142]. Therefore, analysis of ACTA2 
abundance was examined by immunofluorescence upon Tead1 deletion and 
overexpression at postnatal stages P3, P12 and P24. Analysis revealed that 
cardiomyocytes of Tead1-cKO mutants at P3 displayed reduced ACTA2 signal 
compared to control hearts (Figure 56). In contrast to Tead1-cKO mutants, 
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Tead1-overexpressing hearts at P3 showed increased ACTA2 intensity in 
cardiomyocytes.  
 
 
Figure 56. Decreased ACTA2 in cardiomyocytes of P3 pTead1-cKO hearts. 
Representative fluorescent images of P3 heart sections. Cardiomyocytes of control (A) 
and eTead1-cOE hearts (C) are strongly positive for ACTA2. On the contrary, 
cardiomyocytes of pTead1-cKO hearts (B) display a reduced ACTA2 signal. Notice that 
F-Actin signal in cardiomyocytes and ACTA2 in vessels (V) is of comparable intensities 
in the studied groups (panels D, E, F). Green – TEAD1 / F-Actin, red – ACTA2, blue – 
DAPI; V - Vessels. Scale bar: 30 µm. 
 
The differences between groups in ACTA2 abundance and distribution patterns 
were even more pronounced in P12 and P24 hearts (Figures 57 and 58). As 
shown in Figure 58, ACTA2 and TEAD1 signals in P24 mutant cardiomyocytes 
were almost negligible, whereas all cardiomyocytes in control hearts remained 
TEAD1pos and several of them showed a strong ACTA2 signal (Figure 58) 
implying that ACTA2 abundance declines in parallel with TEAD1. These finding 
were further strengthened by immunofluorescent analysis of control and Tead1-
overexpressing hearts, which clearly showed that ACTA2 is more abundant in 
Tead1-overexpressing cardiomyocytes compared to control cardiomyocytes 
(Figure 59). 
As expected, ACTA2 intensity was unaltered in SMCs of coronary vessels in all 
studied groups including control, cardiomyocyte-specific Tead1 gain- and loss-of 
function hearts irrespective from the examined postnatal stages (Figures 56 - 59). 
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Figure 57. Reduced ACTA2 in cardiomyocytes of P12 pTead1-cKO hearts and 
increased ACTA2 in cardiomyocytes of eTead1-cOE hearts. Cardiomyocytes in 
pTead1-cKO heart (panels B, E) are weakly positive for ACTA2. Cardiomyocytes in 
eTead1-cOE heart (panels C, F) are strongly positive for ACTA2 as compared to control 
cardiomyocytes (panels A, D). ACTA2 signal in vessels (V) is used as internal reference 
and its intensity is comparable in all groups. Red – ACTA2, green – F-Actin, blue – DAPI, 
V – Vessels. Scale bar: 30 µm. 
 
 
Figure 58. Reduced ACTA2 signal in P24 pTead1-cKO cardiomyocytes. 
Representative fluorescent images of P24 control and pTead1-cKO hearts. (A – D) All 
cardiomyocyte of control hearts are TEAD1pos (asterisk, panels C, D), whereas only a 
few cardiomyocytes are ACTA2pos (arrows, panels A, B). (E – H) Cardiomyocytes in 
pTead1-cKO hearts are TEAD1neg (panels G, H) and ACTA2neg (panels E, F). The 
cardiomyocytes in control and in pTead1-cKO hearts are positive for F-Actin (panels B, 
F) and dystrophin (DMD, panels C, D, G, H). ACTA2 signal in vessels (V) is comparable 
in both groups (panels A, B, E, F). Red – ACTA2 / DMD, green – F-Actin / TEAD1, blue 
– DAPI; V – Vessels. Scale bar: 30 µm. 
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Figure 59. Tead1-overexpressing cardiomyocytes remain ACTA2 positive at P30. 
Representative images of P30 heart sections co-stained for ACAT2, TEAD1 and F-Actin. 
Upper panels: In control hearts, all cardiomyocytes are F-Actinpos and TEAD1pos 
(asterisk), whereas only some cardiomyocytes are weakly positive for ACTA2. Lower 
panels: In contrast, in eTead1-cOE hearts the vast majority of cardiomyocytes are 
strongly positive for both TEAD1 and ACTA2 (arrows). ACTA2 signal intensity in vessels 
(V) and F-Actin signal in cardiomyocytes is equal in control and eTead1-cOE hearts. 
Green – TEAD1, red – ACTA2 / F-Actin, blue – DAPI. Scale bar – 30 µm. 
 
Several studies have linked ACTA2 re-expression and ultrastructural features of 
dedifferentiated cardiomyocytes [143, 144]. Therefore, transmission electron 
microscopy analysis of P16 hearts was performed and provided additional 
evidence for a higher abundance of terminally differentiated cardiomyocytes in 
pTead1-cKO mutants than in control hearts. A representative TEM image of 
undifferentiated cardiomyocytes frequently observed in control hearts is shown 
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in Figure 60. According with the previously described ultrastructural features 
[143, 144], undifferentiated cardiomyocytes are characterized by high content of 
mitochondria with varying size and shapes, glycogen deposits as well as low 
content of contractile structures. Differentiated cardiomyocytes observed in 
Tead1-cKO hearts are characterized by a high content of myofibrils, equally 
shaped mitochondria of mostly the same size and low glycogen deposits (Figure 
60).  
 
 
Figure 60. Typical ultrastructural features of differentiated versus undifferentiated 
cardiomyocytes in control and pTead1-cKO mutants (P16). Left panel: 
Representative TEM image of undifferentiated cardiomyocytes (control) characterized 
by high glycogen depositions (red asterisk) and numerous mitochondria (m) with varying 
sizes and shapes as well as low content of contractile structures. Right panel: Fully 
differentiated (pTead1-cKO) cardiomyocytes characterized by densely packed 
myofibrils, equally shaped mitochondria (m) of mostly same size and low glycogen 
deposits. Z – Z-disks. 
 
3.9 Enhanced MYLK4 expression in cardiomyocytes bordering 
infarction 
MYLK4 (Myosin Light Chain Kinase 4) has been previously reported to be 
strongly reduced in cardiomyopathies [145]. The present global transcriptomic 
analysis of early and late PCMs from pTead1-cKO hearts indicated that Mylk4 is 
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one of the most downregulated genes upon Tead1 deletion (Figure 47). In 
addition, elevated Tead1 expression levels in late PCMs of TEAD1 GOF mice 
strongly increased Mylk4 mRNA levels (Figure 47). For this reason, MYLK4 
protein levels were analyzed in control cardiomyocytes and in the settings of 
acute (4 days) and chronic myocardial ischemia (21 days) after myocardial 
infarction (MI) in adult WT mice. Under normal conditions, MYLK4 is not 
detectable in cardiomyocytes, whereas vessels display a strong MYLK4 signal 
(data not shown). During the acute phase of MI, cardiomyocytes bordering 
infarction were MYLK4pos (Figures 61A and 61B). In contrast, in the chronic 
phase, cardiomyocytes bordering post-infarction scars were almost MYLK4neg 
(Figures 61E and 61F), indicating MYLK4 activation mainly in acute ischemic 
cardiomyocytes. It is worthy to note that cardiomyocytes in either acute or chronic 
MI displayed discernible TEAD1 signal confined to cardiomyocyte nuclei (Figures 
61C, 61D, 61G and 61H).  
 
 
Figure 61. Transient myocardial MYLK4 expression in cardiomyocyte bordering 
infarction in acute (4 days) and chronic phases (21 days). Panels A - D: Acute phase 
(4 d after MI). (A and B) show Mylk4pos cardiomyocytes (arrows) bordering infarction. (C 
and D) Cardiomyocytes (arrows) and non-cardiomyocytes (star) are TEAD1pos. Panels 
E - H: Chronic phase (21 d after MI). (E and F) Note that cardiomyocytes bordering 
infarction are MYLK4neg (asterisk). (G and H) Cardiomyocytes (arrows) and non-
cardiomyocytes (star) are TEAD1pos. The scar area (Sc) is outlined with dashed white 
line. V labels MYLK4pos vessels. Green – MYLK4 / TEAD1, red – F-Actin, blue – DAPI; 
V – Vessels, Sc – scar area. 
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3.10 Induced Tead1 inactivation in isolated postnatal 
cardiomyocytes results in formation of inhomogeneous cell 
layer and retraction of filopodia  
An obvious feature of cultured cardiomyocytes isolated from pTead1-cKO mutant 
hearts was an incomplete deletion of Tead1, which resulted in TEAD1-positive 
and -negative cardiomyocytes (Figures 41B and 56B). In order to achieve a 
complete Tead1 inactivation in early PCMs (P3), a transgenic tamoxifen-inducible 
MCM-Cre::Tead1fl/fl strain, referred to as i(inducible)Tead1-cKO, was used. In 
this strain, the Cre-ERT2 fusion-protein is expressed under the control of Myh6 
promoter, which can be activated upon 4-Hydroxytamoxifen (4-HT) 
administration [111]. 4-HT treated control cardiomyocytes displayed 
characteristic spreading morphology and formed homogenous, synchronously 
beating cell monolayers (Figure 62, left panel). In contrast, iTead1-cKO 
cardiomyocytes retracted their filopodia and lost intercellular contacts resulting in 
heterogeneous, asynchronously beating cell layers (Figure 62, right panel).  
 
 
Figure 62. Isolated Tead1-deficient early PCMs undergo atrophy. Representative 
bright field images of isolated postnatal cardiomyocytes from control and iTead1-cKO 
after 8 days of 4-HT treatment. Left panel: Treated control cardiomyocytes appear as 
homogeneous cell culture and display a distinctive spreading morphology (red asterisk). 
Right panel: In contrast, treated iTead1-cKO myocytes retract initially formed filopodia 
(red arrows), which results in a heterogeneous cell layer. 
 
To verify whether Tead1 deletion in cultured early PMCs reflect the in vivo 
observed downregulation of Acta2, co-immunostaining for TEAD1 and ACTA2 
was performed. Similar with our in vivo observations, Tead1-deficient PCMs in 
culture displayed a concomitant loss of ACTA2 signal, as visualized by 
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immunofluorescence (Figure 63). However, a complete deletion of Tead1 was 
not achieved after 8 days of treatment as depicted by the presence of TEAD1pos 
cardiomyocytes. Importantly, F-Actin staining of 4-HT treated control and iTead1-
cKO cardiomyocytes showed regular sarcomeric cross-striations indicating that 
sarcomerogenesis in iTead1-cKO cardiomyocytes is not disturbed (Figure 63).  
 
 
Figure 63. Tead1 deletion reduces ACTA2 in P3 PCMs. (A and E) Representative 
fluorescent images of F-Actin cross-striation in isolated control (A) and iTead1-cKO (E) 
early PCMs. (Panels F - H) ACTA2 signal is diminished in Tead1-deficient myocytes 
(arrows) compared to TEAD1pos/Acta2pos myocytes (asterisks). (Panels B - D) Control 
cardiomyocytes are TEAD1pos / ACTA2pos. Non-cardiomyocytes are depicted with stars. 
Green – TEAD1, red – F-Actin / ACTA2, blue – F-Actin, white – DAPI. Scale bar: 30 µm. 
 
To achieve a higher Tead1 deletion efficiency, an adenovirus expressing a codon 
of improved Cre-recombinase (Ad-Cre), based on knockout approach was used 
in cultured postnatal cradiomyocytes. In order to determine the optimal virus to 
cardiomyocytes ratio (multiplicity of infection, MOI), isolated early PCMs 
conditionally expressing fluorescent Cre reporter (R26-CAGG-GFP) were 
infected with serial dilutions of virus titter (MOI of 10 -100) and scored for infection 
efficiency and cell survival. Infected cardiomyocytes were analyzed in IncuCyteÒ 
live cell analysis system to monitor cell confluence and GFP expression. The MOI 
of 20 was selected for further experiment because of optimal higher 
recombination efficiency and low toxicity (Figure 64).       
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Figure 64. Dose and time-dependent efficiency of Ad-Cre mediated GFP expression 
in early PCMs. (A) Representative bright field (left panel) and merged with GFP (right 
panel) images of infected GFPpos cardiomyocytes (green, asterisk). Note that cells 
displaying non-cardiomyocyte morphologies (white stars, presumably fibroblasts) are 
GFPneg. (B) Step-wise increase of Ad-Cre infected myocytes achieving 70% cell 
confluency at 96 h after transduction. (C) Step-wise increase in confluency of 
recombined GFPpos cells in dependence on MOI of Ad-Cre. Note that non-infected 
myocytes (blue line) display no GFP signal. Blue – no virus, Dark blue – MOI of 10, 
Magenta – MOI of 20, Purple – MOI of 40, Grey – MOI of 60, Red – MOI of 100; h – 
hours. 
 
Next, isolated Tead1fl/fl early PCMs, carrying homozygous conditional Tead1 
allele, were infected with Ad-Cre (MOI of 20) for 6 h to induce Tead1 deletion in 
culture. The infection resulted in efficient recombination after 4 days, which 
reduced Tead1 mRNA level by approximately 90%, consistent with the 
undetectable TEAD1 protein in western blot analysis (Figures 65E and 65F). In 
addition, expression levels of Acta2 and Crhr2 were also 3-fold and 16-fold, 
respectively, reduced compared to control cardiomyocytes, which were infected 
with an empty adenovirus (Ad-empty) (Figure 65E). Time-laps microscopy 
revealed reduced proliferation of Ad-Cre infected cardiomyocytes 4 days after 
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infection (Figures 65A - 65D). The observed increases in cell proliferation 8 days 
after transduction occurred presumably due to non-cardiomyocytes proliferation, 
e.g. fibroblasts (Figure 65C).  
 
 
Figure 65. Ad-Cre mediated Tead1 deletion in isolated PCMs supresses cell 
growth. (A) The curve represents the time course of confluency of control (Ctrl) infected 
(Ad-empty) cardiomyocytes. (B) Control cardiomyocytes forms a homogenous cell layer 
with spread cardiomyocytes (asterisk and boxed region). (C) The curve represents 
Tead1-deficient cardiomyocytes after Ad-Cre infection showing inhibition of cell 
proliferation and confluency 4 days after infection. (D) Tead1-deficient cardiomyocytes 
appear atrophied and retract the initially formed filopodia thereby loosing cell-to-cell 
contacts (arrows and boxed region) 4 days after transduction. (E) Significant expression 
reductions of Tead1 (by 90%), Acta2 (by 65%) and Crhr2 (by 94%) 4 days after Ad-Cre 
transduction. Values are normalized to Gapdh mRNA levels. Data are means ± SD, * = 
P < 0.05, n = 3. (F) Western blot displays strong TEAD1 protein reductions 4 days after 
Ad-Cre infection. GAPDH serves as a loading control. 
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Moreover, EdU-based proliferation assay revealed that Tead1-deficient 
cardiomyocytes displayed a 10-fold lower proliferation rate compared to control 
infected cultures (Figure 66). In addition, 4 days after Ad-Cre transduction all 
cardiomyocytes were TEAD1neg and appeared atrophied (Figures 66B, 66D and 
66F).  
 
 
Figure 66. Adeno-Cre mediated Tead1 deletion in isolated early PCMs results in 
reduced proliferation 4 days after infection. (A, C, E) Representative fluorescent 
images of control infected cultures showing EdUpos PCMs (white arrows, E) with nuclear 
TEAD1 signal (panels A, C). (B, D, F) Ad-Cre infected PCMs are TEAD1neg (panels B, 
D) and EdUneg cells (F). Non-cardiomyocytes are indicated with white stars in all images. 
(G) Ad-Cre infected cultures of PCMs display a 90 % reduction of proliferating EdUpos 
cardiomyocytes compared to control infected cultures. Green – TEAD1 / ACTN2, red – 
EdU / ACTN2, blue – DAPI; hpf – high-power field. Data are means ± SD; **** = P < 
0.001. 
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3.11 FGF2-TEAD1 pathways crosstalk in adult rat 
cardiomyocytes   
It is well established, that the cytokine FGF2 (Fibroblast Growth Factor 2) 
functions as a potent regulator of multiple cellular functions, including cell 
proliferation, differentiation, survival and migration [146-150]. In particular, it has 
been shown that FGF2 in the myocardium acts as a cardioprotective cytokine 
during ischemia and afterload-induced hypertrophy (reviewed in [147]). 
Moreover, FGF2 stimulation of cultured adult cardiomyocytes switches the 
expression of contractile genes from “adult” to “fetal” program [151]. Due to the 
fact that Acta2 expression is strongly stimulated by FGF2 [151], and given that 
Acta2 expression depends highly on TEAD1 (Figures 47-51, 55-59 and 63), we 
analyzed TEAD1 protein level in adult rat cardiomyocytes (ARCs) upon FGF2 
stimulation. Furthermore, it has been reported that stimulation of a1-adrenergic 
pathway in ARCs induces TEAD1 binding to Myh7 promoter thereby enhancing 
Myh7 expression [105]. In order to figure out, if either FGF2 or a1-adrenergic 
pathway induces Tead1 expression in ARCs, we performed independent FGF2 
and epinephrine stimulations combined with TEAD1 western blot analysis and 
time-lapse imaging. Interestingly, only FGF2 stimulation severely increased 
TEAD1 protein level, whereas TEAD1 protein was unaltered in epinephrine 
stimulated ARC, comparable to bovine serum albumin (BSA) stimulated controls 
(Figure 67A).  
A hallmark of FGF2 stimulated ARCs dedifferentiation is the loss of typical road 
shape characteristics and cell size increases upon spreading [148, 152], which 
can quantitatively be measured using time-lapse imaging. In order to analyze if 
FGF2 signaling is mediated via TEAD1, we performed siRNA-mediated 
knockdown (KD) of Tead1 (siTead1) and FGFR1 (siFGFR-1) in FGF2 stimulated 
ARCs. The main reason for targeting FGFR1 (FGF Receptor 1) is the fact that 
this receptor is highly abundant in cardiomyocytes [146, 153, 154]. 
Since FGF2 acts as a pro-hypertrophic cytokine, FGF2 stimulated control treated 
with non-targeting control siRNA (siCtrl) ACRs strongly increased in cell size 
compared to BSA treated siCtrl myocytes (Figures 67D and 67E). Interestingly, 
siTead1 cardiomyocytes did not increase in cell size upon FGF2 stimulation. 
Comparable to siTead1 KD cardiomyocytes, FGF2 stimulation of siFGFR1 KD 
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ARCs inhibited myocyte hypertrophy as judged by the percent of cell confluence 
and cell size (Figures 67D and 67E). Moreover, siTead1 as well as siFGFR1 rat 
cardiomyocytes recapitulated the atrophic phenotype observed in another cell 
system of isolated Tead1-deficient mouse cardiomyocytes (Figures 41B, 42B, 62, 
65C and 65D), suggesting that TEAD1 is regulated likely via FGF2 pathway.  
 
 
Figure 67. FGF2 enhances TEAD1 expression in cardiomyocytes. (A) Increased 
TEAD1 protein level in FGF2 stimulated ARCs, whereas epinephrine (EPI) stimulation 
has no impact on TEAD1 protein level. (B) Efficient siRNA mediated Tead1 knockdown 
(KD) in ARCs. (C) Schematic outline of the performed siRNA mediated KD and FGF2 
stimulation experiments. (D) Tead1 (red lines) as well as FGFR1 (magenta lines) KDs 
display an atrophic phenotype upon FGF2 stimulation, whereas siCtrl FGF2 stimulated 
cardiomyocytes (green lines) appear hypertrophied in comparison to non-stimulated 
ARCs (blue lines). (E) Images of siTead1, siFGFR1 and siCtrl treated road shaped ARCs 
(red arrows) before (4d, upper panels) and after FGF2 stimulation (11d, lower panels) in 
comparison to non-stimulated siCtrl ARCs. Note that siCtrl cardiomyocytes after FGF2 
stimulation (11d) dedifferentiate as characterized by morphology changes e.g. 
spreading, increasing in the size (red asterisk). EPI – epinephrine, d – day(s)  
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4   DISCUSSION 
 
The adult mammalian heart is a dynamic organ, which can adapt to workload 
alteration by physiological and morphological changes. The contraction of all 
cardiomyocytes within the myocardium is highly coordinated and synchronized to 
guarantee an adequate cardiac output, which is constantly increasing from 
embryonic development to postnatal heart growth. While embryonic heart 
development is mainly promoted by cardiomyocyte proliferation, the postnatal 
heart growth is predominantly supported by cardiomyocyte hypertrophy and 
terminal differentiation that limits heart regeneration [20, 24, 25, 27].  
Cardiogenesis is a precisely regulated process governed by signaling pathways 
and transcription factor networks, including GATA4, NKX2.5 (NK2 homeobox 5), 
ISL1 (Islet 1), TBX1 and 5 (transcription factor T-box 1 and 5) (reviewed in [155, 
156]).  
The present study indicates, that transcription enhancer factor 1 (TEAD1) is an 
important regulator of multiple genes responsible for cardiomyocyte proliferation, 
differentiation and growth, which are the hallmarks of cardiomyocyte plasticity. 
Moreover, during development as well as under pathological conditions, like 
hypertrophy, TEAD1 regulates the myocardial fetal gene program [12, 14-19, 73, 
99, 105]. In addition, it has been suggested that TEAD TFs and their 
transcriptional co-activator YAP1 act downstream of the Hippo-signaling 
pathway, which controls multiple cellular processes including regeneration, 
proliferation, stem cell maintenance as well as organ size regulation [89, 90, 140, 
157, 158]. In line with these observations, it has been shown that a-adrenergic 
stimulation of cardiomyocytes activates via TEAD1 the fetal gene Myh7 re-
expression thus facilitating hypertrophic cell growth [15, 64, 105].  
It has been shown, that constitutive Tead1 deletion in mouse is embryonic lethal 
at E11.5 due to heart malformations characterized by ventricular wall thinning 
and hypotrabeculation, whereas myofiber ultrastructure is not altered [12]. In 
order to identify whether cardiomyocytes are the primary cause of this phenotype 
we have conditionally inactivated Tead1 in this cell type during early cardiac 
development and observed similar morphological heart malformations. In 
addition, we showed that the proliferation rate of embryonic cardiomyocytes was 
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significantly reduced, whereas the number apoptotic cells was highly increased. 
In contrast, embryonic cardiomyocytes overexpressing Tead1 displayed 
enhanced proliferation accompanied by an unaltered apoptosis rate. However, 
the increased proliferation of embryonic cardiomyocytes in the latter strain had 
no impact on adult heart size and function, suggesting compensatory 
mechanisms. The present study demonstrated that cardiomyocyte-specific 
deletion of Tead1 in postnatal stage resulted in heart failure because of dilated 
cardiomyopathy (DCM) characterized by reduced cardiomyocyte proliferation 
and increased apoptosis rates associated with severe interstitial fibrosis. 
Importantly, the lethal heart phenotype of these conditional Tead1-deficient mice 
was rescued by cardiomyocyte-specific Tead1 overexpression. 
Combined global expression profiling of Tead1-deficient cardiomyocytes and 
genome wide TEAD1 binding studies in cardiomyocytes, enabled us to identify 
cardiomyocyte-specific direct TEAD1 target genes encoding cytoskeletal and 
contractile proteins, linker proteins between cellular and extracellular matrix, 
smooth muscle proteins and proteins involved in cardiomyocyte metabolism. 
Furthermore, our experiment using isolated adult rat cardiomyocytes stimulated 
with FGF2 demonstrated that TEAD1 protein level was increased downstream of 
the  FGF2-FGFR1-signaling pathway, which has been previously described to be 
involved in cardioprotection, cardiomyocyte development, proliferation, 
hypertrophy as well as angiogenesis in the heart ([151] and reviewed in [147]). 
 
4.1 Embryonic cardiomyocyte-specific Tead1 deletion results in 
embryonic lethality 
Since constitutive Tead1 mutants displayed severe embryonic heart 
malformations and are embryonically lethal [12], an alternative conditional 
targeted strategy for specific Tead1 deletion in early embryonic cardiomyocytes 
was used in the present study. In addition to the previously reported embryonic 
heart phenotype comprising ventricular wall thinning and hypotrabeculation, we 
detected reduced cardiomyocyte proliferation and increased apoptosis rates in 
our conditional Tead1 mutant. Furthermore, on the ultrastructural level we 
observed loosely distributed cardiomyocytes with undeveloped intercalated discs 
and decreased number of sarcomeric structures resulting in shorter myofibers.  
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The present study demonstrating increased cardiomyocyte proliferation in Tead1 
knockout hearts is in good agreement with those obtained in embryonic hearts 
with conditional inactivation of Yap1, which is a well-established TEAD1 
transcriptional co-activator [89]. In addition to reduced cardiomyocyte 
proliferation observed in Yap1 mutants, our Tead1 mutants displayed increased 
apoptosis rates, indicating a potential role of TEAD1 in cardiomyocyte death and 
survival.  
 
4.2 Specific Tead1 deletion in postnatal cardiomyocytes leads to 
severe heart failure  
In order to overcome embryonic lethality of mice with early cardiomyocyte-
specific Tead1 deletion, we have conditionally inactivated Tead1 in 
cardiomyocytes during postnatal stages. These mice died within 4 weeks after 
birth because of severe heart failure. In vivo analysis of Tead1 mutant mice using 
magnetic resonance imaging technique demonstrated contractile dysfunctions 
characterized by reduced left ventricular ejection fraction and biventricular 
dilation. Histological analysis demonstrated ventricular wall thinning, 
cardiomyocyte atrophy and enlargement of the intercellular space. Ultrastructural 
analysis of Tead1 mutant hearts revealed elongation and thinning of 
cardiomyocytes, an enlargement of the intercellular space as well as severe 
myocardial fibrosis. Morphometric analysis of isolated cardiomyocytes from 
Tead1 mutant hearts confirmed the elongation and thinning. Additionally, Tead1 
mutant hearts displayed a decrease in cardiomyocyte proliferation and significant 
increases in cardiomyocyte apoptosis rate, which might also explain the 
occurrence of myocardial fibrosis in these mice. The above-mentioned functional 
disturbances and morphological alterations are compatible with the clinical 
diagnosis of dilated cardiomyopathy (DCM). 
DCM is defined by a pathologically abnormal myocardium and an enlargement of 
the heart, which often affects all four chambers, especially in late disease stages. 
Most commonly, DCM is associated with reduced left ventricular (LV) contraction 
function, although in early stage of the disease the LV may be dilated, with only 
minimally reduced function (as reviewed in [159]). Recent studies have revealed 
an increasing number of gene mutations linked to DCM including structural, 
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sarcomere, costamere, Z band, nuclear membrane genes as well as genes 
regulating transcriptional networks downstream of signaling pathways e.g. AKT-
, GPCR-, NFAT-, WNT- and Hippo-pathways (reviewed in [30, 160-163]). 
Regarding the latter pathway, it has been shown that cardiomyocyte-specific 
overexpression of Mst1, the core-component of the Hippo-signaling pathway in 
mouse, leads to severe DCM associated with increased cardiomyocytes 
apoptosis, ventricular wall thinning and depressed cardiac function [79]. On the 
other hand, postnatal cardiomyocyte-specific inactivation of Yap1, which is 
inhibited by Hippo-pathway activation and is one of known TEAD1 cofactors, 
resulted also in severe cardiomyopathy and heart failure [157, 158]. Given that 
TEAD1 acts downstream of Hippo-pathway, our data in pTead1-cKO mice 
showing a DCM phenotype concur well with above mentioned observations. 
Cardiac interstitial and replacement fibrosis due to cardiomyocytes loss are a 
hallmark of DCM. As reviewed by Dobaczewski [164], elevated TGF-b expression 
levels in myocardium are associated with fibrosis and play an important role in 
cardiac remodeling in DCM and heart failure. In line with this, our gene set 
enrichment analysis of global expression changes in Tead1-deficient 
cardiomyocytes displayed enrichments of genes encoding the TGF-b signaling 
pathway such as Thbs1 (Thrombospondin1), Eng (Endoglin), Furin, Map3k7, 
Rab31 and Tgfb1 (Transforming-Growth Factor b1). Therefore, upregulation of 
the TGF-b pathway observed in our postnatal Tead1 mutant hearts might have 
contributed to myocardial fibrosis in these mice.  
Certainly, myocardial fibrosis, disturbed balance between cell proliferation and 
cell death, cardiomyocyte elongation as well as ventricular thinning might have 
played important roles in contractile cardiac dysfunction observed in Tead1 
mutants. However, the ultrastructural analysis revealed no obvious degenerative 
alterations in Tead1-deficient cardiomyocytes. Therefore, it is tempting to 
speculate that contractile dysfunction of Tead1 mutant hearts in the absence of 
striking morphological alterations in cardiomyocyte sarcomeric structures may 
culminate in heart failure. In favor of this hypothesis speaks numerous studies 
showing that overt heart failure and contractile insufficiency may occur even in 
the absence of degenerative changes in individual cardiomyocytes [165].  
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In agreement with our data on postnatal cardiomyocyte-specific Tead1 
inactivation, a recent report showed that inducible cardiomyocyte-specific Tead1 
deletion in adult murine cardiomyocytes results in severe DCM [18]. Moreover, a 
recently published study of the same research group supports our observations 
and shows that loss of Tead1 expression using Myh6-Cre in mouse 
cardiomyocytes resulted in postnatal lethality at P5-P9. Interestingly, this heart 
phenotype was characterized by reduced cardiomyocyte proliferation, severe 
fibrosis and heart failure due to DCM [108]. However, our study revealed 
additional effects of cardiomyocyte-specific Tead1 inactivation including impaired 
cardiomyocyte differentiation and maturation characterized by disturbed 
myofibrillogenesis. Importantly, these phenotypic changes in our postnatal Tead1 
deletion model occurred at later postnatal stages (at 2-4 weeks). It is worthy to 
note that in comparison to our postnatal MCK-Cre mediated Tead1 deletion, the 
earlier occurred heart phenotype in the Liu et al. study might result from utilizing 
an earlier Myh6-Cre delete allele.  
 
4.3 Tead1 overexpression stimulates embryonic cardiomyocyte 
proliferation resulting in hypertrabeculation    
Myocardial trabeculation increases cardiac output and permits nutrition as well 
as oxygen uptake in the embryonic myocardium prior to coronary vascularization 
without increasing heart size, thereby playing an essential role in the fetal heart 
growth and function. It is well accepted that trabecular cardiomyocytes are at a 
more advanced differentiation stage and therefore proliferate 2-times less than 
cardiomyocytes in the compact layer (reviewed in [164]). Although the 
mechanisms, which regulate cell cycle exit of trabecular cardiomyocytes are only 
partially understood, several studies suggested that trabecular layer growth 
mainly results from migrating cardiomyocytes of the compacted myocardium 
(reviewed in [166, 167]). In this context, the present conditional overexpression 
of Tead1 in embryonic cardiomyocyte resulted in enhanced proliferation, 
especially in the trabecular layer leading to transient ventricular 
hypertrabeculation during embryogenesis. However, this feature had no 
detrimental impact on subsequent postnatal heart growth.  
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The biological functionality and compatibility of TEAD1-Flag-HA (Tead1-Rescue 
strain) was assessed by compound Tead1 allele comprising the conditional 
cardiomyocyte-specific knockout combined with the gain-of-function (GOF) 
transgene. As expected, there were no differences between control and Tead1-
Rescue mice in life span. The present results obtained in mice with 
cardiomyocyte-specific overexpression of Tead1 demonstrating increased 
proliferation rates of trabecular cardiomyocytes during embryogenesis are in 
good accordance with the published observations in mice harboring constitutive 
active YAP1 (Yap1[S127A]) [89, 158]. Taken together, these data indicate highly 
coordinated activities of TEAD1 and YAP1 in the proliferation of trabecular 
cardiomyocytes. This conclusion is furthermore supported by data showing that 
YAP1 regulation of cardiomyocyte proliferation requires direct interaction with 
TEAD, which was demonstrated by two independent approaches using either a 
dominant negative peptide specifically blocking YAP1-TEAD interaction or a 
YAP1 point mutation-defective TEAD interaction [89]. These observations 
suggest that high levels of TEAD1 combined with YAP1 might plausibly extend 
the window of postnatal cardiomyocyte proliferation.  
Interestingly, overexpression of two different constitutive nuclear active YAP1 
mutants (Yap1[S112A], Yap1[S127A]) in embryonic cardiomyocytes resulted in 
increased cardiomyocyte proliferation and thickening of the myocardium [89, 
158]. However, it is worth noting that both YAP1 forms differ in the heart 
phenotype severity. While Myh6-Cre driven Yap1[S112A] overexpression 
resulted in non-lethal heart hyperplasia, doxycycline-induced activation of 
Yap1[S127A] led to myocardial overgrowth, ventricular wall thickening and 
marked expansion of the trabecular myocardium resulting in embryonic lethality. 
Such differences in the phenotype severity of both Yap1 overexpression 
approaches might either be explained by different activities of the YAP1 mutants 
or by divergent activation levels of the utilized overexpression systems (e.g. Cre-
mediated versus doxycycline-inducible). Tead1 overexpression in the present 
study probably reflects the milder phenotype of embryonic Yap1[S112A] 
overexpression. One should, however, consider that transcriptional activation of 
TEAD TFs strongly depends on the presence of cofactors, which provide either 
coactivator, e.g. YAP1, or corepressor, e.g. VGLL-4, functions modulating 
thereby transcriptional network of TEAD TFs targeted genes [82, 86]. This 
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assumption is in line with published observations showing that YAP1 protein is 
robustly present in postnatal as well as juvenile cardiomyocytes and declines with 
age [86, 89]. The endogenous downregulation of TEAD1 coactivators, e.g. YAP1, 
in adult cardiomyocytes might compensate the hyperplastic phenotype in Tead1-
overexpressing mice examined in the present study.  
In contrast to YAP1, the protein level of the TEAD TFs repressor, VGLL-4, 
increases from low level in the new-born heart to high level in the adult heart [86], 
which might counteract Tead1 overexpression observed in our study. It has been 
shown, that VGLL-4 restrains proliferation of postnatal cardiomyocytes by 
inhibiting TEAD1-YAP1 interaction and targeting TEAD1 for degradation. 
Moreover, in early postnatal cardiomyocytes TEAD1 and VGLL-4 interaction is 
inhibited by acetylation of the VGLL-4 TDU-domain, whereas adult 
cardiomyocytes lack this acetylation. This finally results in a switch of interaction 
partners from high-proliferative YAP1 to low-proliferative VGLL-4 in mature 
cardiomyocytes. Of note, an acetylation-resistant Vgll-4 (Vgll4[R]) 
cardiomyocyte-specific overexpression induced severe myocardial dysfunction, 
myocardial wall thinning, reduced cardiomyocyte proliferation and increased 
fibrosis, whereas overexpression of the wild type Vgll-4 did not significantly 
affected heart growth or function [86]. In this regard, the hyperproliferative 
phenotype of Tead1-overexpressing embryonic and early postnatal 
cardiomyocytes as well as the unaltered phenotype in adult hearts observed in 
the present study might be explained by VGLL-4 dependent TEAD1 degradation 
in adult cardiomyocytes. In fact, this could be one of the explanations for 
compensatory mechanism underlying an unaltered morphology of adult Tead1 
GOF mutants, although these mice displayed cardiomyocyte hyperproliferation 
during development and maturation. One strategy to overcome TEAD1 
dependence on coactivators as well as corepressors in cardiomyocytes might be 
the overexpression of a constitutive active TEAD1, a chimeric protein of TEA 
DNA-binding domain of TEAD TFs fused to a strong transactivation domain of 
VP16 herpes simplex virus protein, which was previously reported in mouse 
fibroblasts [137, 168, 169].  
It is worth to mention, that the previously published postnatal MCK-promoter 
driven Tead1 overexpression resulted in late onset (10 month) of cardiac 
dysfunctions, myocardial fibrosis as well as reactivation of the fetal gene program 
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e.g. Acta1 and Myh7 [17]. Importantly, comparable to our 8 weeks old Tead1-
overexpressing mice, this MCK-driven Tead1 overexpression showed no 
phenotypical changes at earlier time points. Moreover, inducible cardiomyocyte-
specific overexpression of Yap1[S127A] during postnatal stages showed 
increased cardiomyocyte proliferation capacity without any obvious heart 
alterations [89]. Interestingly, long-lasting induction of Yap1[S127A] 
overexpression resulted only in slightly decreased heart function and modest 
myocardial fibrosis, however cardiomyocyte size was not increased, indicating 
mild effects of chronic Yap1[S127A] overexpression [90]. These findings are 
comparable to present data obtained in Tead1-overexpressing hearts. 
 
4.4 TEAD1 regulates multiple cardiomyocyte-specific genes 
involved in proliferation, differentiation and survival. 
Several studies have demonstrated transcriptional gene regulation by the 
ubiquitously expressed transcription factor TEAD1 in combination with co-
activators/-repressors e. g. YAP1, WWTR1, VGLLs in various cell types [84, 86, 
97, 140, 170]. Moreover, increased specificity of TEAD TFs mediated gene 
expression is accomplished by interactions with numerous cell-type and -
processes specific transcription factors including MAX, SRF, MEF2, IRF2BP2, 
FOXO, SMADs [14, 16, 96, 98, 100, 101]. In particular, TEAD1 muscle-specific 
gene regulation is predominantly provided by binding to a specific DNA 
sequence, called MCAT-element, which was initially identified in the promoter 
region of the malonyl-coA-acyl carrier protein transacylase gene [10, 70, 171]. 
Moreover, some studies revealed that TEAD1 exerts repressive functions on 
gene expression in the context of target genes, cell types and conditions [86, 102, 
137]. For instance, binding of TEAD TFs to MCAT-elements represses Acta2 
transcription in cultured adult smooth muscle cells (SMCs), whereas in cultured 
myoblasts, fibroblasts and endothelial cells TEAD TFs binding mediates a 
transcriptional activation of Acta2 [63]. Altogether, these observations indicate, 
that TEAD1 regulates gene expression either in combination with activating and 
repressing cofactors, respectively, or cooperatively with additional transcription 
factors to guarantee precise gene expression depending on cell-type and context.  
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A number of studies have examined the TEAD1 DNA binding sites in various cell 
types including skeletal muscle, cancer cell lines in an effort to specify chromatin 
occupancy and transcriptional activity of TEAD1 [15, 18, 48, 136, 170]. While 
these studies have provided important insights into the potential mechanistic role 
of TEAD1 in various cell-types, so far no study has systematically examined 
functional significance of genome-wide TEAD1-DNA binding on global 
transcription, specifically in isolated cardiomyocytes. It should be noted, that 
several TEAD1 gene specific binding studies in cardiomyocytes have addressed 
selected targets e.g. Myh7 [15] , although no global TEAD1 chromatin binding 
profiles were performed so far. 
In order to identify cardiomyocyte-specific TEAD1 target genes, we performed a 
global transcriptome analysis of Tead1-deficient and overexpressing postnatal 
cardiomyocytes, respectively, combined with genome-wide TEAD1-binding 
studies in wild-type (WT) postnatal cardiomyocytes. Cardiomyocyte-specific 
deletion and overexpression of Tead1 in early postnatal cardiomyocytes resulted 
in expression changes of approximately 400 genes and 600 genes, respectively. 
The number of dysregulated genes upon Tead1 deletion and overexpression in 
late postnatal cardiomyocytes was increased and comprised approximately 1000 
and 700 genes, respectively, which might be explained either by an increased 
Cre-mediated recombination efficiency in later stages or secondary effects e.g. 
replacement fibrosis. Our gene set enrichment analysis of Tead1-deficient 
cardiomyocytes revealed decreased expression of gene clusters involved in 
cardiac muscle contraction, fatty acid metabolism and oxidative phosphorylation, 
which goes in line with previously reported inactivation of Tead1 in adult 
cardiomyocytes [18]. Alterations of the latter pathway were also observed in 
mouse myoblast upon Tead1/4 deletion [48, 117]. As expected, these gene 
clusters were transcriptionally upregulated upon Tead1 overexpression indicating 
a direct function of TEAD1 in these transcriptional pathways.  
In addition, the gene clusters responsible for cell-to-cell communication (b-
Catenin), cell adhesion (Fibronectin, Laminins, Collagen 4) and focal adhesion 
(Actinin 1 and 4, Integrin a 5, Collagen 4) proteins were upregulated upon Tead1 
deletion in our postnatal mutants. Upregulation of these gene clusters in Tead1 
mutants might contribute to a premature cardiomyocyte differentiation resulting 
in disturbed hypertrophic growth and proliferation. On the other hand, increased 
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expression of cell-contact proteins might reflect an increased mechanical stress 
on remaining Tead1-deficient cardiomyocytes (as reviewed in [172, 173]). In 
contrast, Tead1-overexpressing cardiomyocytes displayed a downregulation of 
these gene clusters, which might indicate a prolonged maturation process 
supporting enhanced proliferation of Tead1-overexpressing cardiomyocytes. In 
addition, the extended proliferation potential of Tead1-overexpressing 
cardiomyocytes might have been supported by upregulation of genes involved in 
Insulin-, mTOR-, ERBB- and WNT-signaling pathways [174-178].    
In order to specify genes, which might be directly regulated by TEAD1, genome-
wide TEAD1 binding studies using chromatin immunoprecipitation sequencing 
(ChIP-seq) analysis in freshly isolated WT cardiomyocytes were performed and 
further compared with the transcriptome analysis of isolated Tead1-deficient 
cardiomyocytes. Due to technical limitations, e.g. inefficient Tead1 deletion in 
early postnatal cardiomyocytes and insufficient isolation of late postnatal 
cardiomyocytes, for TEAD1 DNA-binding studies, the ChIP-seq analysis of early 
neonatal cardiomyocytes (P3) and transcriptome profiling of late postnatal 
cardiomyocytes (P15-P19) were merged. In total, 63 candidates were 
downregulated upon Tead1 deletion and displayed TEAD1 binding to 
corresponding promoter regions. Surprisingly, only 36 out of the 63 candidates 
contained well-defined TEAD TFs binding-sites known as MCAT-elements. 
However, several studies have shown that TEAD TFs have the ability to bind 
related regulatory sequences including MCAT-like, SV40 GT-IIC, Sph I, Sph II 
regulatory element, which share sequence similarities to MCAT-motives [40, 46, 
179, 180]. Since TEAD TFs binding-sites comprise short degenerated sequences 
of 6 nucleotides, multiple sequence combinations arise, which were restricted in 
our analysis to the most abundant MCAT variants. Integration of TEAD1 ChIP-
seq data with that of chromatin modification showed 26 genes, which were 
associated with active H3K9Ac-marked (histone 3 acetylation on lysine 9) 
regulatory elements [139].  
Based on our analysis data, we depicted genes, which are regulated by TEAD1 
and have been reported to exert important functions in muscle cells. As has been 
shown previously, TEAD1 activates Myh7 (Myosin Heavy Chain b-Subunit) 
expression in rat cardiomyocytes via binding to MCAT-elements, which is in line 
with our ChIP-seq and transcriptome analysis clearly indicating TEAD1 binding 
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to a MCAT-element containing Myh7 promoter region [15, 17, 18]. Moreover, 
downregulation of Myh7 upon Tead1 deletion in postnatal cardiomyocytes 
underlines this result. Due to the fact that Myh7 is barely expressed in fully 
differentiated cardiomyocytes under non-pathological conditions (reviewed in 
[104]), we did not observed Myh7 downregulation in late postnatal Tead1-
deficient cardiomyocytes, although Myh7 was upregulated upon Tead1 
overexpression. 
The present study also identified Acta2 (Smooth Muscle Actin) as a potential 
TEAD1 downstream target gene in cardiomyocytes. Acta2 has been previously 
shown in myofibroblasts and developing smooth muscle cells to be regulated by 
TEAD1 via MCAT elements [60, 63]. Moreover, mutations in MCAT-elements 
resulted in delayed Acta2 expression in smooth muscle cells as well as loss of 
Acta2 expression in cardiac and skeletal muscles during embryogenesis, 
indicating a complex regulation of Acta2 expression determined by the cell type 
and developmental stage, respectively [60].  
It is well established, that smooth muscle genes are implicated in cardiomyocyte 
differentiation and maturation [35, 141, 142]. In line with these observations, our 
transcriptomic and genome-wide TEAD1 binding profiling as well as 
immunohistochemical data strongly indicate that TEAD1 regulates expression of 
Acta2 during cardiomyocyte differentiation and maturation. Specifically, Acta2 in 
embryonic and postnatal cardiomyocytes was reduced in Tead1-deficient or 
increased in Tead1-overexpressing cardiomyocytes. Moreover, ultrastructural 
analysis of Tead1-deficient hearts revealed numerous prematurely differentiated 
cardiomyocytes characterized by compact contractile structures, uniform 
mitochondria and low glycogen content in comparison to age-matched control 
cardiomyocytes characterized by sparely arranged contractile filaments, 
glycogen depositions and polymorphic mitochondria as previously described 
[143, 144]. These findings indicate an important role of TEAD1 and its 
downstream targets including Acta2 in the proper cardiomyocyte differentiation 
and maturation. This assumption is further supported by the observations of Xin 
et al. who showed that ACTA2 protein was up-regulated in adult cardiomyocytes 
overexpressing constitutive active Yap[S112A], which is one of the TEAD1 
cofactors [158]. 
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The expression level of Myocardin (Myocd), a well-known Acta2 upstream 
transcriptional regulator [107], was unaltered in Tead1-deficient and 
overexpressing cardiomyocytes, indicating that TEAD1 acts as a MYOCD-
independent activator of Acta2 expression in this particular cell type. This 
observation is supported by Myocd promoter studies, which showed that TEAD1 
binding site were dispensable for Myocd promoter activation in embryonic heart 
[16]. 
Among well-known TEAD1 downstream targets, we identified 24 novel 
cardiomyocyte-specific TEAD1 regulated genes, including Adprhl1 (ADP-
Ribosylhydrolase Like 1), Coro6 (Coronin, Actin Binding Protein 6), Syde2 
(Synapse Defective Rho GTPase Homolog 2), Fbxl22 (F-Box and Leucine Rich 
Repeat Protein 22), Popdc2 (Popeye Domain Containing 2), Hsd17b7 
(Hydroxysteroid 17-Beta Dehydrogenase 7) and Trim55 (Tripartite Motif 
Containing 55/Muscle-Specific RING Finger Protein 2, Murf-2). These genes are 
known to be responsible for heart development, cardiomyocyte contractility, 
cytoskeleton arrangement and maturation, which are essential features of proper 
biomechanical function ensuring an adequate adaptation of cardiac chambers to 
increased biomechanical forces [181-187].  
Furthermore, we have identified potential TEAD1 targets, which are involved in 
regulation of cardiomyocyte energy homeostasis including Prkaa2 (AMP-
Activated, a-2 Catalytic Subunit), Ckmt2 (Creatine Kinase, Mitochondrial 2, 
Sarcomeric), Nnt (Nicotinamide Nucleotide Transhydrogenase) and Scd4 
(Stearoyl-Coenzyme A Desaturase 4) [188-193]. Multiple studies have 
demonstrated, that the shift of anaerobic glycolysis to mitochondrial respiration 
during differentiation is required to cover energy demands of differentiated cells 
(reviewed in [194]). For example, protein kinase PRKAA2 activates multiple 
catabolic pathways, including fatty acid metabolism, to ensure high levels of ATP 
production [195]. It is likely that downregulation of genes involved in oxidative 
phosphorylation in Tead1-deficient cardiomyocytes might be one of the causes 
for increased apoptosis rate in mutant hearts. Surprisingly, the previously 
reported direct TEAD1 target genes Serca2a and Ppp1R1A in adult 
cardiomyocytes were unaltered in our postnatal Tead1-deficient cardiomyocytes, 
which might reflect the differences in TEAD1 mediated gene transcription in 
postnatal vs. adult cardiomyocytes [18].   
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In addition, we identified a set of TEAD1 target genes including FoxO3 (Forkhead 
Box O3), Crhr2 (Corticotropin-Releasing Hormone receptor 2), Irf2bp2 
(Interferon Regulator Factor 2 Binding Protein 2), Ogn (Osteoglycin / Mimecan), 
Klhl21 (Kelch Like Family Member 21) Klhl38 (Kelch Like Family Member 38), 
Mylk3 (Myosin Light Chain Kinase Family Member 3), Abcc8 (ATP-Binding 
cassette Subfamily C Member 8) and Crip2 (Cysteine Rich Protein 2) [100, 196-
206],  which are involved in various biological processes. FOXO3 is a member of 
FOXO transcription factors family and regulates multiple target genes, which are 
involved in diverse cellular processes including the ubiquitin-proteasome system 
and autophagy in cardiomyocytes [207]. These results are in line with TEAD1 
DNA binding assays and transcriptome profiling studies of myoblast indicating a 
direct regulation of Foxo3 expression by TEAD1 [208]. However, in our analysis 
Foxo3 downregulation was restricted to late postnatal cardiomyocytes, which 
might be explained either by the redundancy of other TEAD TFs or insufficient 
Tead1 recombination in early postnatal cardiomyocytes. Moreover, FOXO3 was 
previously shown to interfere with the Hippo-pathway by activating Mst1 
expression and thereby negatively regulating YAP1 activity in cardiomyocytes 
[209, 210]. 
The present study also identified a set of genes, which were strongly 
downregulated upon Tead1 deletion and upregulated upon Tead1 
overexpression, respectively, however the proximal promoter regions of these 
genes were not occupied by TEAD1. This gene set contains 2 candidates 
including Mylk4 (Myosin Light Chain Kinase Family Member 4) and Sntb1 
(Syntrophin Beta 1) [145, 211]. One explanation for the undetectable TEAD1 
regulatory occupancy in this gene set might be explained by our settings of 
bioinformatic analysis, which were restricted to TSS region plus 5000 bp up- and 
downstream. In this cases TEAD1 might bind to more distal located regulatory 
regions of these genes, which were not included in our analysis. 
A peculiar gene of the TEAD1-occupied promoter region resembles Nmrk2 
(Nicotinamide Riboside Kinase 2 / MIBP Muscle Integrin-Binding Protein), which 
expression was downregulated upon Tead1 deletion in early postnatal 
cardiomyocytes, thus indicating a direct TEAD1 regulation of Nmrk2 at this stage 
[212]. However, in later cardiomyocyte stages, Nmrk2 activation seems to 
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become TEAD1 indispensable, which is indicated by an increased Nmrk2 
expression upon TEAD1 deletion.  
Surprisingly, the expression of two well-established YAP1-TEAD target genes 
Ctgf (Connective Tissue Growth Factor) and Amotl2 (Angiomotin Like 2) was 
unaltered upon Tead1 deletion and overexpression in postnatal cardiomyocytes, 
although both promoters were occupied by TEAD1 and transcriptionally active, 
represented by H3K9Ac marks [48, 140]. The unaltered expression of Ctgf and 
Amotl2 in our study indicates a TEAD1-independent transcription in postnatal 
cardiomyocytes. However, during late postnatal stages Ctgf expression 
increased upon TEAD1 deletion, indicating a potential repressive function of 
TEAD1 during cardiomyocyte maturation. Similar observations were described 
for TEAD4 in C2C12 cells during differentiation, where it acts as a repressor of 
Ctgf [213]. 
Interestingly, our data demonstrated that TEAD1 binds in own transcriptionally 
active promoter represented by a H3K9Ac mark, suggesting that TEAD1 
positively regulates its own expression. A similar autoregulatory transcriptional 
activation loop was previously reported for TEAD4 in myoblast differentiation [48]. 
Moreover, the present study showed that TEAD1 also binds to the Tead4 
promoter region, however the expression levels of Tead4 as well as of Tead2 and 
Tead3 remained unchanged upon Tead1 deletion. 
In line with a recently reported observation in adult cardiomyocytes [18], we found 
that Tead1 specific inactivation in postnatal cardiomyocytes resulted in a 4-fold 
upregulation of Vgll-2 (VITO-1), a skeletal muscle specific TEAD1 coactivator, 
which promotes muscle differentiation by enhancing the expression of muscle-
specific genes [84, 95]. However, we could not detect a TEAD1 binding in the 
Vgll-2 promoter region, indicating a compensatory effect caused by TEAD1 
inactivation.  
In conclusion, our combined transcriptomic and genome-wide binding study of 
TEAD1 in cardiomyocytes resulted in more that 60 TEAD1 directly regulated 
genes, which correlates with the number of direct TEAD4 targets identified by the 
comparison of RNA-seq and ChIP-chip data in C2C12 cells [48]. In total, we 
observed 1675 TEAD1 binding sites, 606 of them were located in the promoter 
regions, which we defined as transcription start site (TSS) plus 5000 nucleotides 
up- and down-stream, respectively. This indicates that multiple TEAD1 binding 
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regulatory sites might be located in far distal promoter regions, reflecting the low 
number of candidates.  
 
4.5 The role of TEAD1 in cardiomyocyte FGF2-signaling  
Multiple studies have shown that FGF2-signaling in the myocardium is 
predominantly mediated by the abundant high-affinity tyrosine kinase receptor 
FGFR-1, and regulates cellular processes including proliferation, maturation, 
hypertrophic growth, dedifferentiation of cardiomyocytes and re-expression of 
fetal contractile gene program [146, 148-151, 153, 154], which resembles the 
phenotype of Tead1 mutants. Our ex-vivo experiments in adult rat 
cardiomyocytes clearly showed the increased TEAD1 protein levels upon FGF2 
stimulation. Moreover, siRNA mediated knock-down of Tead1 as well as Fgfr1 in 
adult rat cardiomyocytes resulted in attenuated hypertrophic growth in response 
to FGF2 stimulation, which is characterized by cardiomyocyte spreading and 
dedifferentiation. Numerous studies showed that dedifferentiated cardiomyocytes 
share common characteristics compared to early postnatal ones [152, 214], 
which supports atrophic phenotype of Tead1-deficient postnatal cardiomyocytes 
in the present study. Of note, Tead2, Tead3 as well as Tead4 siRNA mediated 
knockdowns did not affected cardiomyocyte morphology upon FGF2 stimulation 
suggesting that these TEAD TFs family members can not compensate TEAD1 
function in FGF2-FGFR1 pathway. Taken together, our results indicate a 
potential novel FGF2 mediated TEAD1 regulatory pathway, however, the exact 
regulatory mechanism needs to be further investigated. The potential role of 
TEAD1 in FGF2-signaling and its biological effects is depicted in Figure 68. 
Similar findings were reported in mouse fibroblasts upon FGF1 or FGF2 
stimulation, which resulted in an enhanced Tead4 expression [57].  
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Figure 68. Schematic representation of the hypothetical TEAD1 function in 
cardiomyocyte FGF2-signaling. (A) Active FGF2-FGFR1 pathway might act via Tead1 
transcription activation or TEAD1 protein stability. TEAD1-Coactivator (e.g. YAP1) 
interaction in combination with additional TFs activates TEAD1 target genes expression 
and thereby stimulates cardiomyocyte proliferation, differentiation, survival and growth. 
(B) Inactive FGF2-FGFR1 pathway might cause reduced TEAD1 stability or expression 
level, resulting in decreased cardiomyocytes proliferation, growth, survival and impaired 
differentiation. TF(s) – transcription factor(s); TSS - Transcription Start Site 
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In summary, the present study demonstrates that cardiomyocyte-specific Tead1 
loss in embryonic and postnatal hearts caused end-stage dilated 
cardiomyopathy. This pathological phenotype was characterized by reduced 
proliferation, increased apoptosis and atrophy of Tead1-deficient 
cardiomyocytes. In contrast, embryonic cardiomyocyte-specific Tead1 
overexpression led to hypertrabeculation characterized by increased number of 
proliferating cardiomyocytes without noticeable phenotypic changes in postnatal 
as well as adult hearts. Based on transcriptional profiling in combination with 
genome-wide mapping of TEAD1 binding, this study identified multiple novel 
TEAD1 target genes responsible for cardiomyocyte growth, differentiation, 
contraction, energy homeostasis, sarcomere and cytoskeleton organization of 
maturating cardiomyocytes. Moreover, the present work showed that in 
cardiomyocytes, TEAD1 potentially exerts its biological functions downstream of 
FGF2-FGFR1 pathway, which is well established in induction of cardiomyocyte 
proliferation, differentiation and growth. These findings clearly demonstrate that 
Tead1 loss and subsequent dysregulation of TEAD1 downstream targets during 
cardiomyocyte development and maturation leads to decreased proliferation and 
premature differentiation resulting in limited cardiomyocyte plasticity (Figure 69). 
These processes are crucial prerequisite for proper embryonic and postnatal 
heart growth. 
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Figure 69. Schematic view on effects of TEAD1 regulated gene network in 
differentiating cardiomyocytes. (A) TEAD1-Coactivator interaction in combination with 
additional TFs activates transcription of downstream target genes involved in variety of 
cellular processes, e.g. proliferation, survival, differentiation, in healthy heart. (B) Tead1 
loss results in reduced expression of target genes thereby impairing numerous cellular 
processes e.g. proliferation, survival, differentiation, which causes premature 
cardiomyocyte differentiation leading to limited cardiomyocyte plasticity and onset of 
dilated cardiomyopathy. TF(s) – Transcription Factor(s), TSS - Transcription Start Site. 
 
 
 
 
 
 
 
Discussion 
 134 
4.6 Future directions  
 
This study provides novel insights into TEAD1 regulated transcriptional network 
as well as functional consequences of Tead1 inactivation during embryonic and 
postnatal cardiomyocyte differentiation and maturation. Importantly, this study 
demonstrated that TEAD1 acts as a regulator of cardiomyocyte proliferation and 
differentiation processes, which are essential for sustained cardiac function 
during heart maturation. Furthermore, the expression of TEAD1 regulated genes 
is not coordinated by a single transcription factor, rather, it is controlled by 
multiple mechanisms including cognate transcription factors as well as cofactors, 
their combinatorial interactions, posttranslational modifications and accessibility 
to DNA. The orchestrated protein interaction between TEAD1, cofactors and 
other transcription factors exerts a strong impact on the diversity of TEAD1 target 
genes expression in particular for embryonic, postnatal and adult 
cardiomyocytes. Towards a more comprehensive understanding of TEAD1 
function in cardiomyocyte, detailed interactome studies comparing different 
conditions, e.g. stages and disease, are needed. 
Multiple studies have addressed TEAD TFs function in various cell types, 
however functional insights in cardiomyocytes are limited to TEAD1 and TEAD4. 
In order to analyze the potential functional redundancy of TEAD TFs in 
cardiomyocytes, a combinatorial inactivation of TEAD TF family members is 
required. Since our cardiomyocyte-specific Tead1 gain-of-function hearts were 
phenotypically unaltered, the expression of a constitutive active Tead1 version 
would uncouple TEAD1 from the requirement of additional cofactors and uncover 
potential regenerative functions in mature myocardium.   
The present study suggests that the FGF2-FGFR1 signaling pathway is one, but 
not the only, plausible upstream TEAD1 activator in cardiomyocytes, however, 
additional pathways should be analyzed, in order to determine positive or 
negative impact on TEAD1 biological function.  
Finally, a more comprehensive understanding of TEAD1 role in cardiomyocytes 
will contribute to the understanding of cardiac diseases pathogenesis and 
development of novel therapeutic strategies.
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IV.   ABBREVIATIONS 
 
4-HT  4-Hydroxytamoxifen  
Abcc8  ATP-Binding Cassette Subfamily C Member 8 
Acta1 Skeletal Muscle a-Actin 
Acta2  Smooth Muscle a-aActin 2 
Ad-Cre Adenovirus expressing a codon of improved Cre-recombinase 
Adprhl1  ADP-Ribosylhydrolase Like 1  
Adra1c  α1c-Adrenergic Receptor 
AFA Adaptive Focused Acoustics 
Ajuba  LIM Domain-Containing Protein Ajuba 
Amotl2  Angiomotin Like 2 
Amp Ampicillin 
APS Ammoniumperoxodisulfat 
ARCs  Adult Rat Cardiomyocytes 
BSA Bovine Serum Albumin 
C  Capillary  
CAMS Cell Adhesion Molecules 
CAT  Chloramphenicol acetyltransferase 
cDNA Complimentary DNA 
ChIP-seq  Chromatin immunoprecipitation sequencing 
Chrnb1 β-Acetylcholine Receptor 
Ckmt2 Creatine Kinase, mitochondrial 2 (Sarcomeric) 
CL Compact Layer 
COL1  Collagen 1 
Coro6  Coronin, Actin Binding Protein 6 
Crhr2  Corticotropin-Releasing Hormone receptor 2 
Crip2  Cysteine Rich Protein 2  
CTGF Connective Tissue Growth Factor 
Ctrl.  Control 
DAPI  4′,6-diamidino-2-phenylindole 
DAPI  4′,6-diamidino-2-phenylindole 
DCM Dilated Cardiomyopathy  
dd. Distilled Deionized 
DMD  Dystrophin 
DMEM Dulbecco’s Modified Eagle Medium  
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DNA  Deoxyribonucleic Acid 
dNTP DeoxyriboNucleotide TriPhosphate 
E day of embryonic development 
e.g.  for example (Latin) 
EB Extraction Buffer  
ECM Extracellular Matrix  
EdU  5-Ethynyl-2’-Deoxyuridine 
EPI Epinephrine  
Epi  Epicardium 
ES  Enrichment Score 
et al. and others (Latin) 
etc. and son on (Latin) 
EtOH Ethanol 
ex vivo out of living (Latin) 
FAM Fluorescein Amidite 
FBS Fetal Bovine Serum 
Fbxl22  F-Box And Leucine Rich Repeat Protein 22  
FC  Fold Change  
FCS Fetal Calf Serum 
FGF  Fibroblast Growth Factor 
FGFR1  FGF Receptor 1 
for forward 
Foxo2  Forkhead Box A2 
FoxO3  Forkhead Box O3 
Gapdh  Glyceraldehyde-3-Phosphate Dehydrogenase 
GFP  Green Fluorescent Protein 
GOF  Gain-Of-Function 
GSEA   Gene Set Enrichment Analysis 
h Hours 
HE-stained  stained with Hematoxylin and Eosin  
HEK Human Embryonic Kidney  
hpf high-power field 
HRP Horseradish Peroxidase  
Hsd17b7  Hydroxysteroid 17-Beta Dehydrogenase 7 
i.p. intraperitoneal 
ICM(s)  Isolated Cardiomyocyte(s) 
ID  Intercalated Disk 
Abbreviations 
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IGV  Integrative Genomic Viewer 
In Situ  in place (Latin) 
in vitro in the glass (Latin) 
in vivo within the living (Latin) 
IP Immunoprecipitation  
IRES  Internal Ribosomal Entry Site 
IRF2BP2  Interferon Regulator Factor 2 Binding Protein 2 
kb kilobase 
KD  Knockdown 
KHB Krebs-Henseleit Bicarbonate Buffer 
Klhl21 Kelch Like Family Member 21 
Klhl38  Kelch Like Family Member 38 
KO  knockout 
LA  Left Atrium 
LATS Large Tumour Suppressor Kinases 
LB Lysis Buffer 
LOF  Loss-Of-Function 
Luc Luciferase 
LV  Left Ventricle 
LVEF Left Ventricular Ejection Fraction 
m  Mitochondria  
MAX  MYC Associated Factor X  
MCAT  Muscle Specific Cytidine-Adenosine-Thymidine-Sequence 
MCK  Muscle Creatine Kinase 
MCM MerCreMer 
MEF2  Myocyte Enhancer Factor 2  
MI  Myocardial Infarction 
min minute(s) 
MOI  Multiplicity Of Infection 
MRI  Magnetic Resonance Imaging 
mRNA  messenger RNA 
MST STE20-like protein kinase 
MTOR  Mechanistic Target Of Rapamycin Kinase 
Myh6  Myosin Heavy Chain 6, cardiac muscle α Isoform, α-MHC 
Myh7  Myosin Heavy Chain 7, cardiac muscle β Isoform, β-MHC 
Mylk3  Myosin Light Chain Kinase Family Member 3 
Mylk4  Myosin Light Chain Kinase Family Member 4 
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Myocd  Myocardin 
N(UC)  Nucleus 
neg  negative 
Nmrk2  Nicotinamide Riboside Kinase 2 / MIBP Muscle Integrin-Binding Protein 
Nnt Nicotinamide Nucleotide Transhydrogenase  
Nppa  Natriuretic Peptide A 
Nppb  Natriuretic Peptide B 
OD Optical Density  
OE  Overexpression  
Ogn  Osteoglycin / Mimecan 
P  postnatal day 
P/S Penicillin / Streptomycin 
PAA Polyacrylamide 
PBS Phosphate Buffered Saline 
PCM(s)  Postnatal Cardiomyocyte(s)  
PCR Polymerase Chain Reaction 
PFA Paraformaldehyde 
PFU Plague forming units 
Popdc2  Popeye Domain Containing 2 
pos  positive 
Ppp1R1A  Protein Phosphatase 1 Regulatory Inhibitor Subunit 1A 
Prkaa2  AMP-activated, a-2 catalytic subunit 
qRT-PCR  Quantitative Real-Time Polymerase Chain Reaction 
RA  Right Atrium 
rev reverse  
RNA  Ribonucleic Acid 
ROSA26  Reverse Oriented Splice Acceptor, Clone 26 
rpm rotation per minute 
RT Room Temperature 
RV  Right Ventricle 
Scd4  Stearoyl-Coenzyme A Desaturase 4 
Serca2a  ATPase Sarcoplasmic/Endoplasmic Reticulum Ca2+ Transporting 2 
siRNA  Small interfering RNA 
SMCs  Smooth Muscle Cells 
Sntb1 Syntrophin Beta 1 
SRF Serum Response Factor 
SRY Sex-Determining Region Y 
Abbreviations 
 xiv 
Syde2  Synapse Defective Rho GTPase Homolog 2 
TEAD (TEF) Transcription Enhancer Factor  
TEAD1 Transcription Enhancer Factor 1 (protein symbol in mouse) 
Tead1 Transcription Enhancer Factor 1 (gene and mRNA symbol in mouse) 
TEM Transmission Electron Microscopy  
TF(s) Transcription Factor(s) 
TG Transgenic 
TGFβ Transforming Growth Factor β 
TL Trabecular Layer 
Tnni3  Troponin I3, cardiac type 
Tnnt2  Troponin T2, cardiac type 
Tpm1  α-Tropomyosin 
Trim55 Tripartite Motif Containing 55/Muscle-Specific RING Finger Protein 2, Murf-2 
TUNEL  Terminal deoxynucleotidyl transferase dUTP nick end labeling  
U Unit 
V  Vessel(s) 
VEGF  Vascular Endothelial Growth Factor 
Vg Vestigial 
VGLL-1 Vestigial Like Family Member 1 
VGLL-2 Vestigial Like Family Member 2, VITO-1 
VGLL-3 Vestigial Like Family Member 3 
VGLL-4  Vestigial Like Family Member 4 
VIC fluorescent dye dev. by Applied Biosystems 
vs. against (Latin)  
WT Wild-Type  
Wwtr1 WW Domain Containing Transcription Regulator 1 (TAZ) 
XMLC Xenopus laevis myosin light-chain 2 
YAP1  Yes-Associated Protein 1 
Z  Z-disk(s) 
β-PKC  β-Protein Kinase C 
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